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Abstract
Introduction: Statin drugs are a highly e cacious treatment for hypercholesterolemia and
adherent treatment with statins reduces the risk of cardiovascular disease. Although statins are
generally well tolerated, myalgia (muscle pain) is a common side e↵ect and can lead to non-
compliance with treatment. Increased systemic exposure may contribute to the development
of myalgia. Drug-drug interactions inhibiting statin metabolism and impaired drug transporter
function may lead to decreased statin clearance. Establishing accurate predictive models is
an important step towards preventing adverse drug events by titrating statin dosing to limit
systemic exposure.
Objectives: 1) To develop an algorithm to select concomitant medications for incorpora-
tion into the existing systemic exposure model and assess their predictive impact; 2) to apply
nonlinear techniques to model systemic statin exposure, and assess their e↵ectiveness and fea-
sibility; 3) to identify novel genes and corresponding single nucleotide polymorphisms using
next generation sequencing (NGS) in patients whose statin plasma concentrations were under-
predicted using the original systemic exposure model to guide future biological research.
Methods: Data from a previously-collected prospective cohort of 130 patients prescribed
rosuvastatin and 128 patients prescribed atorvastatin were used in this analysis. Concomitant
medications were selected using penalized regression. Stable feature selection was achieved
by repeated cross validation. Generalized additive models (GAMs) and support vector regres-
sion (SVR) were assessed as candidate nonlinear models. Candidate patients were chosen for
NGS sequencing based on the proportional di↵erence between their true and predicted values
from the original systemic exposure model. Variant prioritization used the Sequence Kernel
Association Test.
Results: Atorvastatin linear model fit was statistically significantly improved by incorpo-
rating the selected concomitant medications, but rosuvastatin model fit was not. Predictive
performance was not improved using GAMs or SVR compared to linear regression, likely due
to small sample size. Three candidate genes and corresponding observed variants were identi-
fied and discussed as potential predictors of systemic rosuvastatin exposure.
Conclusion: Linear modelling of systemic atorvastatin exposure can be improved by in-
corporating concomitant medications. The feasibility of using nonlinear predictive models is
limited by small sample size. Future research on newly identified interacting medication and
genetic variants may provide new insights regarding underlying molecular mechanisms a↵ect-
ing systemic statin exposure.
Keywords: Statins, hypercholesterolemia, nonlinear modelling, clinical pharmacology,
plasma concentration, next generation sequencing
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Chapter 1
Background
1.1 Use of Statins for Hypercholesterolemia
Cardiovascular disease (CVD) is a leading cause of mortality around the globe; it has been es-
timated that cardiovascular diseases are responsible for approximately 30 percent of global
mortality1. Hypercholesterolemia (elevated blood levels of low-density lipoprotein (LDL)
cholesterol) is a major risk factor for CVD. When high levels of LDL cholesterol are in the
circulatory system, these particles penetrate the innermost layer of cells in the walls of arteries
and accumulate, causing inflammation. The immune system recognizes this as damage, and
capped plaques full of fat-engorged leukocytes form in the area. Stroke and myocardial infarc-
tion can then result from these plaques being disrupted and forming clots in the bloodstream1.
It has also been determined that cardioprotective cholesterol exists in the form of high-density
lipoprotein (HDL), which removes lipids from the blood more e↵ectively than LDL as the
lipids are packed more densely, and also stops the formation and oxidization of LDL plaques1.
Prior to the discovery of statin drugs, blood cholesterol management strategies were limited to
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diet modification, and the use of niacin, fibrates, probucol and bile-acid sequestrants, most of
which had limited success or undesirable side e↵ects2. The development of statin drugs was a
major breakthrough for treating CVD as statins provide a reliable and highly e↵ective means
of reducing LDL cholesterol levels within the body3. Statins achieve lipid-lowering by com-
petitively inhibiting 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), which is a key enzyme in
the cholesterol synthesis pathway1. Atorvastatin (trade name Lipitor) and rosuvastatin (trade
name Crestor) are very popular prescription options for statin therapy, and have been found to
be generally well tolerated. Atorvastatin was found to have greater cholesterol-lowering ca-
pabilities than previously developed statin drugs including pravastatin, lovastatin, simvastatin
and fluvastatin in a randomized open-label clinical trial (the CURVES study)4. A benefit of
rosuvastatin is that it has a high potency to lower cholesterol, and has a lower potential for
interactions with other medications compared to atorvastatin. There is less of a potential for
interactions with other drugs since rosuvastatin is minimally metabolized before performing
its intended action, unlike other statins5; interactions may happen when di↵erent chemicals
associated same metabolic enzymes or drug transporters, and are competitvely inhibiting or
inducing one another. Additionally, like all statin drugs it is primarily active in the liver rather
than the surrounding tissues (in which it can produce muscle pain), and it has a good dura-
tion of action6. A substantial body of research exists comparing the e↵ectiveness and safety
of atorvastatin versus rosuvastatin7;8;9;10. One meta-analysis on the risks and benefits of these
two drugs comparatively found that rosuvastatin is more e↵ective at reducing LDL cholesterol
than atorvastatin at 1:1 and 1:2 dose ratios of rosuvastatin to atorvastatin; there was no sig-
nificant di↵erence found at the dose ratio of 1:4 for rosuvastatin to atorvastatin10. Dosing for
atorvastatin and rosuvastatin is regulated according to prescribing information; within these
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regulations, atorvastatin dosing typically ranges from 10-80 mg per day with oral administra-
tion, while rosuvastatin doses generally range from 5-40 mg per day11.
1.2 Statin-Induced Myopathy
Major adverse e↵ects of treating hyperlipidemia using statins are myopathy and myalgia; these
are problems that a↵ect the skeletal muscles12. In extreme cases statins can cause rhabdomy-
olysis, in which striated muscles experience damage, disintegration and necrosis. Muscle cells
contain creatine kinase (CK), which leaks into plasma as a result of the muscle damage13. El-
evated CK plasma level is used as a metric of muscle damage, and the diagnostic threshold for
myopathy is a concentration that is >10 times greater than the normal range in plasma14;15;16.
In severe cases rhabdomyolysis can be fatal17; however, muscle damage to this extent is very
rare (0.003 - 0.1%)18. More often patients experience myalgia, a less severe disorder charac-
terized by muscle pain and weakness, but not usually elevated levels of CK19. Even so, less
severe statin-associated myalgia has the potential to severely decrease the quality of life for pa-
tients taking this medication; additionally it may decrease compliance with the medication20,
resulting in a lowered dose of the medication, or pursuit of an alternative therapy.
1.2.1 Myalgia Definition, Incidence and Risk Factors
The exact definition of what constitutes clinically relevant myalgia di↵ers between di↵erent
studies, but in general encompasses the experience of muscle pain, soreness, weakness, cramp-
ing, tenderness, sti↵ness and/or heaviness20. The muscle pain or weakness caused as a result
of statin exposure can appear or worsen during exercise, when general muscle injury can oc-
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cur; however, many patients also experience myalgia at rest20. The lack of a general consensus
on an exact definition of myalgia between studies on adverse drug events resulting from statin
exposure makes estimating the prevalence di cult. In clinical trials of statins, the incidence of
myalgia is reported to be around 1.5-3%, comparable to that of patients taking a placebo20;18.
The incidence of myalgia observed in these trials is probably lower than would be seen in the
general clinical population however, because often patients particularly at risk for myotoxic-
ity are excluded from study populations, as are patients who have extensive comorbidities and
concomitant medication use12. Unfortunately, no clinical trials have been performed using a
consensus definition of myalgia and non CK-elevated myopathy, which makes it di cult to ac-
curately compare the risk of these adverse drug events between di↵erent HMG-CoA inhibiting
drugs, although atorvastatin is thought to have a higher risk than other statin drugs12. Various
community-based studies have estimated the incidence of myalgia to be between 5-20%19;18;21,
a↵ecting a significant portion of patients treated using statins.
Specific risk factors for statin-induced myalgia are predominantly those that a↵ect the con-
centration of statins in the plasma and surrounding muscle tissue, interacting medications, and
factors for independent muscle injury. These include statin dose, polymorphisms decreasing
the function of drug transporters responsible for hepatic statin uptake or e✏ux, impairment
of liver and kidney function, age (especially persons over 80 years), frail body condition, fe-
male sex, conditions like diabetes and hypothyroidism, and acute factors such as addictive drug
use, excessive alcohol consumption, heavy exercise and muscle inflammation, and extensive
surgery12;15. Ethnicity has also been shown to be strongly associated with statin plasma level,
with Asian patients having a rosuvastatin plasma concentration approximately double that of
Caucasian patients, despite taking the same dose of medication22. Importantly, the risk of
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myalgia among patients taking statin drugs is dose dependent; systemic exposure to statins
outside of the liver where their primary mechanism of action lies, particularly in the plasma
and surrounding muscle tissue11, is thought to play a causal role in the development of these
adverse drug events19. The risk of myalgia based on systemic exposure has been found to be
independent of the level of lipid-lowering achieved by statin therapy12, although this e↵ect is
debated in the literature.
1.2.2 Statin Plasma Level and Drug Transporters
Drug transporters are important determinants of statin concentration in the liver, bloodstream,
and muscle tissue23. Uptake transporters of the organic anion transporting polypeptides (OATP)
family are members of the solute carrier transport SLCO superfamily of genes24, and are largely
responsible for delivering statins into the liver. For example, OATP1B1 is particularly impor-
tant when considering the uptake and distribution of statins in the body, as it is thought to be
the main carrier of statins into the liver; indeed, OATP1B1 is expressed only on the basolateral
membrane of the liver23. Polymorphisms decreasing the function of this transporter are associ-
ated with higher area under the curve (AUC) of plasma exposure for many types of statins and
may correspond to higher risk for patients of experiencing muscle pain or muscle damage as a
result of toxicity23. Importantly, OATP1B1 c.521T>C, an impaired-function SNP resulting in
a change from thymine to cytosine, has been shown to strongly associate with myopathy in pa-
tients prescribed simvastatin and atorvastatin, as reported in genome wide association studies
(GWAS)11. The change from thymine to cytosine results in an amino acid change from valine
to alanine. Patients with decreased hepatic expression of this transporter also have a higher risk
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of myopathy because when less of the drug is entering the liver, the bioavailability of the drug
in the plasma increases12.
E✏ux transporters such as ATP-binding cassette (ABC) transporters are also important
for the distribution and removal (excretion) of statin drugs from the body23. Polymorphisms
reducing the function of ABCG2, also known as breast cancer resistance protein (BCRP), have
been shown to increase the concentration of rosuvastatin in the plasma25. With certain SNPs
such as ABCG2 c.421T>C, the transporters are unable to export as much rosuvastatin from the
liver, and the resultant higher concentration in the liver causes a greater lipid-lowering e↵ect23.
Other e✏ux transporters that can a↵ect statin plasma concentration are ABCB1 (P-glycoprotein
/P-gp) and ABCC2 (multidrug resistance-associated protein 2/MRP2)26.
A number of potential causal mechanisms for muscle damage caused by statin use have
been hypothesized. It has been observed that drug transporters responsible for cellular statin
uptake are also expressed in human muscle tissue, such as OATP2B119;23. Because statin
drugs lower cholesterol by distrupting HMG CoA Reductase within the melavonate pathway,
it is possible that the reduction of intermediaries on this pathway within muscle tissue could
be a potential cause. Ubiquinone or Co-Q10 has been observed to be depeleted in muscle
tissue as a result of high-dose statin exposure. It is a component of the mitochondrial electron
transport chain and antioxidant, and thus is important for many cellular functions. However,
a supplementation study failed to observe a role of Co-Q10 in reversing symptoms21. It is
also possible that a decreased mitochondrial volume could be implicated in the development
of myalgia27. Another hypothesis that has been supported by experimental evidence is that
myalgia could be mediated by statin-induced upregulation of the phospholipase C pathway
which causes a large increase in the influx of calcium (Ca2+) into cells, disrupting calcium
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metabolism28. Other mechanisms that might play a role in the development of myopathy and
myalgia are increases in muscle cell apoptosis via pathways upregulated by statin exposure,
and a depletion of enzymes produced by cholesterol synthesis that in turn destabilizes muscle
cell membranes15;29;21.
1.3 Statin-Drug or Herb-Drug Interactions
1.3.1 Statin-Drug Interactions Involving Cytochrome P450 (CYP) En-
zymes
Hypercholesterolemia and cardiovascular disease tend to cluster with other conditions such as
diabetes, obesity and metabolic syndrome15; because of the high level of comorbidity in these
populations and the e↵ectiveness of statins for treating high cholesterol, polypharmacy and
concomitant medication use are very likely among patients who are prescribed statin drugs11.
This is problematic because some statins (i.e. atorvastatin) are significantly metabolized by
the cytochrome P450 (CYP) 3A family of enzymes, namely CYP3A4 and CYP3A55. Ator-
vastatin clearance (around 90%) occurs primarily through CYP3A4, which also metabolizes a
significant portion of other prescription drugs11. When drugs share a metabolic pathway in this
manner, the level of statins circulating in plasma increases as the statin molecules are inhib-
ited from binding with the CYP3A4 enzymes by other drugs, in turn increasing the systemic
exposure of the drug12.
Some examples of drugs that may pose a problem with statins because they are known
inhibitors of CYP3A enzymes are cyclosporine, erythromycin, itraconazole and HIV protease
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inhibitors30. Adverse drug events become much more likely in the context of concomitant
medication use; while rhabdomyolysis is rare the number needed to treat in order to see one
case increases from 1 in 22717 for patients on statin monotherapy to 1 in 1672 for patients
concurrently taking statins and fibrates14. An estimated about 60% of rhabdomyolysis cases in
patients using statin therapy for lipid-lowering are thought to be caused by concomitant drug
use12.
Because atorvastatin is metabolized by CYP3A4, patients taking it are more likely to ex-
perience drug-drug interactions (DDIs) than patients taking rosuvastatin, which is not metabo-
lized before uptake into the liver. In general, the following types of medication tend to a↵ect
plasma concentrations of atorvastatin via CYP3A4 inhibition: cyclosporine, an immunosu-
pressant31; antibiotic medications such as erythromycin and clarithromycin; antifungal drugs
such as itraconazole, ketoconazole and fluconazole; HIV protease inhibitors such as ritonavir,
nelfinavir and indinavir; calcium channel antagonists such as diltiazem and verapamil used for
treating hypertension and arrhythmias; grapefruit juice; and others drugs inhibiting CYP3A4.
From the standpoint of metabolism, rosuvastatin is less likely than atorvastatins to have
DDIs, because it is not metabolized by CYP3A4. However, since it is minimally metabo-
lized by CYP2C9, there is a chance of interactions with drugs that are also metabolized by that
enzyme due to competitve inhibition by other metabolites that interact with this enzyme. Addi-
tionally, drugs that tend to independently cause muscular concerns can interact synergistically
with statins to worsen myalgias15;20;32;12;33.
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1.3.2 Statin-Drug Interactions Involving Drug Transporters
Another avenue for potential DDIs with statin drugs involve competitive inhibition of OATP1B1,
as it is a transporter of many substances besides statin drugs. Substances that are also trans-
ported by OATP1B1 include most bile acids, protease inhibitors, some anti-diabetic medi-
cations, among others34. To this date, approximately 65 substances have been identified as
inhibitors of this drug transporter34. Similar to the mechanism behind CYP3A4-related DDIs
with atorvastatin, when other substances transported by OATP1B1 are present in the body
along with statins, the capacity of the transporter to deliver statins to the liver is decreased, as
OATP1B1 is occupied by the transport of other substances. A detailed list of drugs with the
potential to interact with statin medications can be found in Tables 1.1, 1.2, 1.3 and 1.4.
1.4 Predictive Modelling of Systemic Statin Exposure
Two multiple linear regression models were developed at London Health Sciences Center
(LHSC) by DeGorter et al.23 for the purpose of studying the relationship between patient fac-
tors and statin plasma concentration. Atorvastatin and rosuvastatin were modelled separately
to better account for di↵erences in drug metabolism and transport. Both models controlled for
age, body mass index (BMI), sex, self-reported ethnicity, statin dose, and time since last dose
taken. The atorvastatin predictive model additionally controlled for the plasma concentration
of 4 -hydroxycholesterol.
The covariates of interest found to be significant for predicting the log-transformed ator-
vastatin plasma level included 4 -Hydroxycholesterol (a marker for CYP3A activity), and the
OATP1B1 polymorphisms c.521T>C, and c.388A>G. The variables age, dose, and time since
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last dose were also found to be statistically significant. The covariates of interest found to be
statistically significant for predicting the log-transformed rosuvastatin plasma level included
the polymorphisms SLCO1B1 c.521T>C, and ABCG2 c.421C>A. As in the atorvastatin model,
the variables age, dose, and time since last dose were also found to be statistically significant.
The prediction tool based o↵ of these regression models23 was designed to keep the resultant
statin plasma level below the 90th percentile (as it is expected that 1 in 10 individuals will
experience statin-associated myopathy).
1.4.1 Patient Population
Patient-recruitment and data collection for the project were conducted by DeGorter et al. at the
University ofWestern Ontario . A total of 299 adult dyslipidemic patients (over 18 years of age)
taking a stable dose of atorvastatin or rosuvastatin were recruited and followed prospectively
at the LHSC between August 2009 and May 201123. Of these, 9 patients (3 on rosuvastatin
and 6 on atorvastatin) had statin plasma levels that were undetectable, and so were excluded
from analysis23. Inclusion criteria were that the study subject must have taken their medication
within 24 hours of their last clinic visit and availability of a blood sample, and must not have
been on an alternate-day dosing regime for their statin medications. After providing written
informed consent following approval by the Research Ethics Board of Western University, the
following information was collected: detailed medical history, time of last oral statin dose,
and self-reported ethnicity. Information on plasma statin concentration, LDL-C response, de-
termination of total cholesterol, and genotyping were subsequently obtained through analysis
of a blood sample provided by each patient. For full details on recruitment, sample size, and
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number of patients excluded, refer to DeGorter et al.23.
Table 1.1: Medications potentially impacting statin pharmacokinetics (A-A)
Drug/Class Type HypothesizedDDI Mechanism Source
Amiodarone Antiarrhythmic CYP3A4 Inhibitor 35;36;29;37;15;21
Angiotensin II
Receptor Blocker
Candesartan
Fimasartan
Losartan
Telmisartan
Olmesartan
Valsartan
Antihypertensive
ABCG2 Inhibitor
OATP1B1 Inhibitor
OATP1B3 Inhibitor
38
39
38
40;41
42
43
Antibiotics
Azithromycin
Ciprofloxacin
Clarithromycin
Erythromycin
Telithromycin
Troleandomycin
Antibiotic
CYP3A4 Inhibitor
ABCB1 Inhibitor
OATP1B1 Inhibitor
36;21
36
35;12;36;11;33;41
35;12;36;38;33;41
36;11;33
36
Anticoagulants
Acenocoumarol
Warfarin
Anticoagulant
CYP3A4 Inhibitor
CYP2C9 Inhibitor
OATP16A1 Inhibitor
44
35;12;36;45;21
Antiepileptics
Carbamazepine
Oxycarbazepine
Anticonvulsant CYP3A4 Inducer 35
44
Antidepressants
Fluvoxamine
Fluoxetine
Sertraline
Venlafaxine
Antidepressant CYP3A4 Inhibitor
35;44
35
35;44
35
Antidiabetics
Troglitazone
Pioglitazone
Antidiabetic CYP3A InducerCYP2C9 Inducer
46;35;47
38
Azole Antifungals
Fluconazole
Itraconazole
Ketoconazole
Posaconazole
Antifungal CYP3A4 InhibitorCYP2C9 Inhibitor
29
35;12;36;11;21
35;12;36;11;38;33
35;12;36;38;33
11
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Table 1.2: Medications potentially impacting statin pharmacokinetics (B-E)
Drug/Class Type HypothesizedDDI Mechanism Source
Barbituates
Phenobarbital Anticonvulsant
CYP3A4 Inducer
CYP2C9 Inducer 35
Bile Acids
Glycodeoxycholate
Glycochenodeoxycholate
Taurolithocholate
Bile Acid OATP1B1 Inhibitor 34
Calcium Channel
Antagonists
Amlodipine
Azelnidipine
Benidipine
Diltiazem
Mibefradil
Nicardipine
Nifidipine
Verapamil
Antihypertensive CYP3A4 Inhibitor
48
29
38;41
36
36
12;35;36;33;37;21
35;36;33
38
36
12;35;36;38;15;33
Clopidigrel Anti-platelet CYP3A4 InhibitorCYP2C19 Inhibitor
49
36
Colchicine Anti-gout CYP3A4 Inhibitor 21
Cyclophosphamide Antineoplastic CYP3A4 Inducer 35
Cyclosporine Immunosuppressant
CYP3A4 Inhibitor
OATP1B1 Inhibitor
OATP2B1 Inhibitor
OATP1B3 Inhibitor
NTCP Inhibitor
12;15;33
36;21;35;29
11;38;33;34
Corticosteroids
Dexamethasone Corticosteroid
CYP3A4 Inducer
ABCB1 Inducer
35;50;47
50
Danazol CYP3A4 Inhibitor 33;51
Digoxin Antiarrhythmic ABCB1 Inhibitor 35;36;43;52
Erlotinib Antineoplastic CYP3A4 Inhibitor 36
Estrone 3-Sulfate Hormone OATP1B1 Inhibitor 34
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Table 1.3: Medications potentially impacting statin pharmacokinetics (F-N)
Drug/Class Type HypothesizedDDI Mechanism Source
Fibrates
Bexafibrate
Clofibrate
Fenofibrate
Gemfibrozil
Lipid-Lowering Agent
OATP1B1 Inhibitor
CYP2C9 Inhibitor
CYP2C8 Inhibitor
Glucoronidation Inhibitor
32
12
12
12;36;15;29;19
12;36;15;20;29
11;21
Fexofenadine Antihistamine OATP1B1 Inhibitor 43
Flavenoids
Baicalin
Silymarin
Flavenoid OATP1B1 Inducer
OATP1B1 Inhibitor
53
34
Grapefruit
/Citrus juice Nutrient
CYP3A4 Inhibitor
OATP1B1 Inhibitor
35;36;5;29
21;12;38
Histamine H2
Receptor
Antagonists
Cimetidine
Ranitidine
Antacid CYP2C9 Inhibitor
12
12
HIV Protease
Inhibitors
Amprenavir
Atazanavir
Indinavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir
Antiviral
OATP1B1 Inhibitor
ABCG2 Inhibitor
CYP3A4 Inhibitor
35
21
11;34
12;41;21
36;11;15;54
12;36;41;21
12;36;11;15;54;33
36;21
36
Metformin Antidiabetic ABCC2 Inhibitor 55
Midazolam Sedative CYP3A4 Inhibitor 35
Nefazodone Antidepressant CYP3A4 InhibitorCYP2C9 Inhibitor
36;35;12;33;29;21
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Table 1.4: Medications potentially impacting statin pharmacokinetics (P-Z)
Drug/Class Type HypothesizedDDI Mechanism Source
Phenytoin Anticonvulsant CYP3A4 InducerCYP2C9 Inducer
35;36;44
Proton Pump
Inhibitor
Esomeprazole
Omeprazole
Antacid ABCB1 Inhibitor
CYP3A4 Inducer
56
12;35;38;56
Repaglinide Antidiabetic OATP1B1 Inhibitor 43;57
Rifamycins
Rifampicin
Rifamycin SV
Antibiotic
CYP3A4 Inducer
General CYP Inducer
OATP1B1 Inhibitor
33;58;35;36;59
34
Sitagliptin Antidiabetic CYP3A4 Inhibitor 60;61
Sirolimus Immuno-suppressant CYP3A4 Inhibitor
44
Sulfonamides
Sulfaphenazole
Sulphamethoxazole
Antibiotic CYP2C9 Inhibitor 35
44
Tacrolimus Immunosuppressant CYP3A4 Inihibitor 35
36
Tamoxifen Antineoplastic CYP3A4 Inhibitor 35
Vitamin B3
(Niacin) Nutrient OATP16A1 Inhibitor
12;29;62;5
Vitamin D Nutrient CYP Inducer 62;63
Warfarin Anti-coagulant
CYP2C9 Substrate
CYP 3A4 Substrate
OATP16A1 Inhibitor
35;12;36;45;21
Zafirlukast Anti-asthmatic CYP3A4 Inhibitor 44
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Chapter 2
Rationale and Objectives
To best predict systemic exposure of atorvastatin and rosuvastatin, multiple linear regression
models were used that control for a variety of patient factors including genetic polymorphisms
in statin transporters and enzymes involved in their metabolism1. Although studies using the
separate regression models for atorvastatin and rosuvastatin explained a large portion of the
model variance (47% and 56% respectively)1, there is still room for improving the fit of these
models to better predict systemic exposure. We hypothesize that the systemic exposure mod-
els could be improved by both incorporating additional patient factors, and using non-linear
modelling techniques to achieve a closer fit to the data.
The predictive model currently used to predict systemic exposure of statins does not include
concomitant medications2. Given the wide range of comorbidities that are often present with
hypercholesterolemia, most patients in this population will be prescribed concomitant medi-
cations that may interact with drug transporters or drug metabolizing enzymes and therefore
a↵ect drug exposure. Because of the concomitant medications that patients with hypercholes-
terolemia will be prescribed, there is an increased likelihood of drug interactions within this
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population that could be used to predict systemic statin exposure. From a modelling perspec-
tive, the wide range of medicines that could be co-prescribed with statins poses an additional
challenge of potentially having far more medications to account for than patient observations
when training and validating models to predict statin plasma concentration. Importantly, ator-
vastatin has the potential to interact with many di↵erent commonly prescribed medications
because of its pharmacokinetic properties, so creating a well-performing predictive model that
incorporates information about concomitant medication use has the potential to improve the
current systemic exposure model with potential clinical implications. In order to ameliorate
the problem of having many potential relevant medications to include in a predictive model
versus a relatively small sample size, feature selection algorithms can be adapted to take ad-
vantage of substantive subject knowledge in order to create robust selection criteria despite
relatively few observations with which to train models.
In contrast, rosuvastatin undergoes very little metabolism before performing its intended
action in the liver, and so metabolic drug interactions are of less concern for this modelling
application3. Instead, thoroughly assessing genetic variation in patient drug transporters may
be more relevant to the problem of predicting rosuvastatin plasma concentration in a clinical
setting. It is possible that identifying additional genetic markers through the use of Next Gen-
eration Sequencing (NGS) of DNA from patients who have rosuvastatin plasma concentrations
substantially higher than predicted by the original regression model (under-predicted patients)
could account for additional variance in the rosuvastatin cohort, as it is less likely that including
concomitant medications will cause substantial improvement in model fit for this group.
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2.1 Research Objectives
The overarching goal of this thesis is to improve the predictive quality of previously developed
regression models in the context of predicting statin systemic exposure. Improving predictive
quality will be achieved by better accounting for model variance such that the predicted sys-
temic exposure values are closer to the true systemic exposure values for each patient. This
will be accomplished by two strategies: 1) identifying additional clinical factors that improve
the predictive model fit quality; and 2) assessing modelling techniques beyond linear regres-
sion that can incorporate non-linear trends in the data. The two strategies can be further broken
down into three main objectives:
2.1.1 Objective 1
• Adapt existing feature selection techniques for selecting concomitant medications rele-
vant to the problem predicting atorvastatin and rosuvastatin plasma concentration; the
new algorithm must be suitable for use with small datasets in which the number of fea-
tures is much larger than the number of patient observations
• Assess the impact of the selected concomitant medications on the linear model fit for
the atorvastatin and rosuvastatin patient cohorts, in comparison to the fit of the original
systemic statin exposure model using the patient cohorts used to fit the original systemic
exposure model
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2.1.2 Objective 2
• Select and implement appropriate non-linear modelling techniques to explore the e↵ect
of incorporating non-linearity into the atorvastatin and rosuvastatin predictive models for
statin systemic exposure
• Characterize the practical requirements and feasibility of achieving good model fit using
these methods for guiding atorvastatin and rosuvastatin dosing in the context of predict-
ing systemic exposure in order to minimize adverse drug events
2.1.3 Objective 3
• Develop selection criteria to identify rosuvastatin patients with severely under-predicted
statin plasma concentrations based on the original systemic exposure model, as well as
well-predicted controls; gather and process next generation sequencing data from the
identified case and control groups
• Describe the process and analytic/software requirements for cleaning and formatting next
generation sequencing information from a data-science perspective
• Identify and apply an appropriate variant prioritization method to select relevant genes
for further biological analysis
This dissertation is presented in integrated article format, with separate background chap-
ters for each substantive clinical research topic. There are a total of seven chapters. Chapter
1 gave an overview of the use of statins for hypercholesterolemia, potential adverse events
associated with statin treatment, and the mechanisms by which statins are metabolized and
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transported to the liver. A narrative review of the literature on concomitant medication use
with statins is also presented. Chapter 2 outlines the main research objectives and organiza-
tion of this thesis. Chapter 3 provides background on linear regression modelling and feature
selection techniques; the concomitant medication selection algorithm is described, as well as
results from the selection and linear modelling of concomitant medications for atorvastatin and
rosuvastatin. Chapter 4 provides background information on two popular statistical techniques
that are capable of modelling non-linear relationships in data. The implementation and results
of these methods are described and compared to the fit of the original systemic exposure pre-
diction model. Emphasis is placed on the practical aspects of implementing these techniques
for clinical use, particularly with respect to tuning the models and choosing the best possible
model parameters for each method. Chapter 5 is a background chapter giving an overview
of the process of Next Generation Sequencing (NGS), methods for e↵ective phenotype-based
patient sampling, and available techniques for variant selection and prioritization. Chapter 6
characterizes the selection criteria for choosing patients to undergo genetic sequencing, as well
as characteristics of the data obtained from this process. It also contains the workflow for pro-
cessing the NGS data for this clinical modelling problem, as well as genes identified as relevant
by the analysis technique chosen. Chapter 7 provides a summary of the key findings, strengths
and limitations of this thesis. Implications of the findings described herein are also discussed,
as well as future directions for this research.
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Chapter 3
Modelling Atorvastatin and Rosuvastatin
Plasma Concentration Using Selected
Concomitant Medications
3.1 Introduction
Increased systemic exposure to statin drugs is thought to be a risk factor for the development
of myalgia (muscle pain) in patients with hypercholesterolemia participating in lipid-lowering
therapy1.
Concomitant medications are an important consideration when modelling systemic expo-
sure of statins as these interactions have the potential to increase systemic exposure. A common
side-e↵ect of statin treatment for hypercholesterolemia is myalgia; this is thought to be related
to the concentration of statins in blood plasma, which can be a↵ected by the concomitant in-
gestion of many di↵erent substances. Because hypercholesterolemia tends to cluster with other
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chronic illnesses and medications are often prescribed for these comorbid conditions, Drug-
Drug Interactions (DDIs) are likely in the context of statin treatment for hypercholesterolemia.
Advances have been made in previous work to establish an accurate model to predict statin
plasma concentration2; however, concomitant medications were not taken into account in these
models. Incorporating concomitant medications which have the potential to impact systemic
statin exposure has a high potential to increase accuracy in this context. Establishing the most
accurate model possible for predicting systemic exposure is an important problem, since it
could in future be used to guide statin dosing with the goal of minimizing adverse events such
as myalgia.
3.2 Methods: Linear Regression and Feature Selection
3.2.1 Linear Regression
In linear regression we seek to use the values of one or more independent (predictor) variables
to predict the value of an outcome variable. For example, we could use a patient’s age, sex
and BMI to try to predict heart rate. We could then construct a model from an existing data
set, and then use this model to predict heart rate values for future patients. This is often done
via Ordinary Least Squares (OLS), which weights each variable according to its relation to
the outcome variable while minimizing the resulting magnitude of the error of the predicted
values compared to the observed outcome values. This is also useful because it allows us to
make inferences about the relationship between the independent (predictor) variables and the
dependent (outcome) variable. For an outcome variable y and a matrix of predictor variables
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X, our predictions would take the form: yˆ = X ˆ. For this simple example, the residuals (error)
that we are trying to minimize would take the form (y   X )2. OLS computes weights   for
each predictor variable as follows:
yˆ = argmin
 
ky   X k22.
In our specific example predicting heart rate (HR) using multiple covariates, the predictions
would take the following form:
HˆR =  0 +  1 ⇥ age +  2 ⇥ sex +  3 ⇥ BMI.
3.2.2 Variable Selection
Often in clinical modelling applications, we have the choice of including many di↵erent types
of information in regression models and predictive models in general. Some examples of types
of information that could be used in clinical modelling include demographic data such as age,
sex, ethnicity, and marital status; clinical measurements like blood pressure, heart rate, respira-
tion; laboratory results like plasma concentrations of drugs or endogenous biomarkers of organ
function; waveform and longitudinal signal data from instruments monitoring the patient; and
genetic information. It is sometimes tempting to include as much information as possible in a
model to give the best predictions, but this can lead to several pitfalls: including unnecessary
covariates in models can add noise which decreases the accuracy of the predictive model, it
can be di cult to interpret models with a very large number of covariates3, and unique mod-
elling challenges arise when there are more covariates than data observations in the data set to
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be modelled. Additionally, using all possible covariates becomes problematic if they are not
routinely available, are hard to collect, or frequency contain missing data. For these reasons,
it is often desirable to perform feature selection to prune the possible model covariates to only
include those most relevant to the prediction problem at hand. A commonly seen example of
this occurs in clinical pharmacogenetics where thousands of candidate single nucleotide poly-
morphisms (SNPs) may be tested for associations with di↵erences in drug metabolism between
patients. If we want to include information about a patient’s ability to metabolize a particular
drug based on their genetic information, we want to include at most a few di↵erent SNPs, and
not the whole array of candidate genes. Many feature selection methods exist for the purpose
of cutting out variables that don’t add predictive value to models by selecting a subset of the
covariates to include in the model. Some of these include best-subset selection, forward- and
backward- stepwise selection, forward-stagewise selection3, penalized regression, the lasso
and group lasso, and more generally, composite absolutely penalties (CAP) used in regres-
sion4.
Best-Subset Selection
Best-subset selection chooses a subset of size k 2 {1, ..., p} from the p available covariates by
exploring all possible subsets of this size and picking the one with the smallest residual error.
The choice of the size of the subset size k must be determined by the user; this is usually done
to balance bias and variance while maintaining the desired sparsity of the model. Additionally,
smaller models are not necessarily subsets of larger models in this framework: a subset of
size two may not include the same variables found in a subset of size one3. This can make
interpretation di cult within the context of the model that is chosen. Amajor downside of best-
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subset selection is that it is limited to datasets that only have a moderate number of variables,
because it must search through all possible combinations of the covariates to find the best
model for each k. Even with an e cient algorithm to speed the selection process, for datasets
with more than 30 or 40 variables the computational time required becomes prohibitive3.
Forward- and Backward-Stepwise Selection
In contrast, forward- and backward-stepwise selection proceed sequentially from either the
model with only the intercept and no covariates for forward-stepwise selection, or from the full
model including all of the possible covariates for backward-stepwise selection. For forward-
stepwise selection, the variable with the most impact on the model fit is added at each step
k, where k corresponds to the size of the subset. Similarly, for backward-stepwise selection
the variable that contributes the least to the model fit is removed from the pool of candidate
variables at each step k 3. The resulting output of these procedures is a set of nested models
indexed by k, the number of covariates included in the model. Although this may seem less
thorough than looking through all of the possible models of each size and choosing based on
residual error, stepwise selection procedures have the advantage of being applicable to datasets
with a very large number of variables. Additionally, because fewer candidate models are being
compared in terms of error, model variance is reduced (although bias may be increased)3. A
variant of this procedure is called Forward-Stagewise selection, and is a constrained version
of forward-stepwise selection in the sense that the overall model fit does not change when
additional variables are added. At each step in the selection procedure, the model adds the
variable to the model that is most correlated with the current model residual; the value given
to this variable in the model is found by computing the simple linear regression coe cient for
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this model and the current residual and adding that to the variable’s current coe cient value.
Instead of only computing k model fits, forward-stagewise selection continues until none of the
variables are correlated with the residuals. This means that it takes longer to reach the best-
fitting model, but the procedure has computational advantages over stepwise selection methods
when the number of variables to choose from becomes increasingly large3.
Penalized Regression and the Lasso
Another method for selecting variables to include in a model is by modelling all of the candi-
date variables using regression and then shrinking the coe cients using a penalty term. The
resulting regression estimates are smaller and some are shrunk to the point where they have a
value of 0; those variables are then discarded. This is usually done by including a penalty term
in the regression that penalizes the size of the coe cients. These models have the advantage of
reducing the variance of the model estimates that can be problematic in ordinary least squares
(OLS) models. Excessive variance is especially a problem when the number of variables far
exceeds the number of available observations (ie. p >> n). The lasso5 is an example of a
penalized regression model capable of variable selection, and is defined as
 ˆ  = argmin
 
n
1
2ky   X k22 +  k k1
o
.
The `1 norm is used to penalize the coe cients in the lasso, and minimizes the size of
the absolute di↵erences. Looking at the geometry of this norm can help to clarify the e↵ect:
instead of travelling along the diagonal of a grid, the `1 norm only moves in the horizontal
and vertical directions. This can be likened to a taxicab navigating a grid of streets instead of
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travelling to the destination as the crow flies6.
The lasso is a popular example of a bridge regression model, in which a general `  norm
penalty with   values ranging from 0 to 1 may be applied to the model coe cients. The
general form of the bridge penalty is7
T ( ) =
26666664 pX
j=1
| | 
37777775
1
 
= k k  .
The lasso is a special case of bridge regression (  = 1), which has attractive computational
properties for optimization and the regularization path is piecewise linear7. It is also special in
that it can be formulated to calculate the full regularization path in a single step via Least Angle
Regression (LARS)8. LARS was in part inspired by forward-stagewise regression, which is re-
flected in the algorithm that computes the full regularization path. Similar to forward-stagewise
regression, LARS begins with the model including only the intercept. At each step, it chooses
the variable that is most correlated with the current residual; however, instead of only moving
a short distance in that direction, LARS takes the largest step possible in that direction until it
encounters another variable that is just as correlated with the current residual. Once the other
variable is encountered, the direction of the solution path changes, and continues in the direc-
tion equiangular to both predictors. This method is then repeated and the direction changes at
each step to be equiangular with all of the variables seen up until that point. The procedure is
complete when all variables are included in the model8.
38 Chapter 3. Modelling Statin Plasma Concentration with Concomitant Medications
Composite Absolute Penalties (CAP) and the Group Lasso
Composite Absolute Penalty (CAP) models are a general type of penalized regression model
(of which bridge regression is an example), but importantly allow for hierarchical variable
selection. Models of this type allow for prespecified groups of variables (such as sets of dummy
variables, or variables that naturally cluster together, like genomic protein expression data9) to
enter the model simultaneously and can also encourage variables entering the model together
to have coe cients with similar absolute values, depending on the penalties used. A common
example of a hierarchical CAP model is the group lasso. Given an n ⇥ p design matrix X, an
n⇥ 1 binary response variable y, and a vectorG of group indices of length k, the group lasso is
defined as4:
 ˆ = argmin
 
8>><>>: 12ky   X k22 +   KX
k=1
k Gkk2
9>>=>>; .
The group lasso uses a hybrid `1/`2 penalty; instead of encouraging overall sparsity as in the
lasso, groups are encouraged to enter the model sparsely while individual features in the groups
included in the model are not penalized from inclusion in the model. In e↵ect, this form of the
group lasso performs feature selection at the level of factors, or clusters of features. CAP
models generalize this type of feature selection by allowing di↵erent types of penalties to be
applied across di↵erent groups, while maintaining an overall penalty. As described by Zhao et
al.7, the CAP model is constructed by designating Gk groups within the design matrix X with
regression targets y and coe cients  , where k = 1, . . . ,K denotes the group index. Generally
these groupings are constructed to reflect the natural grouping structure of the covariates. For
each groupGk we calculate coe cients  , and then take the norm Nk of the coe cients for this
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group, where:
Nk = k Gkk k
The norms from each group are then aggregated into a K-dimensional vector N = N1, . . . ,NK ,
and then the CAP penalty is calculated using the following formula7:
T ( ) = kNk 0 0 =
X
k
|Nk| 0
and the corresponding CAP estimate is given by:
 ˆ( ) = argmin
 
X
i
L(Yi, Xi,  ) +   · T ( )
where L represents the loss function (often squared loss or logistic loss), and T is a CAP
penalty.
An advantage of the Lasso and CAP penalties in general for this type of research is that
they are primarily meant to be used in the context of predictive modelling, which makes it ap-
propriate for this particular research problem. This is not necessarily true of forward selection,
for which model fit is not directly motivated by prediction quality.
3.3 Linear Regression Models for Predicting Systemic
Exposure of Statins
The current analyses are based on the original model predicting statin systemic exposure by
DeGorter et al. described in Section 1.4. The dataset used for this analysis is limited to a subset
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of patients and covariates that were used to train the final linear models in the original prospec-
tive cohort study (rosuvastatin n = 130; atorvastatin n = 128). The outcome of the original
dose model is log plasma concentration, as in the original model2; looking at log plasma con-
centration is a relatively common practice in clinical pharmacology. Patient characteristics in
the atorvastatin and rosuvastatin cohorts used for analysis in the current work are presented in
Tables 3.1 and 3.2 respectively. Patients did not overlap between the two groups.
Table 3.1: Population characteristics of atorvastatin-prescribed prospective cohort (n = 128)
Patient Characteristic Mean/Proportion SD/Percentage
Age (years) 59.2 13.0
Body Mass Index (kg/m2) 29.1 5.3
Time Pose Dose (hours) 13.0 5.0
4 -Hydroxycholesterol (ng/mL) 21.1 12.9
No. Concomitant Medications 6.7 3.3
Statin Dose
10 (mg) 21 16.4%
20 (mg) 30 23.4%
40 (mg) 54 42.2%
60 (mg) 1 0.8%
80 (mg) 22 17.2%
Sex (Male=1) 78 60.9%
Ethnicity (Non-Caucasian=1) 20 15.6%
Minor Allelic Frequency
OATP1B1 c.521C 29/256 11.3%
OATP1B1 c.388G 113/256 44.1%
3.3.1 Reassessment of the Original Statin Systemic Exposure Model
In order to more easily compare model fit quality between the original systemic exposure model
and models that are developed in the current work, we replicated the original models to obtain
the standardized coe cient estimates and confidence intervals (shown in Tables 3.3 and 3.4).
For the replicated original linear regressions, five-fold cross-validation (CV) was performed
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Table 3.2: Population characteristics of rosuvastatin-prescribed prospective cohort (n = 130)
Patient Characteristic Mean/Proportion SD/Percentage
Age (years) 56.9 12.9
Body Mass Index (kg/m2) 30.4 7.1
Time Pose Dose (hours) 13.6 3.4
No. Concomitant Medications 6.5 3.4
Statin Dose
5 (mg) 20 15.4%
10 (mg) 38 29.2%
15 (mg) 1 0.8%
20 (mg) 36 27.7%
30 (mg) 2 1.5%
40 (mg) 33 25.4%
Sex (Male=1) 90 69.2%
Ethnicity (Non-Caucasian=1) 21 16.2%
Minor Allelic Frequency
OATP1B1 c.521C 49/260 18.8%
ABCG2 c.421A 25/260 9.6%
to calculate Adjusted R2, RMSE and AIC for both atorvastatin and rosuvastatin, in order to
more easily compare them to the models subsequently developed in this thesis. The CV results
for the original models are shown in Table 3.5 The adjusted R2 for the atorvastatin model
was 0.47 (n = 128); of this, the genetic component comprised only 38% of the explainable
variability. The adjusted R2 for the rosuvastatin model was higher than that of the atorvastatin
model: R2 = 0.56 (n = 130), with the transporter gene polymorphisms accounting for 88% of
the explainable variability in this model, in contrast to the much lower value in the atorvastatin
model.
Table 3.5: Original linear regression models CV performance results
Model Adjusted R2 ( ± SD) RMSE (± SD) AIC ( ± SD)
Atorvastatin 0.47 ± 0.03 21.06 ± 10.10 246.07 ± 7.88
Rosuvastatin 0.56 ± 0.03 16.13 ± 4.34 198.69 ± 7.87
Because so few unique values of dose were seen within the patient populations for atorvas-
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Table 3.3: Atorvastatin regression with original covariates (n=128)
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.473 -1.752 to 0.806 0.466
OATP1B1 c.521T>C 0.339 0.055 to 0.624 0.020 *
OATP1B1 c.388A>G -0.278 -0.485 to -0.072 0.009 **
Age (yr) 0.018 0.007 to 0.029 0.002 **
4 -Hydroxycholesterol -0.015 -0.026 to -0.005 0.006 **
Dose (mg) 0.021 0.014 to 0.027 <0.001 ***
Time from last dose (hr) -0.089 -0.117 to -0.062 <0.001 ***
Body Mass Index (kg/m2) 0.025 -0.002 to 0.052 0.065 .
Sex (Male = 1) 0.132 -0.149 to 0.412 0.355
Ethnicity (Non-Caucasian = 1) 0.295 -0.094 to 0.684 0.136
Table 3.4: Rosuvastatin regression with original covariates (n=130)
Estimate Confidence Interval P-Value Sig.
(Intercept) 0.544 -0.286 to 1.373 0.197
OATP1B1 c.521T>C 0.425 0.233 to 0.618 <0.001 ***
ABCG2 c.421C>A 0.301 0.043 to 0.559 0.023 *
Age 0.012 0.004 to 0.02 0.005 **
Dose (mg) 0.048 0.039 to 0.056 <0.001 ***
Time Post Dose (hr) -0.06 -0.092 to -0.029 <0.001 ***
Body Mass Index (kg/m2) -0.01 -0.025 to 0.005 0.179
Sex (Male = 1) -0.159 -0.396 to 0.078 0.186
Ethnicity (Non-Caucasian = 1) 0.051 -0.241 to 0.342 0.732
tatin and rosuvastatin, the original regressions were also replicated with dose represented as a
categorical variable. In order to perform this analysis a single patient on an outlying dose of
atorvastatin (60mg) was removed to facilitate CV performance evaluation (final n =127). No
other obvious outlying characteristics besides dose level were present for this patient. When
dose was represented categorically instead of as a continuous variable, the Adjusted R2 in the
atorvastatin model increased from 0.474 to 0.488. To test whether this di↵erence was due
solely to the lowered variance from removing the patient with the outlying dose, a regression
model with dose as continuous was conducted using the reduced atorvastatin dataset (shown
in Table 3.6). Note that the models are nested in this case, as the continuous-dose linear model
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is nested within the categorical dose model. As such, the linear dose-encoding model could
be replicated in the continuous covariate paradigm with the correct coe cients. When the
reduced continuous-dose model was compared to the categorical dose model with the same pa-
tient population, the change in model fit due to representing dose categorically was statistically
significant (Adjusted R2=0.458 to 0.488, F(2, 115)=4.375, p=0.015). Given that the amount of
variance accounted for the model was reduced by removing the patient with the outlying dose,
it appears likely that the improvement in model fit was caused by the change in representation
of dose from continuous to categorical. For this reason, atorvastatin doses will be represented
categorically in the models subsequently developed in the current work.
Table 3.6: Atorvastatin regression with dose-outlying patient removed and dose as continuous
(n=127)
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.485 -1.749 to 0.78 0.449
OATP1B1 c.521T>C 0.356 0.074 to 0.637 0.014 *
OATP1B1 c.388A>G -0.287 -0.491 to -0.083 0.006 **
Age (yr) 0.017 0.006 to 0.028 0.003 **
4 -Hydroxycholesterol (ng/mL) -0.014 -0.025 to -0.004 0.009 **
Dose (mg) 0.02 0.014 to 0.026 <0.001 ***
Time from last dose (hr) -0.084 -0.112 to -0.057 <0.001 ***
Body Mass Index (kg/m2) 0.024 -0.003 to 0.05 0.076 .
Sex (Male = 1) 0.164 -0.115 to 0.444 0.246
Ethnicity (Non-Caucasian = 1) 0.291 -0.094 to 0.676 0.137
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Table 3.7: Atorvastatin regression with dose-outlying patient removed and dose as categorical
(n=127)
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.435 -1.661 to 0.79 0.483
OATP1B1 c.521T>C 0.402 0.126 to 0.678 0.005 **
OATP1B1 c.388A>G -0.213 -0.417 to -0.008 0.042 *
Age (yr) 0.017 0.006 to 0.028 0.002 **
4 -Hydroxycholesterol (ng/mL) -0.015 -0.026 to -0.005 0.005 **
Dose (20mg) 0.718 0.259 to 1.178 0.002 **
Dose (40mg) 1.154 0.742 to 1.566 <0.001 ***
Dose (80mg) 1.615 1.141 to 2.089 <0.001 ***
Time from last dose (hr) -0.082 -0.109 to -0.055 <0.001 ***
Body Mass Index (kg/m2) 0.015 -0.011 to 0.041 0.263
Sex (Male = 1) 0.076 -0.202 to 0.355 0.587
Ethnicity (Non-Caucasian = 1) 0.189 -0.194 to 0.572 0.330
Similarly, very few unique values were seen between patients with respect to rosuvastatin
dose; the most commonly seen doses were 5 mg (n=20; 15.4%), 10 mg (n=38; 29.2% ),
20 mg (n=36; 27.7%) and 40 mg (n=33; 25.4%). Only one patient in the dataset used to
train the original systemic exposure regression model was on a dose of 15 mg, and only two
patients were on a dose of 30 mg. In order to be able to represent dose as a categorical variable
instead of a continuous variable (as was done in the original regression model), these three
patients were excluded from all future analysis in the current work. No other obvious outlying
characteristics besides dose level were present for these patients. When dose was represented
as a categorical variable instead of a continuous variable, the amount of explained variance in
the model (adjusted R2) increased from 0.562 to 0.635. To tested whether this change in model
fit was due to decreased variance as a result of taking out the three patients with outlying doses,
the regression was also performed on the reduced rosuvastatin cohort with the dose represented
continuously. The adjusted R2 of the original model with the reduced cohort was 0.561; this
was found to be a statistically significant improvement in model fit when compared to the
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categorical-dose regression model with the same patient cohort (F(2, 116)=12.662, p < 0.001).
Table 3.8: Rosuvastatin linear regression with original covariates excluding dose outliers
Estimate Confidence Interval P-Value Sig.
(Intercept) 1.069 0.066 to 2.072 0.037 *
OATP1B1 c.521T>C 0.442 0.241 to 0.643 <0.001 ***
ABCG2 c.421C>A 0.296 0.036 to 0.557 0.026 *
Age 0.013 0.004 to 0.021 0.004 **
Dose (mg) 0.047 0.039 to 0.056 <0.001 ***
Time Post Dose (hr) -0.059 -0.091 to -0.027 <0.001 ***
BMI (kg/m2) -0.01 -0.025 to 0.005 0.186
Sex (Male = 1) -0.126 -0.369 to 0.116 0.305
Ethnicity (Non-Caucasian = 1) 0.005 -0.296 to 0.305 0.976
Table 3.9: Rosuvastatin regression with original covariates excluding dose-outliers and dose as
categorical (n=127)
Estimate Confidence Interval P-Value Sig.
(Intercept) 0.32 -0.454 to 1.093 0.415
OATP1B1 c.521T>C 0.398 0.213 to 0.583 <0.001 ***
ABCG2 c.421C>A 0.341 0.102 to 0.58 0.006 **
Age 0.013 0.005 to 0.021 0.002 **
Dose (10mg) 0.852 0.544 to 1.161 <0.001 ***
Dose (20mg) 1.429 1.117 to 1.741 <0.001 ***
Dose (40mg) 1.999 1.677 to 2.321 <0.001 ***
Time Post Dose (hr) -0.058 -0.087 to -0.029 <0.001 ***
BMI (kg/m2) -0.012 -0.026 to 0.002 0.086 .
Sex (Male = 1) -0.179 -0.402 to 0.043 0.114
Ethnicity (Non-Caucasian = 1) -0.069 -0.345 to 0.207 0.62
3.4 Selection Algorithm
A substantial challenge in choosing concomitant medications for inclusion in a predictive
model for statin plasma concentration is the fact that there are many more potential medi-
cations to choose from than available patient observations. In the setting when the number of
features p is much greater than the number of observations n ((ie. p >> n), leveraging informa-
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tion shared between covariates can help to improve feature selection and the resulting model
fit. In the setting of concomitant medication selection, shared information between individual
drugs can be represented as a grouping of generic medication names based on drug function or
primary method of action. In order to leverage this information, an ontology mapping generic
medications to their corresponding classes of drug function was created by two clinical phar-
macologists in the Division of Clinical Pharmacology at Western University; disagreements on
generic medication classification were discussed until the experts came to an agreement of the
most likely use case based on what the drugs are usually prescribed for in terms of primary
and secondary uses. Because medications can have multiple uses or mechanisms of action, the
ontology created for this analysis was specific to the context of medication uses most likely to
be relevant to comorbidities associated with hypercholesterolemia.
The group lasso is a classic example of this type of modelling method that leverages shared
information between covariates in the model (a more detailed overview is provided in Chapter
3.) In the current application, the generic medications to choose from would be labelled as
belonging to a medication class as specified in the ontology. However, this method did not
give very informative results compared to performing separate analyses for generic medica-
tion names, and the generic medications re-coded to correspond to their respective medication
classes. At a high level, the group lasso penalizes individual groups from entering the model
(having a non-zero coe cient), but once a group - or in this context, class of medications - has
come into the model, the individual medications within the medication class are not penalized
from entering. Because the group lasso does not encourage sparsity within groups, the output
of the model does not necessarily indicate which medications within a particular class are driv-
ing the association with statin plasma concentration. Since the mapping between individual
3.4. Selection Algorithm 47
generic medications and medication classes could change depending on the substantive clini-
cal research topic, having a model that chooses generic medications only while still leveraging
the information about medication classes specific to the modelling application is more useful
for this application than relying on a classification scheme that is not universally applicable.
To take this into account, the medication class information was used in the decision criteria for
choosing individual generic medications without being included in the final selection output.
A number of standard methods of feature selection were described earlier in this chapter.
Unfortunately, many of these methods lack stability when used on datasets with few patient ob-
servations, such as many of those seen in clinical pharmacology applications. The advantage
of using such feature selection techniques is that many have e cient existing implementations
that are capable of handling a large number of covariates. While the group lasso was not an op-
timal method for this modelling problem, the plain lasso is a powerful tool; its full solution can
be calculated instead of having to work over a grid of possible shrinkage parameters. In order
to combat the instability of using the lasso on such a small data set, a resampling method sim-
ilar to the bootstap was used to determine which concomitant medications should be assessed
for predictive ability in a linear regression model with the original model covariates. In each
repetition of the selection algorithm, the dataset was randomly divided into five folds for the
purposes of CV to choose the optimal value of shrinkage for the lasso, the penalized regression
method used to select concomitant medications. Five-fold CV was used instead of ten-fold be-
cause of the prohibitively small size of the dataset; five-fold CV also allowed a greater number
of potential permutations than leave-one-out CV (LOOCV). For each repetition, the variables
in the active set were recorded; the active set contains all of the variables with non-zero co-
e cients in the lasso output for the shrinkage parameter   chosen via CV with the specific
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random permutation sampled for that repetition. The resampled penalized regression protocol
was repeated 1000 times.
The decision criteria used the proportion of times a coe cient for a particular medication
was non-zero in the resampling process to determine whether it would be included in the pre-
dictive model. Generic medications that were present in a greater proportion of model selection
repetitions than the designated selection threshold were automatically included in the set of co-
variates to be put in the final model. The rationale for this is that if a generic drug enters the
model more often than the threshold, it is relatively good evidence that it should be selected for
inclusion in the final predictive model, because the model including all of the generic drugs is
much noisier than the medication class model, given the number of variables to choose from.
Generic medications with non-zero proportions of inclusion in the resampling process were
also selected for inclusion in the model if their respective medication classes were present in a
greater proportion of models than the designated threshold. Choosing based on the medication
class o↵ers more power because there are fewer categories to choose from, and thus a clearer
signal for the detection of relevant model covariates. The full mapping of generic medications
to their corresponding functional classes can be found in Appendix A.
3.5 Concomitant Medication Selection Results
3.5.1 Concomitant Medications in the Prospective Cohort
A full table of the concomitant medications taken by the patients in the atorvastatin and rosu-
vastatin prospective cohorts can be found in Tables A.2, A.4, A.5, A.6 and A.7. On average,
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patients in the atorvastatin cohort had 6.734 (± 3.259) concomitant medications. Patients in
the rosuvastatin cohort had 6.485 (± 3.406). 52 generic medications of 132 total were re-
moved from further analysis in the atorvastatin concomitant medication selection process; 49
were removed because they were only taken by one person in the atorvastatin cohort (singleton
medications), and 3 drugs were removed because the drug name originally used in the patient
chart could not be matched with a generic equivalent. In the rosuvastatin cohort 71 of 157
total concomitant medications were removed because they were singleton medications, and 2
were removed because the drug originally named in the dataset could not be identified with a
generic equivalent. The full list of concomitant medications present in both cohorts is presented
in Appendix A.
3.5.2 Atorvastatin
To decide on inclusion of concomitant medications for the models predicting atorvastatin
plasma concentration, we conducted five-fold CV on the resulting linear models with the se-
lected medications included, as well as the covariates from the original regression model; this
process was repeated 100 times. Adjusted R2, RMSE and AIC were calculated by averaging
over the 500 resulting folds from the linear regressions including the medications selected at
thresholds of 90%, 95% and 99% (Table 3.10). Based on a cuto↵ proportion of concomitant
medications being represented in at least 99% percent of the models in the selection procedure,
the following generic drugs were selected for inclusion in the atorvastatin predictive model:
acetylsalicylic acid, atenolol, candesartan, diclofenac, digoxin, esomeprazole, gliclazide, glu-
cosamine, levothyroxine, losartan, metformin, misoprostol, nifedipine, tamsulosin, valsartan,
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and venlafaxine. When the threshold was lowered to 95% inclusion, hydrochlorothiazide was
also selected. When the threshold was further lowered to 90%, Vitamin B3 was added to
the concomitant medications selected for inclusion. Restricting the number of covariates in
a predictive model is generally desirable for decreasing noise and increasing power, however
using a less conservative selection in this context gives us the opportunity to look at biological
mechanisms for all potential relevant interactions between atorvastatin plasma concentration
and concomitant medications. Because the RMSE and AIC were so similar for all thresh-
olds tested, medications selected in 90% or more of the models in the concomitant medication
selection procedure will be included in subsequent predictive models in the current work.
Table 3.10: Atorvastatin selection threshold cross-validation results
Threshold Adjusted R2 RMSE AIC
90% 0.652 ± 0.030 20.376 ± 8.627 211.752 ± 8.028
95% 0.643 ± 0.030 19.524 ± 8.773 213.655 ± 7.811
99% 0.645 ± 0.029 19.122 ± 8.666 212.333 ± 7.419
3.5.3 Rosuvastatin
Ranitidine was the sole medication selected by the concomitant medication algorithm for in-
clusion in the rosuvastatin regression model. The dearth of concomitant medications relevant
to rosuvastatin plasma concentration in this context is unsurprising given that rosuvastatin un-
dergoes minimal metabolism before performing its intended action in the liver. Ranitidine was
the only medication selected for all threshold values above 90%, and as such was included in
the concomitant linear regression analysis without further selection protocols.
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3.6 Linear Regression With Concomitant Medications
3.6.1 Atorvastatin
When the medications chosen by the selection algorithm were included in a standard linear re-
gression model of atorvastatin plasma concentration along with the original model covariates,
the adjusted amount of variance accounted for in the model (adjusted R2) was significantly
increased from 0.488 to 0.649 (F(18, 97) = 3.940, p < 0.001). When the concomitant medica-
tions were added to the model, the e↵ect of OATP1B1 c.388A>G was attenuated compared to
its e↵ect with only the original covariates included, although the confidence interval was too
wide to achieve statistical significance ( ˆ = -0.141, 95% CI = -0.343 to 0.061, p > 0.05). As in
the model with the original covariates, all dose categories, age and time post dose were signifi-
cant predictors of atorvastatin concentration; BMI, sex and ethnicity remained not statistically
significantly associated with atorvastatin plasma concentration.
Losartan, metformin and tamsulosin were found to be statistically significant predictors of
atorvastatin plasma concentration. Specifically, for patients on losartan compared to patients
not taking losartan, the predicted atorvastatin plasma concentration increased by a factor of
2.659 (95% CI = 1.480 to 4.778, p=0.001); the predicted atorvastatin plasma concentration of
patients taking metformin decreased by factor of 0.705 (95% CI = 0.510 to 0.977, p=0.036)
compared to patients not taking metformin; and taking tamsulosin increased the predicted value
of atorvastatin plasma concentration by a factor of 2.933 compared to patients not taking tam-
sulosin (95% CI = 1.284 to 6.706, p=0.011).
The coe cient estimates for candesartan, diclofenac, digoxin, levothyroxine, and niacin
trended towards significance (p < 0.1). Specifically, for patients taking candesartan, predicted
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atorvastatin plasma concentration increased by a factor of 2.130 (95% CI = 0.996 to 4.559,
p=0.051) compared to patients without; predicted atorvastatin plasma concentration increased
by a factor of 2.924 (95% CI = 0.960 to 8.908, p=0.059) for patients taking diclofenac com-
pared to patients not taking this medication; patients taking digoxin had predicted atorvastatin
concentrations increase by a factor of 1.795 (95% CI = 0.941 to 3.425, p=0.075) compared to
those patients not on digoxin; patients taking levothyroxine saw predicted atorvastatin plasma
concentration decrease by a factor of 0.674 compared to those without (95% CI = 0.425 to
1.067, p=0.091); and predicted values of atorvastatin plasma concentration decreased for pa-
tients taking niacin by a factor of 0.676 (95% CI = 0.432 to 1.055, p=0.084).
The remainder of the confidence intervals for the concomitant medication coe cient esti-
mates were too wide to achieve statistical significance as predictors of atorvastatin plasma con-
centration: acetylsalicylic acid, atenolol, candesartan, esomeprazole, gliclazide, glucosamine,
hydrocholorothiazide, misoprostol, nifedipine, valsartan and venlafaxine all had p values greater
than 0.1 for their respective coe cient estimates. The regression coe cients resulting from the
atorvastatin standard linear regression with inclusion of concomitant medications are shown in
Table 3.11.
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Table 3.11: Atorvastatin linear model including concomitant medications (n=127)
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.338 -1.454 to 0.779 0.55
OATP1B1 c.521T>C 0.411 0.166 to 0.656 0.001 **
OATP1B1 c.388A>G -0.141 -0.343 to 0.061 0.169
Age 0.016 0.006 to 0.026 0.002 **
4 -hydroxholesterol -0.02 -0.03 to -0.01 <0.001 ***
Dose (20mg) 0.741 0.323 to 1.159 0.001 ***
Dose (40mg) 1.1 0.729 to 1.472 <0.001 ***
Dose (80mg) 1.601 1.175 to 2.027 <0.001 ***
Time Post Dose (hr) -0.085 -0.109 to -0.06 <0.001 ***
BMI (kg/m2) 0.015 -0.009 to 0.04 0.225
Sex (Male = 1) -0.051 -0.295 to 0.192 0.677
Ethnicity (Non-Caucasian = 1) 0.063 -0.296 to 0.422 0.729
Acetylsalicylic Acid 0.186 -0.089 to 0.461 0.183
Atenolol -0.304 -0.741 to 0.134 0.172
Candesartan 0.756 -0.004 to 1.517 0.051 .
Diclofenac 1.073 -0.041 to 2.187 0.059 .
Digoxin 0.585 -0.061 to 1.231 0.075 .
Esomeprazole 0.602 -0.231 to 1.435 0.155
Gliclazide -0.347 -1.083 to 0.39 0.353
Glucosamine 0.448 -0.401 to 1.297 0.298
Hydrochlorothiazide 0.095 -0.277 to 0.467 0.613
Levothyroxine -0.395 -0.855 to 0.065 0.091 .
Losartan 0.978 0.392 to 1.564 0.001 **
Metformin -0.349 -0.674 to -0.023 0.036 *
Misoprostol 0.162 -0.905 to 1.23 0.764
Nifedipine 0.34 -0.348 to 1.028 0.329
Tamsulosin 1.076 0.25 to 1.903 0.011 *
Valsartan -0.114 -0.81 to 0.582 0.746
Venlafaxine -0.247 -0.967 to 0.472 0.497
Vitamin B3 (Niacin) -0.392 -0.839 to 0.054 0.084 .
Table 3.12: Atorvastatin linear regression model cross-validation performance results
Model Adjusted R2 RMSE AIC
Atorvastatin 0.474 ± 0.038 21.064 ± 10.103 246.075 ± 7.877
Atorvastatin reduced cohort (RC) 0.458 ± 0.038 18.899 ± 9.219 241.899 ± 7.752
Atorvastatin RC + categorical dose (CD) 0.488 ± 0.040 18.570 ± 9.691 237.875 ± 9.452
Atorvastatin RC + CD + concomitant 0.652 ± 0.027 20.480 ± 8.642 211.646 ± 7.534
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3.6.2 Rosuvastatin
When ranitidine, the sole medication selected by the algorithm, was included in a linear re-
gression of rosuvastatin along with the covariates from the original linear regression model,
the amount of explained variance (adjusted R2) did not significantly change (0.635 vs. 0.633,
F(1,115) = 0.463, p = 0.497)
Table 3.13: Rosuvastatin linear model including concomitant medications (n=127)
Estimate Confidence Interval P-Value Sig.
(Intercept) 1.02 0.099 to 1.941 0.03 *
OATP1B1 c.521T>C 0.403 0.217 to 0.590 <0.001 ***
ABCG2 c.421C>A -0.346 -0.586 to -0.106 0.005 **
Age 0.013 0.005 to 0.021 0.002 **
Dose (10mg) 0.844 0.534 to 1.154 <0.001 ***
Dose (20mg) 1.428 1.115 to 1.741 <0.001 ***
Dose (40mg) 1.990 1.666 to 2.314 <0.001 ***
Time Post Dose (hr) -0.057 -0.087 to -0.028 <0.001 ***
BMI (kg/m2) -0.013 -0.026 to 0.001 0.077 .
Sex (Male = 1) -0.175 -0.399 to 0.049 0.124
Ethnicity (Non-Caucasian = 1) -0.064 -0.341 to 0.213 0.648
Ranitidine 0.273 -0.522 to 1.069 0.497
Table 3.14: Rosuvastatin linear regression model cross-validation performance results
Model Adjusted R2 RMSE AIC
Rosuvastatin 0.560 ± 0.030 16.129 ± 4.341 198.693 ± 7.866
Rosuvastatin reduced cohort (RC) 0.561 ± 0.031 16.040 ± 4.392 195.079 ± 8.051
Rosuvastatin RC + categorical dose (CD) 0.634 ± 0.028 16.314 ± 4.635 178.463 ± 7.608
Rosuvastatin RC + CD + concomitant 0.635 ± 0.028 17.047 ± 5.315 178.968 ± 7.254
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3.7 Discussion
3.7.1 Model Fit with Original Covariates
The fit of both of the linear regression models for the atorvastatin and rosuvastatin prospective
cohorts was significantly improved by modelling dose categorically instead of as a continuous
variable. This improvement could also be explained in part by the probable reduction in vari-
ability caused by the exclusion of the patients on non-standard doses. The doses prescribed
to the patients in each cohort were largely homogenous, with too few unique values to allow
a linear relationship to be accurately modelled, and the individual dose categories capture the
variation lost by the assumption of linearity. Of the two models, the rosuvastatin model was
more impacted by the conversion of the dose encoding. A possible reason for this is that the
relationship between plasma concentration and dose is not linear, and this is the assumption
for continuous variables. Binning the values into a categorical variable allows for the relation-
ship to be expressed without the assumption of linearity. Alternatively, the signal in the model
could have been improved by the removal of the three patients with outlying doses if they had
characteristics that were also inconsistent with the rest of their cohort.
3.7.2 Atorvastatin and Concomitant Medications
A number of medications were chosen by the concomitant selection algorithm for inclusion
in the atorvastatin linear regression model, and several were consistent with previous litera-
ture suggesting a relationship between the medications and atorvastatin plasma concentration.
Among these were candesartan10, digoxin11;12;13;14, esomeprazole15, losartan10, metformin16,
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nifedipine12, valsartan13, venlafaxine11, and vitamin B (niacin)17;18;19;20 . Three angiotensin II
receptor blockers (ARBs) were selected for inclusion in the predictive model. Losartan had
a significant e↵ect in the linear model of increasing predicted plasma concentration, and can-
desartan increased predicted plasma concentration in the final model, although the 95% con-
fidence interval for the estimated e↵ect was too wide by a small margin to achieve statistical
significance. Valsartan was included in the model, but the e↵ect estimate was not statistically
significant. Digoxin had the e↵ect of increasing predicted atorvastatin plasma concentration in
the model, but the 95% confidence interval for the e↵ect estimate was too wide by a small mar-
gin to achieve statistical significance. The direction of the e↵ect was positive, indicating that
in this model the predicted atorvastatin plasma concentration increases for patients who take
digoxin. In previous literature there is mixed evidence on the relationship between dixogin and
atorvastatin pharmacokinetics11;12;13;14. Studies have suggested that digoxin concentration in-
creases in the presence of atorvastatin via ABCB1 or CYP3A4 inhibition14;11; however, further
study is required to determine whether digoxin in turn a↵ects atorvastatin plasma concentra-
tion. While little literature exists on the potential for interactions between esomeprazole and
atorvastatin, a case report was published documenting an incidence of rhabdomyolysis follow-
ing treatment with atorvastatin, esomeprazole and clarithromycin15. While esomeprazole is
mainly metabolized by CYP2C19, a small amount of metabolism occurs with CYP3A4; addi-
tionally, the authors speculate that ABCB1 may have played a role in generating the myotoxi-
city observed in this case15. Metformin has been shown to increase the risk of hepatotoxicity
when taking atorvastatin because it is an inhibitor of the e✏ux protein MRP216. This is re-
flected in the predictive model for atorvastatin concentration ( ˆ = -0.349, 95% CI = -0.674
to -0.023, p = 0.036). Nifedipine had the e↵ect of increasing predicted plasma concentration
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in the regression model, but the confidence interval was relatively wide (95% CI = -0.348 to
1.028, p = 0.329); the width of the confidence intervals in this instance could potentially be due
to the small number of patients taking nifedipine in the atorvastatin prospective cohort (n = 4,
3.1%). A positive e↵ect on plasma concentration would be consistent with previous literature
suggesting that nifedipine inhibits CYP3A4 metabolism12. Venlafaxine increased predicted
plasma concentration in the atorvastatin predictive model, but the e↵ect had a wide confidence
interval (95% CI = -0.967 to 0.472, p = 0.497). Previous studies have found that venlafax-
ine is metabolized in part by CYP3A411;21, suggesting a possible pharmacokinetic relationship
between venlafaxine and atorvastatin. Further work is required to confirm whether these two
drugs have a clinically meaningful interaction, and what the metabolic consequences of such
an interaction would be. The final drug selected for inclusion in the model that is consistent
with previous work on statin metabolism was niacin, or Vitamin B3. Niacin has been found
to alter lipid metabolism, raising protective HDL cholesterol levels22;23;17. Indeed, before the
discovery of statin drugs, it was used independently as a treatment for hypercholesterolemia24.
It is unknown whether niacin is associated with other changes in the blood cholesterol profile
that would impact the metabolism of atorvastatin; further study would be required to establish
a causal relationship between concomitant niacin administration and atorvastatin plasma level.
The current evidence on whether niacin a↵ects atorvastatin plasma concentration and the risk
of myalgia is inconsistent; results range from weak increases in specific patient populations, to
niacin having no significant impact on statin plasma concentration17;18;19;20.
A number of medications were also included as predictors in the linear regression model
that have not previously been known to have an a↵ect on atorvastatin plasma concentration.
These medications include acetylsalicylic acid, atenolol, diclofenac, gliclazide, glucosamine,
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hydrochlorothiazide, levothyroxine, misoprostol and tamsulosin. Of these, the only statistically
significant e↵ect in the model was of tamsulosin, a medication commonly prescribed to men
suspected of having benign prostatic hyperplasia; it is used to treat lower urinary tract symp-
toms that can often result from this condition25. Tamsulosin increased the predicted plasma
concentration in the atorvastatin model by a relatively large margin compared to some of the
other statistically significant e↵ect sizes of the original model covariates ( ˆ = 1.076, 95% CI =
0.25 to 1.903, p = 0.011). Notably, tamsulosin is metabolized in part by CYP3A4, and plasma
concentration of this medication increases in the presence of statin drugs25. It is unknown
whether tamsulosin in turn a↵ects statin plasma concentrations, but given that tamsulosin is a
significant predictor of atorvastatin plasma concentration in the linear model, further research
investigating the pharmacokinetic relationship between these two drugs is warranted. It is im-
portant to note that these relationships may be confounded by the indication, such that it is
really the underlying illness a↵ecting the variation in statin plasma concentration, and not the
medications used to treat it. This is not a problem for the purposes of predictive modelling since
the goal is not inference primarily, but should be closely examined in future work looking at
causal relationships between individual medications and statin plasma concentration.
3.7.3 Rosuvastatin and Concomitant Medications
The identical feature selection procedures for atorvastatin were used to identify potentially
predictive concomitant generic medications for rosuvastatin plasma concentration. Using the
developed concomitant medication selection algorithm, only one medication (ranitidine) was
selected for inclusion in the predictive model. Ranitidine suppresses the production of stom-
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ach acid, and used for the treatment of gastrointestinal issues such as acid reflux, dyspepsia
and gastroduodenal mucosal lesions26;27. These can be caused by stress from critical illness,
or adverse events related to using NSAIDs for the treatment of arthritis; however, it is not as
e↵ective as some other medications used for this purpose such as omeprazole26;28. Ranitidine
is a CYP2C9 inhibitor17; as rosuvastatin is minimally metabolized by this enzyme, it is pos-
sible that ranitidine has a small impact on rosuvastatin pharmacokinetics by way of CYP2C9
inhibition. The ranitidine coe cient estimate in the linear model for rosuvastatin plasma con-
centation was positive with a wide confidence interval; it did not reach statistical significance
( ˆ = 0.273, 95% CI = -0.522 to 1.069, p = 0.497).
When included in a linear regression with the original rosuvastatin model covariates, model
fit was not significantly impacted (F(1, 115) = 0.463, p = 0.497). Based on the model fit perfor-
mance results from the linear regression models with and without the addition of the selected
concomitant medication, it seems likely that the addition of concomitant medications does not
improve model fit when predicting rosuvastatin plasma concentration. It is possible that ran-
itidine was present in 99% of the models generated by the concomitant medication selection
algorithm because it truly has a small impact on rosuvastatin; however this may be an artefact
of small sample size, given that only two patients in the dataset were on this medication (1.5%
of the patients in the cohort). Based on this limitation of small sample size, it is more likely
that the inclusion of ranitidine in the model is reflective of potential outlying characteristics of
the two individuals in the rosuvastatin cohort taking this medication.
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3.7.4 General Discussion
Model fit for the original systemic statin exposure predictive model was significantly improved
for both the atorvastatin and rosuvastatin linear models predicting plasma concentration.
The patients in the atorvastatin and rosuvastatin prospective cohorts are perhaps not repre-
sentative of statin users in the general population, as they were receiving specialized care in
controlling their hypercholesterolemia. The patients recruited for the original study performed
by DeGorter et al. received additional testing to tailor statin medication dosing based on their
genetic profile. The patients used to generate the concomitant medications model may be more
complex than general population of hypertensive patients in the community; however, patients
with advanced hypercholesterolemia that is not responding adequately to statin treatment are
often prescribed more than one drug to maximize cholesterol-lowering e cacy29. Patients on
statins, especially with complicated illness, often experience polypharmacy which makes this
population advantageous for studying the e↵ects of concomitant medications on statin plasma
concentration.
3.8 Conclusions
In the current work we aimed to characterize concomitant medication use in the atorvastatin
and rosuvastatin prospective cohorts, and to develop a selection algorithm to identify concomi-
tant medications that would improve the prediction of statin plasma levels. The medications
selected by the algorithm were then added to the original covariates used to train the original
statin systemic-exposure linear regression models to guide statin dosing. Before proceeding
with the concomitant medication selection, we recoded dose as a categorical variable instead
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of being represented continuously. This significantly improved the model fits for both atorvas-
tatin and rosuvastatin. Rosuvastatin is minimally metabolized and has a smaller probability of
concomitant medication interactions, so it is relatively unsurprising that we were unable to im-
prove the prediction quality in the rosuvastatin model using this data. Instead, we suggest that
the rosuvastatin predictive model could be further improved by identifying novel SNPs that
are predictive of statin plasma concentration, and using these to augment the original linear
regression model for rosuvastatin.
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Chapter 4
Non-linear Modelling of Statin Plasma
Concentration
Augmenting the atorvastatin model by including concomitant medication information was
greatly successful in improving model accuracy. However, even with taking the log of plasma
concentration, both models had covariates that had a high possibility of a non-linear relation-
ship with the outcome variable, such as the time post-dose that plasma concentration was mea-
sured. We hypothesize that using non-linear modelling techniques will increase the predictive
performance of the atorvastatin and rosuvastatin systemic-exposure models originally devel-
oped by DeGorter et al.1.
4.1 Background: Methods for Modelling Non-linearity
Ordinary linear regression models are very popular because they are relatively easy to imple-
ment and interpret. For each covariate used to predict the outcome variable, it is possible to
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obtain a coe cient value that gives a clear depiction of the direction, magnitude and confi-
dence intervals for the coe cient e↵ect estimates. Unfortunately, much of the data generated
in health care settings has non-linear relationships between the predictor and the outcome vari-
able. One example of a non-linear predictor variable in a healthcare setting is the number of
hours since a dose of medication if one is trying to accurately model drug plasma concentra-
tion2. Another example in a similar vein is trying to predict hot flashes in patients on tamoxifen
over the course of therapy using patient age as a predictor; age changes with menopausal sta-
tus, and is strongly associated with hot flash severity3. While linear regression is not capable
of leveraging these relationships to improve predictive performance, many non-linear methods
have been developed to more accurately model these variables.
4.1.1 Generalized Linear Models (GLMs)
Generalized Linear Models (GLMs) extend the functionality of linear regression modelling
by allowing the use of any exponential distribution via a link function or kernel function that
transforms the linear model into the exponential model. A basic GLM can be written in the
following form:
g(µi) =Xi i
where µi is the expected value of the response variable for the i-th observation (corresponding to
row i in the design matrixX; g transforms the expected outcome value using the link function
specified in accordance with the model distribution; and   is the vector of coe cients for each
predictor variable4. An example of a potential link function is the identity link function. With
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the identity link function, the expected values of the outcome are left unchanged:
g(µi) = µi.
Linear regression is a special case of a GLMwhich uses the Normal distribution and the identity
link function. Another popular type of GLM is the logistic regression model, which is used
to model binary outcomes. The logistic regression model uses a Binomial distribution and the
expected outcome values are transformed using the logit link function:
g(µi) = ln
 
µi
1   µi
!
.
GLMs di↵er from ordinary linear regression in that model fitting using an exponential dis-
tribution and link cannot be done in a single step, and the solution is not exact. Instead of
solving for the exact coe cient values using least squares, maximum likelihood estimation
(MLE) is used to come to the solution over a number of iterations4. MLE relies on the assump-
tion that the data that is being used to generate the model (yi, where i = 1, ..., n) is a random
sample from some probability distribution. This distribution has a probability density of Pr✓(y),
where ✓ is a vector of parameters characterizing the density. In MLE, we try to approximately
solve for these parameters ✓ under the assumption that the best values for ✓ are those that give
the highest probability of generating our random data sample outcome (y)5. Formally, MLE
maximizes the log-probability L of our random sample y:
L(✓) =
NX
i=1
log Pr✓(yi)
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GLMs use this method to find the each value of   in our regression model for the distribution
and link function we have specified. At each step or iteration, the value of the parameters
are updated, and the MLE is calculated. This process continues until no more adjustments
to the parameters increase the value of the maximum likelihood above a specified threshold
(generally very small), and the algorithm converges.
4.1.2 Generalized Additive Models (GAMs)
Generalized Additive Models (GAMs) are very similar to generalized linear models, with the
di↵erence being that the continuous variables in the dataset are modelled using a set of smooth
functions instead of a single coe cient. In the regression setting, predictions generated by a
GAM usually take the following form5:
E(Y |X1, X2, ...Xp) = ↵ + f1(X1) + f2(X2) + ... + fp(Xp)
where Y represents the outcome variable, X1, X2, ..., Xp represent the continuous independent
predictor variables, and ↵ is a constant similar to an intercept. Alternatively, this can be written
as
Yˆ = ↵ +
pX
j=1
f j(Xj) + ✏
where ✏ is the prediction error5.
The unspecified smooth, non-parametric curves represented by these functions can be fit
by dividing the variable into segments and modelling each segment separately with a smooth
function. This allows the function representing the relationship between the predictor and
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dependent variable to have di↵erent trajectories for di↵erent ranges of values, and is why the
e↵ect of these covariates cannot be represented by a single coe cient value.
There are many di↵erent methods for generating the non-linear representation of a predictor
variable for inclusion in a GAM, some of which require the modeller to input domain-specific
knowledge about the modelling problem at hand, and some of which are automatic, requiring
no additional input6. Some options for the former include using linear basis expansions to
give a global non-linear representation of the covariate, and piecewise polynomial functions
or splines to give local trajectories for di↵erent ranges of values of the predictor variable. A
simple example of this is a linear spline. The first step to building this type of spline model is to
choose the points (called knots) that separate the range of the predictor into di↵erent sections
of lines with di↵erent slopes; the slope can change at the knot between sections7. This results
in a piecewise linear function8.
Knot locations can be chosen based on domain knowledge; however, this type of domain
knowledge is not always available, and/or there is no good justification for exact locations for
the placement of individual knots. Often in this case, knots are placed at the quartile values and
the data points between them are smoothed with separate smoothing functions7. The choice
of how many knots to include in a model can also be di cult; it is often best to compromise
between having a model that is as simple as possible, but also does not model too much of the
noise or error in the variable.
Polynomial and Natural Cubic Splines
Another example of a commonly used spline in a GAM is the natural cubic spline. Between
each knot, the data is modelled using a cubic polynomial function; these are then connected
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at the knots such that they are continuous at both the first and second derivatives4. Addition-
ally, the final shape of the model is constrained such that the trajectory beyond the boundary
knots (the lowest and highest specified knot values) must be linear5. The linearity constraint is
included because without this constraint, such curved splines tend not to give accurate represen-
tations of the trend of the data at the tails (the outer ranges of values of the predictor variable)8.
The inability of polynomial splines to give reasonable predictions beyond the boundary knots
usually makes it very di cult to extrapolate from the data at hand to data with a wider range
of values7.
Instead, more complicated methods can be used to obtain the smoothing functions for each
continuous covariate; many of these can be characterized as scatterplot smoothers, referring to
two-dimensional scatterplot graphs with the dependent variable on the y axis, and the indepen-
dent variable on the x axis6. An example of one such method that is capable of more accurately
modelling the tails of the sample distribution is the use of thin plate regression splines.
Thin Plate Regression Splines
One of the largest challenges of using cubic splines is finding the optimal number and place-
ment of knots to define the smoothing basis functions8 One way to avoid this di culty is to use
a smoother that does not require the specification of knot placement, such as thin plate splines9.
Instead, thin plate splines can be calculated using a closed-form solution; the main problem to
be solved in this formulation is the tradeo↵ between how well the spline function should fit the
data, and how smooth it should be8. A spline with a lot of curves that is very wiggly might be
an excellent fit for the specific data set it is being trained on, but generalizability may su↵er
because the model does not perform well on other datasets generated from the same underlying
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distribution. The wiggliness of the thin plate spline function is controlled by a penalization pa-
rameter  , which is solved for by optimization8. Thin plate splines have the capacity to achieve
an optimal smoothing solution in terms of minimizing error and maintaining good model fit8.
Unfortunately, the optimization procedure required to solve the original formulation of thin
plate spline functions was very computationally expensive, and using this smoothing method
with a large number of variables was infeasible, since the resourced required were a cubic
function of the number of model parameters8.
Thin plate regression splines were developed as a way to take advantage of the attractive
theoretical properties of thin plate splines while being computationally e cient enough to be
used with large datasets10. They decrease the computational requirements of the optimization
problem by restricting the space of potential solutions in terms of how much wiggle can be
present in the spline function8. The reformulation of thin plate splines to thin plate regression
splines provides a useful method for smoothness estimation based in statistical theory instead
of heuristic methods10; as such, they are a popular method for use with GAMs.
4.1.3 Support Vector Regression (SVR)
Support Vector Regression (SVR) is a popular machine learning technique for predictive mod-
elling problems with continuous outcome variables; this paradigm is called Support Vector
Machine (SVM) or Support Vector Classification (SVC) for binary outcomes. The concept be-
hind SVR is most easily demonstrated using the classic SVM binary classification paradigm:
in this scenario the goal is to create a classification model that uses a line to separate the two
classes of the binary outcome variable, leaving the widest margin possible between the two
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classes. The term “support vectors” in SVM refers to the observations or training examples
that determine the size and placement of the margins between the hyperplane separating the
observations from each class, and the nearest observation to it for either class, as shown in
Figure 4.1.
The concept between the SVM binary classifier can also be applied to regression problems;
in this paradigm, the support vectors are the observations forming the outer envelope or margin
in which the majority of observations are enclosed. Two model parameters are particularly
important to consider when training a SVR model: epsilon, and cost. Cost in the context of
SVR tuning refers to the desired ratio of training errors in positive versus negative training
examples11. In the context of clinical research, a higher cost value selected during CV would
indicate a larger penalty on errors incurred on training examples for cases versus training error
for observations in the control group. The width of this envelope is given by epsilon (✏),
which controls how much error is permissible in the model between the model fit and training
observations12. A higher value of epsilon indicates a larger margin of error between the training
data and model fit; a wider epsilon envelope is less sensitive to variations in the training data
and thus less prone to overfitting. A depiction of the basic structure of a SVR model fit is
shown in Figure 4.2.
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Figure 4.1: Simple support vector machine (SVM) binary classifier
SVMs and SVR are especially well-suited to non-linear models because they allow the
user to transform the data into a higher dimension via a kernel, after which it is possible to fit a
hyperplane to separate classes in the high dimensional space, or construct a more accurate SVR
for models in which covariates are non-linear. Linear, radial and polynomials are especially
popular for use in SVR.
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Figure 4.2: Simple support vector regression (SVR) model structure
4.2 Background: Model Performance Evaluation Metrics
4.2.1 Model Fit
Choosing the right method to model a dataset is a crucial step in building a predictive model.
However, making sure that the model fits the data well based on the purpose of prediction is
equally important. Predictive modelling is an art as much as a science, and requires balancing
competing goals. For example, a model that fits a dataset perfectly will probably perform
poorly when trying to predict outcomes from new data observations. Similarly, often there are
many candidate models that could be used for a particular data set. Several metrics of model
fit quality exist that can be used to choose the best model for the prediction problem at hand.
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4.2.2 Overfitting and Underfitting
Predictive modelling often involves a choice between using a simple model, a complicated
model, or something in between. An example of a simple model is plain linear regression;
all of the covariates in the model are linearly modelled with respect to the outcome variable,
and no extra parameters besides the regression coe cients are needed to specify the model
fit. The advantage of using a simple model is that they are generally easy to use and interpret.
However, a risk that comes with simple modelling techniques is under-fitting. Under-fitting
occurs when the model does not have enough parameters to capture the variability in the model
and therefore cannot generate accurate predictions.
An example of a situation involving under-fitting would be trying to model a parabolic
response using linear regression; the line cannot capture the curved shape of the relationship,
and would not be as informative as a non-linear model. On the other hand, over-fitting occurs
when the model captures the noise or error in the data instead of the true underlying trend. If
the data is non-linear, a very simple model will not be as informative as a more complicated
model that captures variation outside the boundaries of linear modelling so a balance between
under- and over-fitting the data is required. Examples of what under-fitting and over-fitting
look like compare to a good model fit are shown in Figure 4.3. One of the goals of achieving a
good model fit is balancing model complexity with the quality of model fit with respect to the
data.
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Figure 4.3: Visual examples of under- and over-fitting
4.2.3 Assessing Model Fit
Root Mean Squared Error (RMSE)
Perhaps the simplest way to assess model fit is to look at the magnitude of the di↵erences be-
tween the predicted values and true values of the outcome variable generated by the predictive
model; these are called the residuals. To calculate RMSE, we square the residuals, add them,
and take the square root; squaring them alleviates the problem of errors in opposite directions
cancelling each other out, and taking the square root after returns them to the original scale of
the deviations. Formally,
 ˆe =
s
1
n   (p + 1)PNi=1 r2i
where ri is the residual for observation i, n is the number of total observations, and p is the num-
ber of covariates in the model7. RMSE is also the squared deviation of the error term, which
gives an idea of the spread of the errors from the predictions in the model. Unforunately, RMSE
is only available for models with continuous outcome variables (ie. not logistic regression)7.
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Adjusted R2
Adjusted R2 is a measure specific to regression models with continuous outcomes. It describes
the amount of variance that can be explained in the model by the covariates included. R2 is also
called the coe cient of determination; it can be thought of as the squared correlation between
the true y values and the predicted outcome values generated by the model from the particular
sample of data used. Formally, R2 is calculated using the following formula13:
R2 =
PN
i=1(yˆi   y¯)2PN
i=1(yi   y¯)2
where y¯ is the sample mean of the outcome variable; yi is the value of the dependent variable
for observation i; and yˆi is the predicted outcome value for observation i. The quantity in
the numerator is known as the regression sum of squares (the explained variance), and the
denominator represents the total sum of squares (the total variance)13.
While R2 is a useful measure in theory, it is biased based on the size and specific sample
used to calculate it; it tends to be an inflated estimate of the explained variance accounted for
in the model14. Because of this, it is recommended to use an adjusted R2 value when using
it as a metric for model quality, or e↵ect size. The adjustment is based on assumptions of
the sampling error in the dataset used for the regression model, which depends on the number
of observations, the number of covariates in the model, and the true size of the e↵ect in the
population14. Many di↵erent corrections are available to adjust for this bias, all of which make
slightly di↵erent assumptions about the sample properties. One commonly used adjustment is
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the Wherry method (Wherry formula-1)15:
Rˆ2adj = 1  
N   1
N   p   1(1   Rˆ
2)
where N   p   1 is the residual degrees of freedom. This is the method used by the lm16
command for linear modelling in R.
4.3 Implemented Methods
4.3.1 GAM
For both the atorvastatin and rosuvastatin models, Generalized Additive Models (GAMs) were
fit using thin-plate to model non-linearity in the continuous covariates. Two models were fit for
both atorvastatin and rosuvastatin, using smoothing parameters   for each continuous variable
chosen either by cross-validation or a fixed smoothing parameter. The fixed parameter models
were performed to show the di↵erences between tailored model fit and fit achieved by arbitrary
parameter selection using a moderate smoothing parameter value. The R package mgcv was
used for this process10;4;17;8. Conveniently, the mgcv package included an implemented CV
strategy for the purpose of choosing the best smoothing parameters.
For each GAM fit, 5-fold CV was performed to calculate model error in order to com-
pare the relative performance between models after the smoothing parameter selection was
performed using the implemented package function. For each fold in the CV, the model was
trained on a randomly selected (without replacement between folds) portion of data, compris-
ing 80% of the available observations. Predictions were then generated using the newly trained
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model for the remaining fifth of the data set, and root mean squared error (RMSE) was calcu-
lated for the di↵erence between the predicted values generated by the trained model for that
fold, and the the corresponding true plasma concentration values.
4.3.2 SVR
For both the atorvastatin/concomitant-medication model and the rosuvastatin plasma concen-
tration models, support vector regression models were fit with a linear kernel, a low degree
polynomial kernel (degree=3), a higher degree polynomial kernel (degree=5), and a radial
kernel. This range of kernels was chosen to give the best picture of how each method might
perform, and what the strengths and weaknesses of each model type are for these data sets. The
R package e107118 was used to tune and fit the model for each SVR.
Similar to the procedure used to assess model fit for the GAMs, 5-fold CV was used to
obtain RMSE for the fitted SVR models; however, the SVR models required an additional step
to tune the model for each fold prior to assessing fit. A ready-implemented CV procedure for
choosing epsilon and cost values was available with the software packaged used; this procedure
used 10-fold CV over a grid search of epsilon specified by the user. The set of parameter values
used in the current work for the grid search over epsilon was ✏ = (0.1, 0.2, ..., 1.0) and the set of
cost values used to tune the models was c = (22, 23, ..., 29). The final parameter values chosen
for each fold were those that produced the lowest error over the grid search implemented in the
e1071 R package. RMSE was calculated using the predictions from the tuned model for each
test fold. The tuned values of epsilon and cost for each model were also recorded. Earlier in
this dissertation, it was observed that model parameter selection was unstable for such a small
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sample size when choosing concomitant medications for atorvastatin and rosuvastatin. To
increase robustness, the CV method was repeated 100 times; the mean and standard deviation
of both cost and epsilon were calculated from the resultant 500 total folds. The average values
of cost and epsilon chosen by the CV procedure were then used to train a final model fit for
each type of kernel for both the atorvastatin and rosuvastatin cohorts.
4.4 Results
4.4.1 GAMs
Atorvastatin
The overall results of the GAM models for the atorvastatin cohort with the addition of all
concomitant medications chosen by the selection algorithm described previously were similar
to those found in the original linear regression model in the magnitude and direction of e↵ect
size for the parametric covariate estimates, but explained slightly more of the variance. The
linear regression model is nested withing the generalized additive model: the results can be
replicated by choosing linear functions for the continuous covariates smoothed in the non-
linear model. This allows direct comparison of the model fits for the linear regression and
GAM models using the F test19. The adjusted R2 for the GAM with smoothing parameters
chosen by CV (GAMCV ) was 0.663 (± 0.028), compared to the adjusted R2 value of 0.677
(± 0.031) for the GAM with fixed smoothing parameter values (GAMfixed ). For reference,
the original atorvastatin linear model without concomitant medications (with dose represented
categorically) had an adjusted R2 of 0.489 ± 0.040 (RMSE = 18.570 ± 9.691); the atorvastatin
4.4. Results 83
linear regression model including all concomitant medications chosen using the previously
described selection algorithm had an adjusted R2 of 0.652 ± 0.027 (RMSE = 20.480 ± 8.642).
While the GAMfixed  explained slightly more of the model variation than the GAMCV , the error
was lower for the latter (RMSECV = 20.474 ± 8.626 versus RMSEfixed  = 21.186 ± 9.066).
Overall, the GAMCV  fit was statistically significantly di↵erent from the fit of the linear model
(F(0.509, 96.491) = 8.163, p = 0.017), but the GAMfixed  fit was not (F(5.701, 90.790) = 1.502,
p = 0.189). The di↵erence in fit between the GAMs was not statistically significant after
adjusting for multiple comparisons (F(6.210, 90.790) = 2.048, p = 0.189, method: Benjamini
& Hochberg20), while the di↵erence between the fit of the linear model and the GAMCV 
was only marginally short of statistical significance (p = 0.052) after applying the adjustment
for multiple comparisons. The Benjamini & Hochberg method was chosen to gain additional
statistical power, as it is a less conservative test than the Bonferroni correction21.
Other di↵erences in model fit were observed between the model fit with smoothing pa-
rameters chosen via CV, and the model fit using arbitrary fixed smoothing parameters. The
parametric covariate estimates that were precise enough to achieve statistical significance in
the linear model and both GAMs were S LCO1B1 c.521T>C, atorvastatin dose (20mg, 40mg
and 80mg), and concomitant use of losartan, metformin and tamsulosin. In the linear regres-
sion model, the coe cient estimates for candesartan, diclofenac, digoxin, levothyroxine and
niacin trended towards statistical significance. In the GAMs, the estimates for candesartan
and diclofenac confidence intervals su ciently narrowed to achieve statistical significance.
Specifically, the estimated atorvastatin plasma concentration for patients with concomitant use
of candesartan compared to those without increased by a factor of 2.255 (p = 0.034) in the
GAMCV  fit compared to a non-statistically significant increase of a factor of 2.130 (p = 0.051)
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in the linear regression model. A narrower confidence interval for this estimate was achieved
in the GAMfixed  the estimated atorvastatin plasma concentration increased by a factor of 2.377
in this model (p = 0.027). The estimated atorvastatin plasma concentration for patients taking
diclofenac concomitantly with atorvastatin increased by a factor of 3.149 in the GAMCV  (p =
0.041) compared to the non-statistically significant increase in the estimated plasma concentra-
tion by a factor of 2.924 (p = 0.059) in the linear regression model. Similar to the findings for
candesartan, a narrower confidence interval was seen in the diclofenac coe cient estimate gen-
erated by the GAMfixed  ( ˆ = 1.323, p = 0.019). Finally, the relative confidence of the estimated
e↵ect of niacin on atorvastatin plasma concentration value di↵ered between the linear regres-
sion model and the GAMs. The estimated e↵ect size of niacin on predicted atorvastatin plasma
concentration was -0.446 in the GAMCV  (p = 0.049) compared to the estimated e↵ect size
of -0.392 (p = 0.084) seen in the linear regression model. Additional statistical significance
was seen in the estimated e↵ect size generated by the GAMfixed  ( ˆ = -0.591, p = 0.012). The
model summary for the GAMCV  parametric covariates is shown in Table 4.1 The GAMfixed 
parametric covariate summary is shown in Table 4.3.
The greatest di↵erences observed between the GAMCV  and GAMfixed  fits were in the ap-
proximate significance and shape of the smoothed continuous covariates, which was expected.
The model summary for the R mgcv package includes an estimate of how complex (wiggly)
the smoothing function is for each non-parametric covariate, in the form of estimated degrees
of freedom (eDF). In the GAMCV , age, 4 -hydroxycholesterol, and BMI were not given com-
plex smoothing functions, and were treated like parametric covariates (eDF = 1.000); despite
their lack of a complex smoothing function, the age and 4 -hydroxycholesterol terms achieved
statistical significance (p < 0.05). The only covariate given a non-linear smoothing function in
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this model was time post dose, which also had a statistically significant e↵ect (eDF = 1.509, F
= 27.159 p <0.001). In contrast, all of the continuous covariates included in the GAMfixed  for
atorvastatin were given curved smoothing functions, because no penalty was applied to the use
of these additional degrees of freedom when considering smoothing parameter value selection.
The model summary for the GAMCV  non-parametric covariates is shown in Table 4.2, and
the GAMfixed  non-parametric covariate summary is shown in Table 4.4.
Table 4.1: Atorvastatin CV-smooth GAM parametric coe cients
Estimate Std. Error P-Value Sig.
(Intercept) -0.443 0.200 0.029 *
S LCO1B1 c.521T>C 0.414 0.121 <0.001 ***
S LCO1B1 c.388C>A -0.150 0.100 0.136
Dose (20mg) 0.757 0.207 <0.001 ***
Dose (40mg) 1.117 0.184 <0.001 ***
Dose (80mg) 1.602 0.211 <0.001 ***
Gender (Male = 1) -0.082 0.122 0.505
Ethnicity (Non-Caucasian = 1) 0.057 0.178 0.750
Acetylsalicylic Acid 0.194 0.136 0.158
Atenolol -0.268 0.218 0.222
Candesartan 0.813 0.378 0.034 *
Diclofenac 1.147 0.553 0.041 *
Digoxin 0.580 0.320 0.073 .
Esomeprazole 0.491 0.418 0.243
Gliclazide -0.370 0.366 0.314
Glucosamine 0.416 0.421 0.325
Hydrochlorothiazide 0.115 0.185 0.535
Levothyroxine -0.380 0.228 0.098 .
Losartan 0.984 0.290 0.001 **
Metformin -0.388 0.164 0.020 *
Misoprostol 0.153 0.529 0.773
Nifedipine 0.328 0.340 0.337
Tamsulosin 1.134 0.411 0.007 **
Valsartan -0.076 0.345 0.826
Venlafaxine -0.258 0.356 0.470
Vitamin B3 -0.446 0.224 0.049 *
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Table 4.2: Atorvastatin GAM CV-smooth covariates (approximate significance)
Smoothed Covariate Estimated DF Reference DF F P-value Sig.
s(Age) 1.000 1.000 10.516 0.002 **
s(4 -hydroxycholesterol) 1.000 1.000 18.265 <0.001 ***
s(Time Post Dose) 1.509 1.851 27.159 <0.001 ***
s(BMI) 1.000 1.000 1.911 0.170
Table 4.3: Atorvastatin fixed-smooth GAM parametric coe cients
Estimate Std. Error P-Value Sig.
(Intercept) -0.402 0.202 0.049307 *
S LCO1B1 c.521T>C 0.399 0.123 0.002 **
S LCO1B1 c.388C>A -0.169 0.100 0.093 .
Dose (20mg) 0.735 0.209 <0.001 ***
Dose (40mg) 1.118 0.187 <0.001 ***
Dose (80mg) 1.544 0.215 <0.001 ***
Gender (Male = 1) -0.117 0.135 0.387
Ethnicity (Non-Caucasian = 1) 0.0245 0.182 0.893
Acetylsalicylic Acid 0.223 0.138 0.109
Atenolol -0.178 0.221 0.424
Candesartan 0.866 0.385 0.027 *
Diclofenac 1.323 0.556 0.019 *
Digoxin 0.542 0.320 0.094 .
Esomeprazole 0.335 0.428 0.436
Gliclazide -0.411 0.367 0.266
Glucosamine 0.414 0.425 0.332
Hydrochlorothiazide 0.170 0.192 0.377
Levothyroxine -0.363 0.235 0.125
Losartan 0.994 0.289 <0.001 ***
Metformin -0.419 0.170 0.015 *
Misoprostol 0.024 0.536 0.964
Nifedipine 0.279 0.339 0.413
Tamsulosin 1.191 0.421 0.006 **
Valsartan -0.002 0.345 0.996
Venlafaxine -0.225 0.367 0.542
Vitamin B3 -0.591 0.231 0.012 *
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Table 4.4: Atorvastatin GAM fixed-smooth covariates (approximate significance)
Smoothed Covariate Estimated DF Reference DF F P-value Sig.
s(Age) 2.686 3.356 3.381 0.020 *
s(4 -hydroxycholesterol) 2.521 3.165 5.684 0.001 **
s(Time Post Dose) 2.640 3.255 17.842 <0.001 ***
s(BMI) 2.364 2.987 1.182 0.328
Rosuvastatin
The linear model fit for the rosuvastatin cohort di↵ered statistically significantly from the
model fits of the rosuvastatin GAMCV  (F(0.331, 115.67) = 8.715, p = 0.038) and the rosu-
vastatin GAMfixed  (F(4.856, 110.81) = 2.709, p = 0.038), even after adjusting for multiple
comparisons (method: Benjamini & Hochberg20). The rosuvastatin GAMCV  and GAMfixed 
were not statistically significantly di↵erent, although this e↵ect was marginal (F(6.586, 108.82)
= 1.997, p = 0.065). The adjusted R2 for the GAMCV  was 0.640 ± 0.026 (RMSE = 16.259 ±
4.872) and 0.667 ± 0.028 for the GAMfixed  (RMSE = 16.035 ± 4.614), while the adjusted R2
for the linear rosuvastatin regression model was 0.634 ± 0.028 (RMSE = 16.314 ± 4.635).
The estimated parametric coe cient values for both GAM models were very similar to
those seen in the linear regression for rosuvastatin; no additional covariate estimates achieved
statistical significance that did not in the linear regression model, although the estimates dif-
fered slightly. The parametric covariate estimates that were statistically significant in all three
models were for S LCO1B1 c.521T>C, ABCG2 c.421C>, and dose (10mg, 20mg and 40mg).
The coe cient estimates for ethnicity and gender remained non-statistically significant as in
the linear model, although in the rosuvastatin GAMfixed  the gender coe cient estimate trended
towards statistical significance ( ˆ = -0.204, p = 0.065), and was a great deal more precise than
the estimate found in the linear regression model with dose represented categorically ( ˆ =
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0.076, p = 0.587) and somewhat more precise than the estimate generated in the rosuvastatin
GAMCV  ( ˆ = -0.181, p = 0.107).
The treatment of the continuous variables in the rosuvastatin GAMCV  was similar to that
seen in the atorvastatin GAMCV : the majority of the variables were treated linearly instead
of being given smoothing curves that required more degrees of freedom. In contrast to the
atorvastatin GAMCV , time post dose was treated linearly for the rosuvastatin GAMCV  (eDF =
1.000, p <0.001). BMI was also modelled using a linear function, and trended towards achiev-
ing statistical significance, unlike in the rosuvastatin linear regression model (eDF = 1.000, p
= 0.094). The only continuous covariate given a non-linear smoothing function in the rosuvas-
tatin GAMCV  was age (eDF = 1.331, p = 0.005). As in the atorvastatin model, the rosuvastatin
GAMCV  did not penalize the use of curved smoothing functions to represent the continuous
variables in the model. Qualitatively, the smoothing functions generated for the rosuvastatin
cohort using fixed smoothing parameters were more curvy or “wiggly” than the smoothing
functions in the atorvastatin GAMfixed  (figures shown in Appendix C). Despite having a very
slightly lower RMSE found via CV than the GAMCV  (16.035 ± 4.614 versus 16.259 ± 4.872),
the covariate estimates in the GAMfixed  generally had wider 95% confidence intervals than
those in the GAMCV , based on the approximate p values provided in the GAM output. The
optimization model error (ML) was also higher for the GAMfixed  than the GAMCV  (79.990
± 3.563 versus 77.155 ± 3.707), suggesting that overfitting may be present in the model with
arbitrary smoothing parameter values. The GAMCV  results for the parametric and smoothed
rosuvastatin covariates can be found in Tables 4.5 and 4.6 respectively. The GAMfixed  results
for the parametric and smoothed rosuvastatin covariates can be found in Tables 4.7 and 4.8 The
results comparing the overall model fit for the atorvastatin and rosuvastatin cohorts is presented
4.4. Results 89
in Table 4.9.
Table 4.5: Rosuvastatin CV-smooth GAM parametric coe cients
Estimate Std. Error P-Value Sig.
(Intercept) 1.446 0.2508 <0.001 ***
S LCO1B1 c.521T>C 0.400 0.093 <0.001 ***
ABCG2 c.421C>A -0.348 0.119 0.004 **
Dose (10mg) 0.571 0.128 <0.001 ***
Dose (20mg) 1.149 0.134 <0.001 ***
Dose (40mg) -0.863 0.154 <0.001 ***
Gender (Male = 1) -0.181 0.111 0.107
Ethnicity (Non-Caucasian = 1) -0.073 0.138 0.598
Table 4.6: Rosuvastatin GAM CV-smooth covariates (approximate significance)
Smoothed Covariate Estimated DF Reference DF F P-value Sig.
s(Age) 1.331 1.597 5.581 0.005 **
s(Time Post Dose) 1.000 1.000 15.646 <0.001 ***
s(BMI) 1.000 1.000 2.852 0.094 .
Table 4.7: Rosuvastatin fixed-smooth GAM parametric coe cients
Estimate Std. Error P-Value Sig.
(Intercept) 1.506 0.245 <0.001 ***
S LCO1B1 c.521T>C 0.397 0.092 <0.001 ***
ABCG2 c.421C>A -0.366 0.116 0.002 **
Dose (10mg) 0.557 0.126 <0.001 ***
Dose (20mg) 1.145 0.131 <0.001 ***
Dose (40mg) -0.909 0.151 <0.001 ***
Gender (Male = 1) -0.204 0.109 0.065 .
Ethnicity (Non-Caucasian = 1) -0.066 0.134 0.623
Table 4.8: Rosuvastatin GAM fixed-smooth covariates (approximate significance)
Smoothed Covariate Estimated DF Reference DF F P-value Sig.
s(Age) 2.930 3.683 4.294 0.003 **
s(Time Post Dose) 3.030 3.750 5.214 0.001 **
s(BMI) 2.228 2.750 1.285 0.270
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Table 4.9: CV results for atorvastatin and rosuvastatin GAMs
Model Cohort Thin Plate CV Parameters Thin Plate Fixed Parameters
RMSE Adj. R2 ML RMSE Adj. R2 ML
Rosuvastatin 16.259 0.640 77.155 16.035 0.667 79.990
± 4.872 ± 0.026 ± 3.707 ± 4.614 ± 0.028 ± 3.563
Atorvastatin 20.474 0.663 74.698 21.186 0.677 80.087
± 8.626 ± 0.028 ± 3.882 ± 9.066 ± 0.031 ± 4.551
4.4.2 SVR
Atorvastatin
In order to find the optimal model parameters cost and epsilon for each kernel used to train
the atorvastatin SVR models, a repeated 5-fold bootstrap CV method was employed. However,
this procedure posed a problem with the atorvastatin data set including all selected concomitant
medications. Because some of the atorvastatin model covariates were very sparse, it was not
feasible to conduct cross validation with the dataset including the full complement of concomi-
tant medications because of collinearity introduced by splitting the data into test and training
sets. For a number of the medications that had particularly few patients with concomitant use,
the randomly sampled test set comprising 20% of the available patient observations often failed
to include a patient taking that particular medication. This in turn caused convergence issues
because the column in the test dataset for that medication contained no variation. It was pos-
sible to train SVR models on the full atorvastatin dataset without CV, but this did not give as
robust an estimate of model performance as assessing di↵erent permutations of the data.
In order to facilitate the SVR optimization to converge for models trained on the atorvastatin
data set, concomitant medications with less than 10 patients taking them were excluded from
the SVR to decrease model sparsity; the concomitant medications excluded were candesartan,
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diclofenac, digoxin, esomeprazole, gliclazide, glucosamine, losartan, misoprostol, nifedipine,
tamsulosin, valsartan and venlafaxine. The remaining concomitant medications included in
the atorvastatin model were acetylsalicylic acid, atenolol, hydrochlorothiazide, levothyroxine,
metformin, and niacin (vitamin B3). The performance of the full dataset was compared to the
predictive of the reduced dataset using a two-step tuning procedure, since it was not feasible
to obtain parameters estimated by CV for the full dataset. The first step of the manual tuning
procedure was the same as that of the CV tuning procedure: a grid-search was conducted over
epsilon values of ✏ = (0.1, 0.2, ..., 1.0) and cost values of c = (22, 23, ..., 29). A graph was then
generated of error values across the standard range of epsilon and cost values; darker areas of
the graph represent parameter combinations resulting in lower error than light regions. Based
on the graph colouring, the user then specified a more specific region for fine tuning of the
parameter values. The second grid search was subsequently conducted between the minimum
and maximum epsilon values specified by the user, increasing in intervals of 0.05, and between
the minimum and maximum cost values specified by the user, increasing in intervals of 5. An-
other graph showing the model error for the range of epsilon and cost values in the grid search
was generated from the second tuning procedure to show the size of the optimal regions for the
more finely-tuned parameter combinations. The final values of epsilon and cost selected were
those that produced the lowest error in the second grid-search of manual tuning procedure.
Unsurprisingly, the reduced models tuned using the two-step procedure performed much more
poorly than the models that included all of the concomitant medications. There are a num-
ber of potential reasons why this could be the case, the first of which is possible overfitting.
In the linear regression model, the inclusion of the concomitant medications made a signifi-
cant contribution to the amount of variability explained in the model, based on the adjusted R2
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values from that analysis. However, additional parameters must be estimated in order to fit a
SVRmodel. In combination with the relatively large number of sparse concomitant medication
variables, it is possible that the model fits that were manually tuned fit our specific full dataset
well, but would perform poorly on other datasets sampled from the same underlying distribu-
tion because the parameters are not generalizable. The polynomial kernel SVRs and the radial
kernel SVR for the full concomitant medication model had performance comparable to that of
the atorvastatin linear regression model: Degree 3 polynomial kernel RMSE = 23.533; Degree
5 polynomial kernel RMSE = 20.173; radial kernel RMSE = 16.805, versus RMSE = 20.480
± 8.642 for the linear model. The final fit plots for the atorvastatin SVR models are shown in
Figures 4.4, 4.64.7, 4.8 and 4.9.
Table 4.10: Atorvastatin SVR: manual tune model fit summary
Kernel Model RMSE Support Vectors Epsilon Cost
Linear Reduced 45.532 57 0.55 30
Full 32.342 37 0.75 320
Polynomial Degree 3 Reduced 38.381 60 0.55 5
Full 23.533 86 0.4 15
Polynomial Degree 5 Reduced 39.048 72 0.50 10
Full 20.173 86 0.35 345
Radial Reduced 31.164 84 0.35 5
Full 16.805 88 0.3 10
Table 4.11: Atorvastatin SVR CV summary (reduced model)
Kernel RMSE Support Vectors Epsilon Cost
Linear 18.964 65.464 0.348 157.848
± 10.154 ± 17.807 ± 0.197 ± 179.335
Polynomial Degree 3 20.553 56.372 0.546 22.304
± 10.759 ± 21.625 ± 0.305 ± 33.586
Polynomial Degree 5 20.561 59.898 0.514 144.466
± 10.903 ± 20.922 ± 0.302 ± 210.891
Radial 19.841 68.974 0.378 8.784
± 10.376 ± 19.492 ± 0.265 ± 9.132
4.4. Results 93
● ●
●
●
●
●●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
0 5 10 15 20 25 30 35
0
5
10
15
20
25
30
35
SVM Polynomial Kernel: Predicted vs Raw 
Atorvastatin_allconcom Plasma Concentration
True Plasma Concentration Value
Pr
ed
ict
ed
 P
las
m
a 
Co
nc
en
tra
tio
n 
Va
lue
SVM Linear
Full Model
(a) Linear kernel
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
●
●
●●
● ●
●
● ●
●
●
●
●
● ●
●
●
● ●
●
●
0 5 10 15 20 25 30 35
0
5
10
15
20
25
30
35
SVM Radial Kernel: Predicted vs Raw 
Atorvastatin_allconcom Plasma Concentration
True Plasma Concentration Value
Pr
ed
ict
ed
 P
las
m
a 
Co
nc
en
tra
tio
n 
Va
lue
Full Model
(b) Radial kernel
Figure 4.4: Atorvastatin SVR with all concomitant medications
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Figure 4.5: Atorvastatin SVR with all concomitant medications
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Figure 4.6: Atorvastatin reduced-model linear kernel SVR model fit
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Figure 4.7: Atorvastatin reduced-model degree 3 polynomial kernel SVR model fit
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Figure 4.8: Atorvastatin reduced-model degree 5 polynomial kernel SVR model fit
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Figure 4.9: Atorvastatin reduced-model radial kernel SVR model fit
Rosuvastatin
The rosuvastatin SVR model fits assessed in the 5-fold CV procedure varied in quality in a
manner similar to the model fits for the atorvastatin cohort. The model error for the rosuvastatin
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linear kernel SVR (RMSE = 16.864 ± 5.252) and the radial kernel SVR (RMSE = 17.715
± 5.472) were comparable to the error seen in the rosuvastatin linear model using dose as
a categorical covariate (RMSE = 16.314 ± 4.635). The linear kernel SVR had a very high
amount of variability in the optimal cost parameters chosen during CV (c = 174.896 ± 179.610)
in comparison to the average radial kernel model cost (c = 9.896 ± 13.574). In comparison to
the linear and radial kernel SVRs for rosuvastatin, the polynomial kernel SVRs assessed in the
CV analysis had substantially higher error, and comparably large variability in the quality of
model fit (degree 3 polynomial kernel RMSE = 26.028 ± 21.760; degree 5 polynomial kernel
RMSE = 25.907 ± 31.254). All of the rosuvastatin SVR model fits achieved by the two-step
tuning procedure had substantially higher RMSE values than were found in the CV model fit
assessment. The final model fits for the full rosuvastatin cohort are shown in Figures 4.10,
4.11, 4.12 and 4.13.
Table 4.12: Rosuvastatin SVR CV summary
Kernel RMSE Support Vectors Epsilon Cost
Linear 16.864 43.636 0.526 174.896
± 5.252 ± 14.409 ± 0.137 ± 179.610
Polynomial Degree 3 26.028 68.250 0.379 17.912
± 21.760 ± 16.534 ± 0.211 ± 30.486
Polynomial Degree 5 25.907 64.298 0.489 23.976
± 31.254 ± 25.085 ± 0.359 ± 40.836
Radial 17.715 73.694 0.285 9.896
± 5.472 ± 13.268 ± 0.127 ± 13.574
Table 4.13: Rosuvastatin SVR: manual tune model fit summary
Kernel RMSE Support Vectors Epsilon Cost
Linear 34.384 29 0.75 70
Polynomial Degree 3 28.280 64 0.55 70
Polynomial Degree 5 34.861 65 0.60 80
Radial 29.151 83 0.35 5
98 Chapter 4. Non-linear Modelling of Statin Plasma Concentration
●● ●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0 5 10 15 20 25
0
5
10
15
20
25
SVM Polynomial Kernel: Predicted vs Raw 
Rosuvastatin Plasma Concentration
True Plasma Concentration Value
Pr
ed
ict
ed
 P
las
m
a 
Co
nc
en
tra
tio
n 
Va
lue
SVM Linear
(a) CV parameter selection
●● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0 5 10 15 20 25
0
5
10
15
20
25
SVM Polynomial Kernel: Predicted vs Raw 
Rosuvastatin Plasma Concentration
True Plasma Concentration Value
Pr
ed
ict
ed
 P
las
m
a 
Co
nc
en
tra
tio
n 
Va
lue
(b) Manual parameter selection
Figure 4.10: Rosuvastatin linear kernel SVR model fit
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Figure 4.11: Rosuvastatin degree 3 polynomial kernel SVR model fit
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Figure 4.12: Rosuvastatin degree 5 polynomial kernel SVR model fit
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Figure 4.13: Rosuvastatin radial kernel SVR model fit
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4.5 Discussion
4.5.1 GAMs
Most of the di↵erences between the GAMCV  fit compared to the GAMfixed  fit appear to stem
from the trade-o↵ between the degrees of freedom used and the amount of smoothing given to
the continuous covariates. In the CV parameter model, the use of non-linear smoothing param-
eters for the continuous covariates was penalized to a larger extent than in the GAMfixed , in
which no such penalization was present. The increase in quality of model fit for the atorvastatin
GAMCV  over the linear model fit can thus be largely explained by the non-linear adjustment
to the modelling of time post dose. Based on the combined performance of the CV-smoothed
and fixed-parameter smoothed GAMs, it appears that the true e↵ect sizes for candesartan and
diclofenac are larger than the coe cient estimates observed in the linear regression model.
This can be inferred based on increased statistical significance seen in the GAMs that resulted
in higher estimated changes in the predicted atorvastatin plasma concentration.
Both of the fitted GAMs for the rosuvastatin model statistically significantly improved
model fit. While the two fitted GAMs did not di↵er significantly, the fixed smoothing parame-
ter rosuvastatin GAM o↵ered a slight improvement in model fit over the smoothing parameters
chosen via CV, while this was not seen with the atorvastatin GAMs. A possible explanation
for this is that the rosuvastatin model contains fewer parametric and non-parametric covari-
ates than the atorvastatin GAM, thus using fewer degrees of freedom in the model to perform
additional coe cient estimates. Because fewer coe cient estimates are needed in the rosu-
vastatin GAMs, using additional degrees of freedom on non-linear smoothing parameters for
the continuous covariates has less of a negative impact on model error. This is not taken into
4.5. Discussion 101
consideration when choosing smoothing parameters using CV, although this method is cer-
tainly the most consistent approach. A consequence of having arbitrarily smoothed functions
for each covariate is additional noise in the model, which can be seen both in the increased
RMSE found in the CV for the GAMfixed , and the wider confidence intervals of the smoothing
functions based on the resultant approximate p values. The sample size used to construct the
GAMs for both cohorts was also small; it is possible that with a larger data set, using curved
smoothing functions instead of linear functions for the continuous covariates would carry less
risk of overfitting, and consequently be penalized less. The graphs comparing the smooth
curves between the GAMCV  and the GAMfixed  for both atorvastatin and rosuvastatin may be
found in Appendix B.
4.5.2 SVR
Both the atorvastatin and rosuvastatin SVRs had better overall fit when trained using parame-
ter obtained via CV. However, performance varied widely between folds for some of the kernel
types, like the polynomial kernels and the linear kernel. The linear kernel SVR for the atorvas-
tatin cohort had a mean cost of 157.848 ± 179.335; similarly, the degree 5 polynomial kernel
SVR had a mean cost of 144.466 ± 210.891. This phenomenon was also observed in the ro-
suvastatin linear kernel SVR, which had a mean cost of 174.896 ± 179.610. The RMSE for
these models was comparable to the performance of the linear regression model, but the wide
variation in cost across folds suggests that the optimal parameters for these kernel types are
very sensitive to di↵erences between individual data sets, which is not ideal for a predictive
model. In contrast, the radial kernel SVR had relatively low variability in cost across folds for
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both the atorvastatin and rosuvastatin datasets, and performance comparable to that of the lin-
ear regression models. Because of this, the radial kernel SVR would likely be the most stable
choice for training a predictive model using SVR to predict statin plasma concentration in a
clinical setting.
Overall, the performance of the SVRs was not significantly better than the performance of
the linear regression models or GAMs. A potential reason for this is that it was possible to
obtain a reasonably accurate estimate of the e↵ect on plasma concentration for the full comple-
ment of selected concomitant medications for the atorvastatin cohort in the linear regression
and GAM. The concomitant medications improved model fit, and seemed to explain a good
deal of the variability of the upper tail, where the highest errors were for the reduced models.
It was possible to obtain reasonable e↵ect estimates for all of these covariates in the linear
models because no extra parameters were necessary for model fit. However, this type of spar-
sity is problematic when training SVR models, because extra parameters specifying model fit
must be selected in order to achieve a fit with reasonable accuracy. The large RMSE values
observed for all kernels types of the atorvastatin SVR compared to the error in the linear re-
gression model were likely due to one outlying patient with a particularly high atorvastatin
plasma concentration. This patient’s plasma concentration was predicted poorly by all of the
SVR models trained on the reduced concomitant medication atorvastatin dataset.
In general, the performance of the model parameters chosen via CV resulted in less overall
error than the models trained manually, perhaps because of the small size of the data set. Se-
lecting overall tuning parameters on such a small dataset by CV did not give stable results for
some of the kernels, where performance varied widely for di↵erent parameter combinations of
cost and epsilon. At this time, using the linear regression model or GAM to guide clinical deci-
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sions on statin dosing for new patients seems to be a better option than using SVR. If more data
were available, it is possible that the SVR would o↵er increased predictive performance, since
the ratio of parameter values to be estimated versus the number of available training observa-
tions would be more reasonable. Additionally, the SVR would have the advantage of being
able to manually set the cost value higher to reduce model error for patients who were under-
predicted using the original linear regression mode developed by DeGorter et al., in order to
achieve conservative dosing recommendations.
4.6 Conclusions
Modelling atorvastatin plasma concentration with GAMs resulted in improved model fit over
the linear regression models, as it allowed for modelling non-linearity in the continuous vari-
ables where advantageous. Most of the smoothing values chosen by CV had a low number
of degrees of freedom, and were smoothed to the point of being linear. However, time post
dose and age were given non-linear smooth fits for the atorvastatin and rosuvastatin groups,
respectively.
At this time, SVR does not appear to be a feasible modelling strategy for this dataset be-
cause of the small number of observations available, compared to the required number of model
parameters to be fit. At best, the predictive performance approached the accuracy of the linear
regression model. However, the linear regression model and GAMs are more easily inter-
pretable than the SVR results, which are a further reason to prefer using them over SVR when
it does not o↵er a substantial advantage in predictive performance.
104 Chapter 4. Non-linear Modelling of Statin Plasma Concentration
References
[1] Marianne K DeGorter, Rommel G Tirona, Ute I Schwarz, Yun-Hee Choi, George K
Dresser, Neville Suskin, Kathryn Myers, GuangYong Zou, Otito Iwuchukwu, Wei-Qi
Wei, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and ro-
suvastatin concentration in routine clinical care. Circulation: Cardiovascular Genetics,
6(4):400–408, 2013.
[2] Markus Gulilat, Anthony Tang, Steven E Gryn, Peter Leong-Sit, Allan C Skanes, Jef-
frey E Alfonsi, George K Dresser, Sara L Henderson, Rhiannon V Rose, Daniel J Lizotte,
et al. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine
care. Canadian Journal of Cardiology, 33(8):1036–1043, 2017.
[3] Laura E Jansen, Wendy A Teft, Rhiannon V Rose, Daniel J Lizotte, and Richard B Kim.
Cyp2d6 genotype and endoxifen plasma concentration do not predict hot flash severity
during tamoxifen therapy. Breast cancer research and treatment, pages 1–8, 2018.
[4] Simon Wood. Generalized additive models. Chapman & Hall/CRC, 2006.
[5] Trevor Hastie, Robert Tibshirani, and Jerome Friedman. The elements of statistical
learning. Springer-Verlag, 2009.
[6] Trevor Hastie and Robert Tibshirani. Generalized additive models. Statistical Science,
1(3):297–310, 1986.
[7] Werner Vach. Regression models as a tool in medical research. CRC Press, 2012.
[8] Simon N Wood. Generalized additive models: an introduction with R. CRC press, 2017.
REFERENCES 105
[9] Jean Duchon. Splines minimizing rotation-invariant semi-norms in sobolev spaces. In
Lecture Notes in Mathematics, volume 571, pages 85–100. Springer, 1977.
[10] Simon N Wood. Thin plate regression splines.
Journal of the Royal Statistical Society: Series B (Statistical Methodology), 65(1):95–
114, 2003.
[11] Katharina Morik, Peter Brockhausen, and Thorsten Joachims. Combining statistical
learning with a knowledge-based approach: a case study in intensive care monitoring.
Technical report, Technical Report, SFB 475: Komplexita¨tsreduktion in Multivariaten
Datenstrukturen, Universita¨t Dortmund, 1999.
[12] Raphael Pelossof, Andrew Miller, Peter Allen, and Tony Je-
bara. An SVM learning approach to robotic grasping. In
Robotics and Automation, 2004. Proceedings. ICRA’04. 2004 IEEE International Conference on,
volume 4, pages 3512–3518. IEEE, 2004.
[13] Inge S Helland. On the interpretation and use of r2 in regression analysis. Biometrics,
43(1):61–69, 1987.
[14] Lesley F Leach and Robin K Henson. The use and impact of adjusted r2 e↵ects in pub-
lished regression research. Multiple Linear Regression Viewpoints, 33(1):1–11, 2007.
[15] Ping Yin and Xitao Fan. Estimating r 2 shrinkage in multiple regression: a comparison
of di↵erent analytical methods. The Journal of Experimental Education, 69(2):203–224,
2001.
106 Chapter 4. Non-linear Modelling of Statin Plasma Concentration
[16] R Core Team. R: A Language and Environment for Statistical Computing. R Foun-
dation for Statistical Computing, Vienna, Austria, 2014. Available online at http:
//www.R-project.org/.
[17] Simon N Wood. Fast stable restricted maximum likelihood and
marginal likelihood estimation of semiparametric generalized linear models.
Journal of the Royal Statistical Society: Series B (Statistical Methodology), 73(1):3–36,
2011.
[18] David Meyer, Evgenia Dimitriadou, Kurt Hornik, Andreas Weingessel, and Friedrich
Leisch. e1071: Misc Functions of the Department of Statistics, Probability Theory Group
(Formerly: E1071), TU Wien, 2015. R package version 1.6-7.
[19] Julian J Faraway. Extending the linear model with r, 2006.
[20] Yoav Benjamini and Yosef Hochberg. Controlling the false dis-
covery rate: a practical and powerful approach to multiple testing.
Journal of the Royal Statistical Society. Series B (Methodological), 57(1):289–300,
1995.
[21] Shawn R Narum. Beyond Bonferroni: less conservative analyses for conservation genet-
ics. Conservation Genetics, 7(5):783–787, 2006.
Chapter 5
Background: Next Generation Sequencing
Next Generation Sequencing (NGS) of patient genomes has gained popularity as a way to
study genetic risk factors for disease, and to guide treatment regimes based on the prognosis
suggested by genetic factors. It is only within the past decade that NGS technologies have be-
come e cient, a↵ordable, and accessible enough to allow researchers to study on a widespread
scale. One of the largest and most well-known projects that has emerged in this area was the
1000 genomes project1, in which researchers proposed to sequence the genomes of 1000 vol-
unteers from around the globe. The objective of the project was to catalogue variability in the
human genome, including rare variation. The now-completed final product includes the genetic
sequencing information of 1092 individuals from 14 di↵erent populations, and is a resource for
researchers studying genetic origins of disease2.
The cost of genomic sequencing was originally prohibitive both in terms of financial re-
sources and time required to produce results. Fortunately advances in technology have brought
the cost of the first attempt to sequence the genome from 3 billion dollars over 12 years down to
1000 dollars and a single day of processing time using the current capabilities3. With genetic
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sequencing becoming more feasible for large-scale research, some of the main challenges in the
field are e ciently organizing, analysing and interpreting the huge amounts of data produced
by this technology.
5.1 DNA Structure
Many NGS technologies function by synthesizing or amplifying genomic DNA and learning
the sequence in the process. DNA synthesis is a complex process, and understanding the basic
structure of DNA is critical for understanding the data generated using these technologies.
The basic molecules and structure of DNA will be described in the following section, along
with relevant information on protein coding and its applicability to detecting disease based on
genetic variation between patients.
5.1.1 Basic Structure
Genomic DNA is two-stranded, and has a double helix structure that resembles a ladder. The
sides of the ladder are composed of alternating deoxyribose sugar and phosphate groups, and
and the rungs of the ladder are formed of the four nitrogenous bases adenosine (A), thymine
(T), cytosine (C) and guanine (G). These are attached to the sides of the ladder in pairs: A pairs
with T, and C pairs with G (Figure 5.1). Each pair of nitrogenous bases is held together by
hydrogen bonds, but the two strands can be separated (like a zipper) for duplication and DNA
synthesis4.
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Figure 5.1: DNA Structure: a) double helix form, b) straightened, c) strands separated
5.1.2 Protein Coding and Polymorphisms
DNA contains the blueprint for proteins to be synthesized within the body; proteins consist of
sequences of amino acid residues. Segments of DNA within the genome that encode proteins
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to be expressed are termed exons; the intervening segments are intronic, or introns5. Both
introns and genetic material between genes are called non-coding regions. The function of the
eventual protein to be synthesized depends on its folded 3D shape, which in turn depends on
the nucleotides in the exonic DNA sequence being in the correct order. When polymorphisms
(alterations) occur in the sequence, it can cause the protein to fold improperly. Proteins are
built by constructing a chain of amino acids, which are in turn coded for in DNA or RNA in
chunks of three nucleotide bases. These sets of three nucleotide bases are termed “codons”,
and there are 64 in total. The majority of these code for amino acids; however, 3 of 64 codons
are signals for termination5. Polymorphisms in DNA can change which amino acid is inserted
into the peptide chain, which can in turn change the way the protein folds. If a polymorphism
results in a terminal codon accidentally being read, the rest of the peptide chain to be folded
into the final 3-D protein will not be produced.
Depending on which bases have been changed, the polymorphism may increase, decrease
or negate the functionality of the protein relative to its ”wild” (most common) type; how-
ever, polymorphisms are often synonymous and do not result in changes in the expressed
protein. Polymorphisms in exonic DNA sequences that alter protein function are termed non-
synonymous (in which case the protein is altered because of amino acids being changed) or
non-sense (in which the protein is truncated prematurely because a stop codon has )6. When
only one base in the sequence is changed, it is termed a single nucleotide polymorphism (SNP).
Polymorphisms that occur in intronic DNA segments can alter the amount of protein produced,
but do not alter the sequence of amino acids6. Longer sequences of genes can also be altered;
these are termed structural variations7.
Genetic polymorphisms can take di↵erent forms: some examples are substitutions, dele-
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tions, insertions, copy number variations, translocations, frameshift alterations, and inverted
sequences5 (shown in Figure 5.2). A substitution occurs when a nucleotide in the sequence
is exchanged for another in comparison to a reference genome. Deletions occur when the se-
quence is missing a base compared to a reference genome; similarly, insertions occur when an
extra base is present in the sequence compared to a reference genome. In addition to single
bases being inserted or deleted, larger sections of DNA can also be a↵ected in this manner5.
Together, these types of polymorphisms are termed indels. Importantly, insertions and dele-
tions of bases in the reference genome can cause frame-shift polymorphisms, wherein the read
frame is shifted forward or back, in turn causing subsequent codons to be misread as well. In-
sertions and deletions are less likely to cause as much change when they are in sets of three, as
subsequent codons will not be misread. If the added codon(s) are not terminal, a single amino
acid will be added or removed from the peptide chain for each inserted sequence of three5.
Copy number variations occur when a single base or section of the reference genome has a
di↵erent number of copies in the DNA sequence; deletions are a special case of copy number
variations where fewer copies of the base are present in the DNA6. Translocation polymor-
phisms occur when a single base or larger section of DNA is in a di↵erent location in the
sequence compared to the reference genome. Similarly, inverted sequence variations can occur
where the bases in a larger region of DNA are reversed in the order found in the reference
genome. By observing where in the genome these changes occur and their frequency in the
population, individual sequence changes can be analyzed and associated with the risk of dif-
ferent diseases.
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Figure 5.2: Di↵erent types of structural variation (polymorphisms)
5.2 NGS Data and Workflow
The process of acquiring NGS data requires three main processing and analysis components.
The first phase of NGS data acquisition involves the benchwork and preprocessing of the DNA
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sample and obtaining DNA sequence reads using NGS8. The secondary step in NGS data pro-
cessing uses various algorithms and computational processes to align the DNA sequence ob-
tained in the primary analysis to a reference genome, and determine where variation is present
in the sequenced DNA. The final component of NGS processing seeks to interpret the infor-
mation generated in the previous two steps and determine whether variants present in the DNA
have clinical relevance8.
However, the low-level methodological details of how to use processed NGS data for the
purpose of predictive modelling are not often discussed in the research literature concerning
NGS, which can make using these techniques daunting for researchers that have not dealt
extensively with NGS analysis. Additionally, fewer tools are available for prioritizing data
from non-coding regions (introns) of the genome for predicting disease risk or drug response
than for exomes, which have multiple established software options for variant annotation5. The
following section provides a brief overview of the workflow required to obtain and process
NGS data, and the resulting contents of the data available for analysis from a data-science
perspective.
5.2.1 Primary Processing
During the genetic sequencing process, each DNA fragment may “read” a number of di↵erent
times. After sequencing, all of the recorded fragment reads must be aligned and then compared
to a reference genome to check for variants5. The number of times a particular nucleotide in a
certain position is identified is called read depth or sequence coverage, and provides a measure
of confidence in the sequencing accuracy for that particular location9. The read depth may vary
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substantially between di↵erent nucleotides even within the same fragment of DNA. Overall
indicators of the quality of coverage include average read depth, and minimum read depth;
user of the latter was recommended by Muzzey et al. because 50 reads generally gives a very
high confidence in the accuracy of the nucleotide identified, and further reads beyond this tend
to increase the cost of sequencing more than they improve accuracy3.
5.2.2 Secondary and Tertiary Processing
The second step in NGS analysis is to identify which nucleotides in the sequenced DNA have
changed in comparison to the reference genome, and for each change, what type of variation
is present8. This process is called variant calling, and developing optimal strategies for iden-
tifying these changes is an active area of research at present. Variant calling covers a wide
range of methodologies, including the use of support vector machines (SVMs), Bayesian ap-
proaches10, hidden Markov models (HMMs) and other machine learning techniques11. The
exact statistical methods used for variant calling depends on the sample size available (often
limited); whether the goal is to identify common variants (commonly defined as those found
in >5% of the population12) or rare variation6;13; and the section of the genome to be se-
quenced14. This process is challenging because there are potentially many machine-produced
artifacts from the sequencing process that could be falsely identified as relevant variants7. The
Sequence/Alignment Mapping (SAM) format and its complementary binary format (BAM)
are frequently-used alignment formats that were designed to perform e cient and accurate
identification of true variants, and are produced in a typical NGS workflow for use in fur-
ther processing15. The process of properly aligning the sequence to the reference genome and
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calling relevant variants can also involve filtering out variants that do not result in a protein
structure change, variants that do not cause a frameshift in alignment, duplicate segment data,
and variants that have been previously studied in other databases16.
After variants have been identified by comparing the newly sequenced DNA to the refer-
ence genome, the tertiary step of the workflow is to identify if any have clinical relevance to
the substantive problem application. Various annotation techniques are available to help with
this process, and they use existing genomic databases to flag the likelihood of each variant
to cause changes to the structure of the protein that it is associated with. ANNOVAR is an
example of a frequently-used annotation tool which is able to draw on previously dissemi-
nated genomic knowledge from a wide variety of sources that conform to a specific format
(Generic Feature Format version 3 (GFF3); two of the major sources of annotation informa-
tion are the 1000 Genomes Project and dbSNP16. Importantly, ANNOVAR also draws scores
predicting the functional impact of polymorphisms from other software. One program used is
SIFT (Sorting Intolerant from Tolerant17), which is an algorithm predicting the e↵ect of amino
acid substitutions in sequenced data. PolyPhen-2 is another algorithm used by ANNOVAR that
detects missense variations that can have deleterious e↵ects, and uses a Naive Bayes classifier
to accomplish this task18.
While the information provided by ANNOVAR allows clinical researchers to more easily
prune the available SNPs for inclusion in statistical modelling and decision support, several
drawbacks make using this information infeasible for some research goals. Firstly, ANNO-
VAR deals only with SNPs (substitution, insertion and deletion), and thus is not well suited to
studying larger structural variation in DNA sequences. Additionally, annotation methods like
SIFT and PolyPhen-2 do not actually predict disease risk, but protein nonfunction and while
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there is significant overlap, protein nonfunction is not a wholly accurate proxy for the risk of
disease acquisition14. Another di culty in using previously annotated information about varia-
tion present in patient samples is that almost all of the annotated variants in these databases are
for polymorphisms in coding regions of DNA. Because exonic DNA comprises only approxi-
mately a small fraction of the genome17, much less information is available on the frequency
and predicted e↵ects of non-coding variants comparatively. Despite this, the CADD (Com-
bined Annotation-Dependent Depletion) score evaluates the likelihood of variants to impact
disease risk for both intronic and exonic regions of DNA19;20. Mutations in exonic regions of
DNA are easier to study, and many tools have evolved for looking at only this portion of the
genome; indeed, Whole Exome Sequencing (WES) is a commonly-used and less expensive
alternative to sequencing an individual’s entire genome21. A similar method, targeted exome
sequencing (TES), further decreases the costs of sequencing by only sequencing a pre-selected
panel of protein-coding genes relevant to the specific variant identification problem of inter-
est22. Unfortunately, identifying clinically relevant variants is still a hard problem with exonic
data, particularly when the variants observed in the data have not been previously annotated14.
Additionally, it has been found that whole genome sequencing (WGS) actually has a higher
level of uniformity in detecting SNPs and indels, and thus WGS may be more e cient despite
the fact that it currently incurs greater financial cost to perform21. Ultimately, the choice to
use WGS, WES or TES is dependent on the research question posed, the resources available
for sequencing, the study design and individual researcher preferences; this is also true for the
choice of statistical method used for variant calling and variant prioritization.
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5.3 NGS Statistical Methods
Since the advances in cost- and time-e↵ective genome sequencing using NGS techniques, more
than 2000 polymorphisms in DNA that are associated with disease have been identified in
genome wide association studies (GWAS)23. Polymorphisms that are present in a relatively
large portion of the population are more likely to be identified in GWAS as being associated
with disease risk or drug response because a higher minor allele frequency (MAF) o↵ers more
power when looking at the associating of each SNP individually with disease. In contrast,
polymorphisms with MAF below 5% are much harder to detect in this type of analysis, be-
cause achieving adequate statistical power for these analyses would require a prohibitively
large sample size. Additionaly, the technique of examining the association between each rare
variant and disease risk separately requires thorough correction for multiple testing23. For-
tunately many options for RV identification have been developed since the advent of lower
resource-intensive sequencing techniques. Statistical techniques for identifying both rare and
common variation in NGS data will be discussed in the following section, with an emphasis on
challenges associated with small data sets.
5.3.1 Rare Variant Association Analysis
Two models for the e↵ect of genetic variants on complex disease have been proposed: the
Common Disease Common Variant (CDCV) hypothesis, and the Common Disease Rare Vari-
ant (CDRV) hypothesis. The CDCV theory postulates that many common variants with small
to moderate e↵ects are the main cause of common diseases; in contrast, the CDRV hypothesis
states that complex disease is caused by rare variants with a large e↵ect on phenotype. It has
118 Chapter 5. Background: Next Generation Sequencing
been observed that a more likely causal scenario involves the contribution of both common and
rare variants to the development of complex disease24.
Although associating rare genetic variation with phenotype or disease state poses method-
ological challenges, researchers have hypothesized that RVs can add significant insight to the
knowledge already gleaned from identifying common variants13, particularly when the impact
of the variant is strong25. Common variants are commonly defined as those with the MAF
occurring in more than 5% of the population. However, there is no consensus as to the ex-
act definition of what constitutes “rare” variation. In previous work, RVs have been variously
defined as MAF below 0.5%26, below 1%13;27;28, below 3%29, below 5%12, or below an un-
specified cuto↵24. The practice of setting an exact threshold to define which variants should
be considered rare has been noted to be arbitrary and is dependent on the characteristics of
the disease and genes under study25. Regardless of the di↵ering definitions of what constitutes
rarity between studies, many methods have been developed to increase the power to identify
RVs in sequenced data and relate these to disease status or phenotype. These techniques range
from the use of di↵erent sampling practices to advanced statistical modelling and correction.
5.3.2 Extreme Phenotype Sampling
One of the challenges associated with studying rare genetic variation in association with phe-
notype or disease risk is the di culty of detection; often in order to observe the rare variation,
infeasibly large samples would be required27. A way of circumventing the need to sequence
a prohibitive number of samples is to use Extreme Phenotype Sampling (EPS); in this method
phenotypic extremes of the disease spectrum of interest are sequenced in order to increaseMAF
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of the RVs in the sampled DNA30;27. EPS is also alternatively known as trait dependent sam-
pling31. EPS boosts the power of RV detection by increasing the likelihood that variants related
to the condition of interest will be present in the sequenced DNA sampled and often results in
much higher risk ratios observed for RVs than those observed in typical GWAS32. An example
of a study that has successfully used EPS to identify RVs was performed by Lange and col-
leagues; the authors were able to identify RVs associated with low density lipoprotein (LDL-C)
levels by sequencing patients with extremely high cholesterol and extremely low cholesterol
and comparing their genetic profiles33. Extremes in this context are usually defined as the 5th
and 95th percentiles of the trait distribution28. EPS has been promoted as much more power-
ful and cost e↵ective alternative to random patient sampling to identify RVs29;34. However, it
has been noted that Type I error rates and bias may be inflated when using EPS with classic
linear regression, particularly when stratifying on more than one phenotypic trait. To deal with
this, it has been suggested that the use of iterative maximum likelihood estimation (MLE) opti-
mization can decrease the probability of false positives when detecting RVs in association with
extreme phenotypes31. Other strategies have also been suggested to improve performance for
RV identification with EPS: Li et al. proposed a two stage approach in which the extreme tails
of the sample are tested, followed by the patients with non-extreme phenotypic values34. The
authors of this work also suggested an “almost-extreme” sampling method wherein the most
extreme values at the tails are discarded because of increased risk of measurement error and
variation, and the analysis is performed on the tails of the truncated distribution34.
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5.3.3 Burden Tests
While testing the association between single SNPs and phenotype or disease risk works quite
well for common variants, this method is severely underpowered for RVs because of the re-
duced likelihood of seeing the variant in any given patient population sampled35. Alternative
methodologies for identifying rare variants can be roughly divided into either burden tests, or
nonburden tests29. Both types of analysis combine the rare variation in a prespecified region
of sequenced data (such as a gene, or moving window of a fixed size), but di↵er in how the
variation is represented. Burden tests capture the number of variants in a given region, and
generally assume that each variant in a region a↵ects the risk of disease in the same direction
(deleterious or protective) and with the same magnitude29. Often the variants in a region are
thresholded based on their rarity, so that all of the variants collapsed into a single indicator for a
given region have equivalent frequency33. The Combined Multivariate and Collapsing Method
(CMC) is a commonly used burden test formulation developed by Li and colleagues24 that
combines a method of collapsing rare variation with a multivariate test. In the Cohort Allelic
Sums Test (CAST) collapsing method36, each case or control is given a variable that indicates
whether that individual has any rare variation (one or more copies of the variant allele) at the
specified location:
Xi =
8>>>>>>>><>>>>>>>>:
1 if rare variation present
0 otherwise
The amount of variation in a region can be tested between cases and controls in this paradigm
using the  2 test for the collapsed measure of variation24. In the multivariate test paradigm, all
genetic variants in a given region are tested for association with disease risk or phenotype si-
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multaneously. Genetic variation is defined slightly di↵erently than in the collapsing paradigm,
with specific indicators for one or two copies of the variant allele being present in a given
location j for patient case i24:
Xi j =
8>>>>>>>>>>>>>><>>>>>>>>>>>>>>:
1 if 0 variant alleles
0 if 1 variant allele
 1 if 2 variant alleles
Yi j is defined similarly for non-cases (controls) in the sample. Using this notation, the vector of
genotypes for patient i is given by Xi = (Xi1, ..., XiM)T , where M is the number of variant sites.
Similarly, Yi = (Yi1, ...,YiM)T denotes the vector of M genotypes for patient i of the control
population. We can also define a vector of genotypes X¯ j and Y¯ j for the case population and
control population respectively at variant site j, adjusted for the number of cases and controls
present in the sample:
X¯ j =
1
NA
NAX
i=1
Xi j Y¯ j =
1
NA¯
NA¯X
i=1
Yi j.
Hotelling’s T 2 test can be used to determine whether the presence of variation di↵ers between
cases and controls in the multivariate test paradigm:
T 2 =
NANA¯
NA + NA¯
(X¯   Y¯)TS  1(X¯   Y¯)
where S denotes the covariance matrix for the indicator variables across variants, X¯ = (X¯1, ..., X¯M);
Y¯ = (Y¯1, ..., Y¯M), and NA and NA¯ denote the number of cases and controls, respectively24. Con-
ceptually, in the above formula X¯ and y¯ represent the “mean” genotype over the cases and
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controls, respectively. The CMC method combines these strategies of capturing genetic vari-
ation by first collapsing over a group of markers of genetic variation according to predefined
criteria such as MAF, and then applying the multivariate test to the groups of collapsed markers.
The burden test score can alternatively be written more simply in the following form37:
Q =
26666664 mX
j=1
wj
nX
i=1
 
Yi   cµi,0  Xi j377777752
where n is the number of sequenced subjects, m is the number of variants in the region of
study, Yi is the phenotypic outcome, µˆ0 is a vector containing the estimated probabilities of the
outcome phenotype under the null hypothesis, and wj is the pre-specified weight for variant j.
Note that this form of the burden test score di↵ers considerably from the above T 2 equation; in
this formulation, Y indicates cases versus controls, and the covariate matrix X is defined for all
subjects.
Burden tests o↵er a substantial increase in power to detect the e↵ect of RVs in regions
where the variants have the same e↵ect on the outcome of disease. However, in cases where
the RVs have e↵ects in opposite directions using burden tests that collapse variation in this
way can have a severely detrimental e↵ect on detection power. This is because the e↵ects of
variants in a region (positive and negative) towards the risk of disease can cancel each other
out and thus fail to be identified27. Additionally, the CMC method does not easily allow the
inclusion of other covariates of interest (such as family history or other clinical factors that
might a↵ect patient phenotype), which is a substantial modelling drawback24.
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5.3.4 Nonburden Tests
Burden tests are a powerful tool in circumstances where RVs are predictive of a phenotype
to the same extent and with the same e↵ect (deleterious or protective)24. However, when
RVs in a region of DNA are being aggregated, it is more probable that both deleterious and
protective RVs will be present; at minimum, it would be very di cult to ensure that only RVs
a↵ecting phenotype in the same direction would be present in any given subsection of RVs to be
aggregated. Nonburden tests aggregate variation over prespecified regions of DNA, but unlike
burden tests they allow for expression of di↵erent qualitative and quantitative e↵ects of RVs on
disease risk. The Sequence Kernel Association Test (SKAT) is an example of a nonburden test
that provides a measure of association between phenotype and rare genetic variation.
Sequence Kernel Association Test
The Sequence Kernel Association Test (SKAT) captures rare genetic variation by calculating a
P value for each region of DNA over which variants are aggregated. For the linear modelling
context, SKAT follows the classic regression formulation:
yi = ↵0 +↵0Xi +  0Gi + ✏i
where the phenotype of individual i is denoted by yi; ↵0 is a constant intercept;Xi is a vector of
m covariates to be adjusted for;Gi = (Gi1,Gi2, ...,Gip) denotes the genotype for each individual
at each of p variant locations; ✏i is an error term; ↵0 is the vector of regression coe cients
for the m adjustment covariates; and   is our quantity of interest: the vector of regression
coe cients for each of the p variants38. The null hypothesis   = 0 is tested using a variance-
124 Chapter 5. Background: Next Generation Sequencing
component score statistic Q, defined as:
Q = (y   µˆ)0K(y   µˆ)
where µˆ denotes the predicted mean of the outcome variable y under the null hypothesis and
K = GWG0 is the kernel matrix where genotype is denoted byG. Within the kernel matrix,
W represents the weight given to the genotype for a particular variant. Alternatively, the SKAT
score statistic can be written as37:
Q⇢=0 =
mX
j=1
w2j
2666664 nX
i=1
 
Yi   cµi,0  Xi j37777752
where m is the number of the number of variants in a region, n is the number of sequenced
individuals, and wj is the weight for variant j. In this formulation, ⇢ denotes the correlation
structure of the variants and the outcome phenotype; in the case of SKAT, the variants need not
all have the same e↵ect on the outcome and so ⇢ = 0. The score statistics for burden and the
SKAT described above look very similar, because the equations di↵er only by the treatment of
the weighting on the variants; the weights are squared for the SKAT only. Conceptually, the
score statistic describes the amount of variation in y that is associated with genetic polymor-
phisms.
Choosing a good pre-specified weight for each variant can increase the power to detect
RV associations with phenotype; however, in practice it is unknown which variants should
be weighted more heavily because they are more predictive of patient phenotype. Wu et al.
propose to use a beta distribution density function with parameter values related to the MAF in
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the observed sample for each variant38. Based on the CDRV theory, variants that are rare are
assumed to have a larger e↵ect and thus should be weighted more heavily than variants with a
higher MAF; however, weights can be chosen according to whatever theory the user ascribes
to. The e↵ect of weighting is similar to a prior distribution; it is easier to detect e↵ects of
variants that are given high weight, but that makes variants with lower weight more di cult to
detect.
SKAT Reformulations
SKAT is a generalization of the C-alpha test, which uses permutation to calculate the p values
for aggregate variants in a region of DNA38. Either continuous or binary outcomes may be
used with the SKAT. Permutation methods involve resampling the available data (similar to the
bootstrap); while they can greatly enhance accuracy, they also incur significant computational
burden. SKAT has the advantage of not relying on computationally expensive permutation
methods to determine the association between variants and phenotype, and additionally allows
the user to control for relevant covariates38. The SKAT o↵ers substantial improvements in
power over burden tests when variants in a region have varying qualitative e↵ects on disease
risk (deleterious, null and protective). However, when variants in a region all influence the
risk of disease in a similar direction and magnitude, burden tests have the advantage of power
and thus the original SKAT formulation is not optimal39. To maximize power in both situa-
tions, an optimal SKAT formulation (SKAT-O) was developed by Lee et al to modulate the test
methodology depending on the correlation structure of the data, denoted by ⇢39:
Q⇢ = (1   ⇢)QSKAT + ⇢QBurden
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The SKAT-O is an additive linear combination of burden testing and the SKAT; in the SKAT-O,
variant regions with more homogenous e↵ects are calculated using the burden score statistic,
and variant regions with heterogeneous e↵ects are treated using the original SKAT score statis-
tic39. Lee et al. give a strategy for searching over multiple values of ⇢ while controlling the
Type I error rate39.
Another extension of the SKAT accommodates testing both common and rare variants in
a region. In this formulation (the RC-SKAT), the regression equation is further broken down
with separate weighting schemes for rare and common variants37:
g[E(Yi)] = ↵0 +↵0Xi +  1Ri +  2Ci
where g(·) is a link function; ↵0 is the intercept for the linear model;Xi is the covariate design
matrix for subject i;Ri is the matrix of rare variants for subject i; Ci is the matrix of common
genetic variants; and ↵0,Ri and Ci are the coe cient vectors for the covariates, rare variants,
and common variant e↵ects respectively. The e↵ects of the common and rare variants on dis-
ease risk are assessed jointly using an weighted sum of the score test statistics for each. Under
the CDRV theory, genetic variations that are rare are hypothesized to have stronger causal ef-
fects on disease risk than common variations, and thus the common and rare variants in this
model are given di↵erent weighting schemes that reflect this37. Other alternatives for mod-
elling the joint e↵ect of common and rare variants on disease risk proposed by the authors who
developed the RC-SKAT are an adaptive sum test, or Fisher’s Combination Method, instead of
a simple weighted sum. Finally, SKAT has also been reformulated to accommodate small sam-
ple sizes, which are often used by necessity in WGS and WES because of the prohibitive costs
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involved in sequencing a large number of subjects. The original formulation of the SKAT has
been found to be conservative for small sample sizes, which already su↵er from low power40.
The SKAT adjustment for small sample sizes increases the power of the test by adjusting for
the skew and kurtosis of the sample40.
Kernel Choice
One of the fundamental strengths of the SKAT is the use of a kernel function to test vari-
ant association; the kernel test evaluates pairwise genetic and trait similarities for all of the
patients and variants in the sample, and the level of similarity is then used as a proxy for geno-
type/phenotype association35. The linear kernel is a popular choice for constructing a similarity
matrix. The linear kernel formula is given by
K(Zi,Zi0) = Z0i Zi0 .
Although only linear kernel machines are usually discussed in the context of the SKAT, they are
not always a good fit for the data. Many kernels can be used for this purpose, and examples of
other candidate kernels for identifying associations in NGS data include the quadratic kernel:
K(Zi,Zi0) = (Z0i Zi0 + 1)
2
and the IBS kernel35:
K(Zi,Zi0) = (2p) 1
2X
j=1
(2   |Zi j   Zi0 j|).
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The associations between the SNPs in Zi and yi are tested using the test score statistic
Q =
(y   by0)0K(y   by0)b 20 .
Using an inappropriate type of kernel can severely reduce the power of the test to identify
associated SNPs. One potential method for choosing a kernel would be to simply test all of
the kernels that may be appropriate given the distribution and assumptions underlying the data
and use the kernel with the greatest statistical significance. However, as in most statistical
paradigms, this type of multiple testing can lead to an increased risk of falsely identifying
associations in the data. Additionally, it is possible to combine multiple kernels as well as
choosing between them. Wu and colleagues developed a testing framework for choosing the
best possible kernel or combination of kernels for use in genetic association studies35. In this
paradigm, a P value can be calculated for a weighted average of kernels directly, or using
perturbation-based inference to compare the performance of di↵erent candidate kernels for the
set of SNPs being tested. In this case, P values are compared instead of a test statistic because
the test scores can be scaled in very di↵erent ways depending on the kernel used, which makes
direct comparison of those statistics infeasible35.
5.3.5 DoEstRare Rare Variant Identification
The previously described methods seek to identify RVs associated with disease risk by evalu-
ating their frequency and associated estimated burden irrespective of the exact position of the
variant’s location. However, it is also possible to take advantage of specific positional infor-
mation for variants to identify associations with disease risk or phenotype. Several methods
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have been developed for this purpose, but the method using this strategy found to be the most
e↵ective for identifying RVs most recently is the Density-oriented Estimation for Rare-Variant
positions (DoEstRare) test25. DoEstRare accomplishes this by using a weighting function to
represent the overall variant frequency and kernel methods to compare the position density of
the variants in cases versus controls, in line with the following hypotheses:
H0 : f A = f U AND pA = pU
H1 : f A , f U OR pA , pU
where f denotes the mutation position density function for a↵ected individuals A (cases) and
una↵ected individuals U (controls), and p denotes the average allele frequency for a↵ected
individuals A (cases) and una↵ected individuals U (controls)25. The test score for DoEstRare
is given by Z Lg
1
|bpA ⇥ bf A(pos)   cpU ⇥ cf U(pos)| dpos
where Lg is the gene’s length, the mean allele frequencies are estimated by bpA and cpU , and
the position density functions are estimated by bf A and cf U . While this method is extremely
powerful for identifying disease associated RVs in large sample sizes that have a relatively
good representation of rare MAFs in the data, the performance of this method deteriorates
when faced with extremely small sample sizes. In the case where few RVs are present in
the sample, the location information is irrelevant because there generally will not be enough
positional overlap between variants in di↵erent individuals25.
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Chapter 6
Identifying Novel Genetic Polymorphisms
to Model Rosuvastatin Plasma
Concentration
6.1 NGS Patient Selection
In order to identify SNPs associated with prediction quality for patients taking rosuvastatin
in our model, we ideally would perform next generation sequencing (NGS) on all of the pa-
tients in the sample so as to have the greatest power to detect rare variation. Unfortunately,
while NGS has become much more a↵ordable and thus accessible, the cost of sequencing a
large number of patients can still be prohibitive depending on the resources available to the
researcher. In order to leverage the most relevant information for our prediction problem, we
employed a method of Extreme Phenotype Sampling (EPS) to identify di↵erences in the ex-
tremes of the sample distribution for our outcome of interest1. Generally EPS is used when
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large phenotypic variation is present for a particular substantive topic. In this case, we can use
the extremes of predictive performance of the regression model to select patients for further
study. This involves identifying patients whose plasma concentrations are predicted well using
the model, and patients whose predicted plasma concentrations based on the model are very
inaccurate, using a common metric of prediction quality. If a patient is poorly predicted, there
are two possible outcomes for their predicted plasma concentration: it is either much lower
than expected, or it could be much higher than expected. Over-prediction would be hypothe-
sized to confer a lower risk of myalgia, since the high estimated statin plasma concentration
would be associated with a more conservative dose of medication given to the patient, if used
for clinical decision support. Under-prediction in this context may be more problematic how-
ever, because if a patient’s plasma concentration were to be higher than their expected value,
they could unknowingly be prescribed a dose that would have a higher possibility of produc-
ing undesirable side e↵ects. We hypothesize that studying the di↵erences in genetic variation
between patients who are well-predicted versus patients whose actual plasma concentration
values are much higher than expected given their model predictions would have the greatest
impact for future studies modelling rosuvastatin plasma concentration as a potential indicator
for the risk of adverse drug events.
6.1.1 Original Rosuvastatin Systemic Exposure Linear RegressionModel
Fit Assessment
A predictive model including common genetic markers for rosuvastatin plasma concentration
has been previously developed by DeGorter et al.2;3. The specific details about the rosuvas-
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tatin patient cohort characteristics can be found in Chapter 4. The outcome of the linear model
was rosuvastatin plasma concentration; this value was log-transformed to make the distribution
more normal. The clinical variables included in this analysis were age, dose (mg; represented
continuously in the originally developed systemic exposure model and converted to a cate-
gorical variable in the augmented model we present), time post dose (hours), BMI (km/m2).
The genetic polymorphisms included in this model were SLCO1B1 c. 521T>C and ABCG2
c. 421C>A. The amount of variability in the outcome measure captured by the original linear
regression model was relatively high: with the original covariates and dose represented cate-
gorically, the model had an R2 value of 0.56 (SD=0.03), obtained by 5-fold cross-validation
(CV), the full method details for which can be found in Chapter 4.
In order to more finely assess the predictive performance of the original systemic exposure
model for the rosuvastatin cohort, we performed an analysis using leave-one-out CV (LOOCV)
for the patients in the rosuvastatin cohort. We chose not do 5-fold CV because wanted to use
the maximum amount of data for every individual prediction, since the dataset is relatively
small. Using the covariates included in the original rosuvastatin systemic exposure model,
predictions were generated for each patient in the rosuvastatin cohort, with the coe cients for
each model obtained by training a linear regression model on the remainder of patients in the
data set. The quality of the model was assessed for each patient by using their profile as a
test case for the model trained on the remaining patients. The following predictive model fit
quality metrics were obtained for each patient in the rosuvastatin cohort: the magnitude of
deviation of the predicted concentration from the true plasma concentration, whether or not
the concentration was under-predicted, squared error, and proportional di↵erence between the
predicted and actual values.
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In addition to obtaining summary statistics from the LOOCV, we also conducted a visual
analysis of the range of predicted versus actual plasma concentration values for the rosuvastatin
predictive model. Using the predicted values obtained from the CV, we made comparative
graphs of the predicted and actual plasma concentrations, for both the raw and log-transformed
values. The log-transformed values for the rosuvastatin cohort were reasonably close to linear;
however, even with the log transform, the tails of the distribution did not fit the assumption of
normality. The skewness of the distribution is likely due to the log transformation and the fact
that one cannot have a negative value for statin plasma concentration; this necessarily increases
the number of patients underpredicted than overpredicted, as the statin plasma concentration
cannot go below zero.
As postulated at the beginning of this section, poor prediction at the upper tail of the plasma
concentration distribution is problematic for predicting statin dose in such a way so as to min-
imize the potential for augmented plasma concentration and thus myopathy, if used in the
context of clinical decision support. The trade-o↵ for this is that focusing on only the up-
per tail may carry the risk of having overly conservative dosing schemes, resulting in lowered
statin e cacy. This risk could be balanced by periodic monitoring of the patient’s statin plasma
and LDL cholesterol levels. The rosuvastatin plasma concentration distributions are shown in
Figures 6.1 and 6.2.
6.1.2 Selection Algorithm for Patient Sequencing
The quality metric of accuracy for selecting patients for NGS was the raw proportional di↵er-
ence between the actual value and the value predicted by the modified rosuvastatin systemic
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exposure model. This metric was chosen because for the purposes of this research question, we
are much more interested in patients who are under-predicted using the original rosuvastatin
systemic exposure prediction model, rather than those who are over-predicted. The propor-
tional di↵erence range of the “well predicted” values was defined as 0 plus or minus the abso-
lute value of the maximum (positive) proportional di↵erence seen in the sample (0 ± 0.778), in
order to ensure that range of well-predicted values was symmetrical. The number of available
patient slots for NGS processing was 48; 54 patients were chosen from the sample in case some
of the samples could not be properly sequenced. All of the patients whose proportional di↵er-
ence values fell outside the specified range of well-predicted variation were to be sequenced;
for the remaining patient slots, a random sample of patients within the specified range of well-
predicted proportional di↵erences were selected as a comparison group. A number of patients
within the lab had already had their genomes analysed with NGS; these patients were excluded
from the candidate patients in the sequencing selection process, but their results were included
in the final analysis for identifying novel variants. The full distribution of proportional di↵er-
ence scores is shown in Figure 6.3, with the under-predicted patients selected for sequencing in
red, the well-predicted patients randomly selected for sequencing in blue, and the unsequenced
patients in white.
6.1.3 Patient Selection Results
48 patients in total were to be selected for NGS. In total, 21 patients in the rosuvastatin cohort
were identified as being cases: these patients were under-predicted using the original model
developed by DeGorter et al.3, and the proportional di↵erence values between their predicted
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Figure 6.3: Rosuvastatin cohort proportional di↵erences between predicted and raw values of
plasma concentration based on the modified systemic exposure linear regression model
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and actual plasma concentrations using that model were relatively large. Of these 21 patients,
5 had been previously sequenced using NGS technology, while one patient’s DNA could not be
sequenced, leaving a total of 20 under-predicted cases for this analysis. A table summarizing
the population characteristics of the under-predicted cases can be found in Table 6.1. Further-
more, 33 individuals were selected for sequencing within the control group of patients who
were well-predicted using the previously developed rosuvastatin systemic exposure regression
model. An additional 17 patients whose proportional di↵erence values fell within the range
of well-predicted plasma concentrations had previously been sequenced by the lab; combining
these, a total of 50 well-predicted control patients were included in the analysis (population
characteristics also summarized in Table 6.1). The population characteristics for the cases and
controls combined are shown in Table 6.2.
Table 6.1: Population characteristics of NGS processed rosuvastatin cases and controls (n=20)
Cases (N=20) Controls (N=50)
Patient Characteristic Mean/Prop. SD% Mean/Prop. SD/%
Age (years) 58.60 11.85 56.10 13.69
Body Mass Index (kg/m2) 30.64 5.88 29.60 5.60
Time Pose Dose (hours) 13.43 4.01 14.01 3.66
Rosuvastatin Dose (mg)
5 9 45.0% 5 10.0 %
10 4 20.0% 14 28.0%
20 1 5.0 % 22 44.0%
30 0 0.0 % 2 4.0%
40 6 30 % 7 14.0%
Gender (Male=1) 10 50.0% 34 68.0%
Ethnicity (Non-Caucasian=1) 3 15.0% 4 8.0%
Minor Allelic Frequency
SLCO1B1 c.521C 4/40 10.0% 22/100 22.0%
ABCG2 c.421A 4/40 10.0% 8/100 8.0%
144 Chapter 6. Novel SNPs for Predicting Rosuvastatin Plasma Concentration
Table 6.2: Population characteristics of all NGS processed rosuvastatin patients (n=70)
Patient Characteristic Mean/Proportion SD/Percentage
Age (years) 56.81 13.16
Body Mass Index (kg/m2) 29.89 5.66
Time Pose Dose (hours) 13.85 3.75
Rosuvastatin Dose (mg)
5 14 20.0%
10 18 25.7%
15 0 0.0%
20 23 32.9%
30 2 2.9%
40 13 18.6%
Gender (Male=1) 44 62.9%
Ethnicity (Non-Caucasian=1) 7 10.0%
Minor Allelic Frequency
SLCO1B1 c.521C 26/140 18.6%
ABCG2 c.421A 12/140 8.6%
6.2 Novel SNP Identification via NGS
6.2.1 DNA Processing
DNA had been previously extracted from a blood sample. Targeted exome NGS was applied
using the PGxSeq panel including 100 genes relevant to drug metabolism, absorption, distri-
bution, excretion and response were targeted for sequencing; full details of these methods are
described by Gulilat et al in as-yet unpublished data4. The Nextera Rapid Capture Custom
Enrichment Kit (Illumina, San Diego, CA) was used to enrich these regions prior to the NGS
process. The NGS procedure was conducted on the Illumina MiSeq Sequencer (Illumina, San
Diego, CA), and took place at the London Regional Genomics Centre in London, Ontario.
Following sequencing, the sequenced genomic information was obtained in the form of
FASTQ files, and then underwent a quality control assessment using FastQC5. Variant calling
and sequence alignment were performed using the CLC Bio Genomics Workbench 7.0 (CLC
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Bio, Aarhus, Denmark) using a custom-automatic workflow4.
6.2.2 Data Processing
Ideally, we would attempt to identify specific novel genetic polymorphisms within each gene;
however, this is infeasible given the small sample size and large number of variants present
in the current work. Instead we aim to identify full genes that are relevant to the problem of
predicting rosuvastatin plasma concentration, and subsequently perform more specific analy-
ses within these genes to locate specific variations that are pertinent to changes in rosuvastatin
plasma concentration. The sequenced and filtered variant information was exported for sta-
tistical analysis in the form of Variant Call Format (VCF) files for each individual patient.
Following this, index files were generated for each patient VCF file in preparation for merging
the files together. The index files were obtained using the tabix command from the SAM-
tools package6; the command performs indexing on compressed TAB-delimited position files
and adds supplemental sequencing information7. Subsequently a shell script generated using
R was used to automate the merging process on the command-line with the Genome Analysis
ToolKit (GATK)8. Following this, the VCFtools software package9 was used to remove longer
indels from the merged data that would interfere with future processing, as well as genes on the
X and Y chromosomes. Auxilliary files (in BIM, FAM, and SSD formats) were required for
later processing steps; these were generated using PLINK on the command-line10; PLINK is an
open-source C/C++ toolkit that was developed for processing large data sets for whole-genome
association studies.
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6.2.3 Methods
The Sequence Kernel Association Test (SKAT) was used to determine di↵erences between the
genetic profiles of patients who were under-predicted versus those who were well-predicted
using the original rosuvastatin systemic exposure model3. The R SKAT11 package was used for
this analysis, using the optimal SKAT-O formulation which combines the burden and SKAT
tests12. Other SKAT formulations could also have been used, and di↵erences in the results of
using these should be compared in future work. Because the dataset contained only a small
number of individuals, the SKAT correction for small sample size was applied13. A linear
kernel was used for this analysis.
Before the data could be processed using the SKAT function, it had to be imported into
R and formatted into the gene matrix Z required as input for the analysis. The first stage
of this process involved loading the zipped VCF file containing the merged data of all of the
sequenced patients; the vcfR package was used for this purpose14. This package was extremely
helpful for getting the data into R; however, the vcfR object was not in a compatible format
to be used with the SKAT function. The second stage of the process of preparing the data for
analysis in R was to reformat the vcfR object into a matrix of genotypes using the vcfR2loci
function implemented in the adegenet R package15;16. This extracted the SNP data into the
right structure, but had to be manually recoded from a matrix of factors to the numeric coding
required by the SKAT function (2 = ’1/1’, 1 = ’0/1’, 0 = ’0/0’, 9 = missing). Once Z was in
the correct format for the analysis, additional processing was required to generate an indexing
scheme to map the SNPs to a gene or region; this was the step that required the BIM, BED,
FAM and SSD auxilliary files. The ANNOVAR software package17 was also required for the
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generation of these files. The Generate SSD SetID function included with the SKAT package
combined these files to create a SetID object. This SetID object then had to be cast to a
variable using the Open SSD function, also included in the SKAT package. In an ideal situation
this elaborate data formatting would be unnecessary, as ANNOVAR is able to identify gene
names based on chromosome location information; we had to perform this step manually due
to software limitations.
Before running the actual SKAT analysis, we fit the null model for dichotomous outcomes
(SKAT Null Model), controlling for the original covariates included in the linear regression
model. At this time, all of the data was formatted properly for input into the SKAT function.
The first time the SKAT.SSD.All function was run, it returned an output consisting of a series
of P values for each gene or region that contained the individual SNPs as specified in the
SetID file. However, it was discovered that one of the auxilliary files contained errors, which
were manually changed in a text editor so as not to require regenerating all of the auxilliary
files. Further attempts to use the SKAT.SSD.All function were fruitless, as were attempts to
manually specify the set ID and use the SKATBinary. The entire data-formatting process was
repeated from after the VCF merge, but no solution in R or the command-line could be found.
The basic SKAT function for a SNPs in a single set was still operational, so in the end a for
loop was used to manually iterate over all of the sets (>1000) and calculate the approximate
P value for each gene. The P values were then compiled and the Holm method was applied
to correct for multiple testing18. The choice of correcting method wound up being somewhat
irrelevant, given that the only corrected P value below 1.0 was for NR1I2 (P = 0.99), and this
did not di↵er meaningfully for the other available methods with this package.
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6.2.4 Results
Most of the P values returned from the SKAT procedure were 1.0; however, 41 total genetic
regions had P values below this level, of the 1212 genetic locations in the dataset located in
the 100 gene targeted sequencing panel. Given the potential for an inflated family-wise error
rate (Type I/ ↵ error) due to multiple testing, it would not be meaningful to discuss the genes
highlighted in this analysis in terms of traditional “statistical significance” (ie. P < 0.05).
Instead, the top three genes with the lowest P values found in the SKAT analysis will be
discussed. Other genes may also be relevant, but without a larger sample size for sequencing,
it is di cult to determine with more precision which specific regions they include. The top 10
genes with the strongest signal for the current prediction problem are shown in Table 6.3, and
subsequently described using information from the GeneCards database19.
Table 6.3: Rank and unadjusted P values from SKAT procedure
Rank Gene Unadjusted P Value
1 ABCC1 0.022
2 NR1I2 0.031
3 SLCO1B3 0.035
4 MTHFR 0.058
5 C1orf167 0.058
6 CBR3 0.085
7 SLCO2B1 0.094
8 ATIC 0.108
9 POR 0.169
10 SLC22A1 0.171
The gene with the strongest signal resultant from the SKAT analysis was the ATP Binding
Cassette Subfamily C Member 1 gene ABCC1, which is also known as Multidrug Resistance-
Associated Protein 120. Importantly, ABCC1 is an e✏ux transporter acknowledged to be
strongly associated with intracellular statin accumulation, and has been shown to be expressed
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in skeletal muscle tissue21. In the same study, it was shown that intracellular statin toxicity was
ameliorated by over-expressing this e✏ux protein21. Individual variants of ABCC1 and their
corresponding frequencies in the case and control cohorts are shown in Table C.1.
The gene with the second strongest signal resultant from the SKAT analysis was the preg-
nane X receptor (PXR); this is also known as the human orphan nuclear receptor22 or the
Nuclear Receptor Subfamily 1 Group I Member 2 (NR1I2)23;24. PXR is a transcription factor
of xenobiotic- and drug-inducible expression of key genes that encode members of the phase
I and phase II metabolic enzymes and drug transporters, including ABCG224, of which rosu-
vastatin is a substrate. ABCG2 regulates systemic exposure to rosuvastatin by controlling its
e✏ux and limiting its absorption from the gut25. No direct association between rosuvastatin
pharmacokinetics and PXR was found in a recently performed study26 examining the impact
of polymorphisms in PXR, ABCG2, and other genes. However, given its control of ABCG2
expression in the gut and liver, it is possible that further study into PXR as a mediator of rosu-
vastatin pharmacokinetics is warranted. The variants present in the case and control cohorts as
well as their MAFs are shown in Table C.2.
The gene with the third strongest signal produced by the SKAT analysis was Solute Car-
rier Organic Anion Transporter Family Member 1B3 (SLCO1B3), which codes for the drug
transporter OATP1B3, which is known to transport rosuvastatin27. OATP1B3 has been dis-
cussed as an important factor in the hepatic clearance of its associated substrates, including
rosuvastatin28;29, which can contribute to systemic exposure.
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6.2.5 Discussion
All of the top three genes identified in the SKAT analysis are associated with rosuvastatin drug
transport, which provides a potential explanation of why these particular genes have su cient
signal to distinguish under-predicted rosuvastatin patients from well-predicted controls. Be-
cause of the relatively small sample size of the current study, the results are exploratory and
should be used to guide further biological inquiry into specific polymorphisms in these genes
that have the potential to a↵ect rosuvastatin plasma concentration, and whether inclusion of
these SNPs as predictors could be used to increase the accuracy of the original rosuvastatin
systemic exposure model.
A major obstacle in the current work was obtaining results from the analysis because of
di culties in using software that is currently the state-of-the-art for this type of modelling. An
amazing amount of work has gone into developing each piece of open-source software used
to format and process the NGS data; however, coordinating these separate processes incurs a
prohibitive technical burden. This is especially true for researchers who are not familiar with
shell-scripting and using the command-line. Even installing the packages for use in processing
the data was challenging, given that some operating systems (such as macOS) do not possess
the necessary command-line tools by default.
In general, we were unable to find any thorough tutorials that guided the user from the
data in FASTQ format to the eventual analysis we performed. The creation of a technically
accessible open-source application to facilitate genetic analysis should be considered an open
software engineering problem; until then, statistical analysis of NGS data may be performed
suboptimally just because of the practical di culties involved in its execution. For example,
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in the current work we were unable to use the SKAT analysis specific to common and rare
variants, and testing multiple kernels was infeasible due to the computational requirements of
manually iterating over each collection of SNPs. Ease of use should be a primary consideration
when designing software for a non-technical user base, as not all genetic researchers possess
extensive skills in bioinformatics.
6.2.6 Conclusions
In the current work, we presented results from an exploratory analysis that highlights genes
that may be of relevance for the problem of more accurately predicting rosuvastatin plasma
concentration, and in particular identifying individuals who are at risk of having much higher
than expected plasma concentrations that would put them at a higher risk for adverse drug
events. The three genes with the strongest signal resulting from this analysis all have extensive
ties to pathways regulating lipid metabolism. However, further biological research must be
done to confirm this relationship and identify specific polymorphisms in these genetic regions
that could be particularly predictive of rosuvastatin plasma concentration. A limitation of this
work is the subjects for the NGS analysis were selected using the phenotypes generated original
linear regression model, and not the slightly improved GAMmodel fit; this was simply because
of research timing (the two analyses were run concurrently).
A substantial barrier to performing the analysis described in this chapter is the technical
burden required to install and use the necessary individual software components. We propose
that developing a user-oriented software interface that improves ease of use should be consid-
ered an open software engineering problem.
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Chapter 7
Discussion and Conclusions
The primary objective of this thesis was to explore avenues for improving a previously devel-
oped algorithm to predict atorvastatin and rosuvastatin plasma concentration using clinical and
genetic determinants. This was achieved by 1) developing a selection algorithm to identify
relevant concomitant medications to improve model fit; 2) exploring the use of non-linearar
modelling techniques in the atorvastatin and rosuvastatin cohorts in comparison to the original
linear model used to predict systemic exposure1; and 3) selecting patients for DNA sequencing
and conducting exploratory analysis to identify potentially relevant genes and their associated
variants for further biological study. This final chapter will identify the key contributions to
the relevant literature made in this thesis, as well as the main strengths and limitations of the
current work. Future directions for this research will also be discussed.
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7.1 Summary of Key Contributions
7.1.1 Objective 1
The first objective of the current work was to review the literature on appropriate variable selec-
tion techniques that could be used to identify concomitant medications associated with changes
in atorvastatin and rosuvastatin plasma concentration, and assess the e↵ect of their inclusion
in the quality of fit for the linear regression models. The initial product of this objective was
a narrative review detailing which medications found in the literature could theoretically im-
pact statin plasma concentration. Following this, we characterized concomitant medication use
in the atorvastatin and rosuvastatin patient cohorts. The final methodological product of this
research was the development of a robust concomitant medication selection paradigm, which
used penalized regression to determine which medications had the strongest predictive signal
in relation to changes in plasma concentration. The selection algorithm leverages information
on the medication class to overcome the modelling challenges associated with having many
more covariates than available observations.
A number of concomitant medications were identified as being associated with atorvastatin
plasma concentration. These included: acetylsalicylic acid, atenolol, candesartan, diclofenac,
digoxin, esomeprazole, gliclazide, glucosamine, hydrocholorothiazide, levothyroxine, losar-
tan, metformin, misoprostol, nifedepine, tamsulosin, valsartan, venlafaxine and vitamin B3.
Many of these medications had been identified in the narrative review as having the potential
to a↵ect atorvastatin plasma concentration; however, several medications had not been previ-
ously mentioned in the body of literature examined in the current work. These concomitant
medications included acetylsalicylic acid, atenolol, diclofenac, esomeprazole, gliclazide, glu-
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cosamine, hydrochlorthiazide, levothyroxine, misoprostol and tamsulosin. We recommend that
further biological research be conducted to determine if there are causal e↵ects between these
medications and changes in atorvastatin plasma concentration. The inclusion of all of the se-
lected medications in the atorvastatin linear model for dose-prediction had a significant impact
on model fit, and greatly increased the variance explained in the linear regression.
In contrast, only one medication was identified as being associated with rosuvastatin plasma
concentration. Ranitidine was identified by the concomitant medication algorithm as being
associated with rosuvastatin plasma concentration. However, it is likely that this association
is spurious. Reasons for this include a lack of evidence in previous literature, a lack of any
plausible causal mechanisms between the pathways a↵ected by both drugs, and that only a
very small number of patients in the rosuvastatin cohort had concomitant use of ranitidine. The
inclusion of this medication in the linear model had no significant impact on model fit. The lack
of concomitant medications associated with rosuvastatin plasma concentration is consistent
with the literature suggesting that genetic variation and polymorphisms in drug transporters
may have a greater e↵ect on changes in rosuvastatin plasma concentration than concomitant
medications2, because rosuvastatin is minimally metabolized, unlike atorvastatin3. Despite
not identifying any concomitant medications that increased the predictive ability of the model,
the model fit of the linear regression model was improved by modelling rosuvastatin dose
as a categorical variable instead of a continuous variable. This is likely because very few
unique doses were present in the rosuvastatin cohort, which would make establishing a linear
relationship between dose and plasma concentration very di cult.
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7.1.2 Objective 2
The second objective of the current work was to explore whether non-linearar modelling tech-
niques could be of use in improving the predictive capability of the dose-prediction linear
regression model with the atorvastatin and rosuvastatin cohort data. The two techniques tested
were generalized additive models (GAMs) with linear, degree 3 polynomial, degree 5 polyno-
mial, and radial kernels; and support vector regression modelling (SVR) We also examined the
e↵ect of choosing smoothing parameters for the GAMs via cross-validation (CV) or using fixed
parameters with a moderate smoothing value. We employed CV to assess model error and fit
for each GAM both with fixed parameters and parameters chosen by CV within the GAM.
The atorvastatin GAM with smoothing parameters chosen by CV o↵ered a significant im-
provement in model fit over the atorvastatin linear model including the concomitant medica-
tions, while the atorvastatin GAMwith arbitrary smoothing parameters did not. This e↵ect was
attenuated when corrected for multiple comparisons, but still trended towards statistical signif-
icance. The parameters chosen by CV penalized the smoothing of age, 4 -hydroxycholesterol
and BMI to the point where they were treated much like the parametric covariates and mod-
elling using linear functions. However, a significant non-linearar relationship between time
post dose and atorvastatin plasma concentration was identified in this analysis, based on the
additional e↵ective degrees of freedom used to generate the curve using the smoothing func-
tion. Both of the GAMs fitted for the rosuvastatin cohort di↵ered significantly from the orig-
inal linear model, even after adjusting for multiple comparisons. The two GAM fits were not
statistically di↵erent from each other, although the rosuvastatin GAM with fixed smoothing
parameters o↵ered a marginally better fit than the GAM with parameters chosen by CV. Like
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the atorvastatin GAM with parameters chosen by CV, the smoothing of the majority of contin-
uous covariates was penalized to the point of linearity; however, time post dose and BMI were
modelled linearly, while the relationship between age and rosuvastatin plasma concentration
had a significant non-linearar component.
In contrast to the GAMs for atorvastatin and rosuvastatin, SVR does not appear to o↵er any
substantial benefit in terms of model fit for any of the kernels tested at this time. This is likely
due to the small sample size of our cohort; additional parameters of cost and epsilon must be
tuned for the SVR to be fit, which was not possible with the amount of data available. In order
to perform CV to assess the fit of the models for atorvastatin, all concomitant medications used
by less than 10 patients were removed prior to fitting the SVR. It is possible that SVR could
o↵er improvements in model fit over the linear model and GAM if more data were available to
choose appropriate tuning parameters for the rosuvastatin and atorvastatin cohorts. However,
we do not recommend using SVR for this dataset at present, particularly since both the GAM
and linear models are easier to interpret from a clinical perspective.
7.1.3 Objective 3
The final objective of this thesis was to select patients in the rosuvastatin cohort to undergo
more thorough genetic sequencing, in order to identify novel genetic variation that may play
a role in increasing or decreasing rosuvastatin plasma concentration. A variation of extreme
phenotype sampling4;5 was employed in order to increase the likelihood of identifying relevant
rare genetic variation despite our relatively small sample size. Proportional di↵erence values
between the predicted and actual rosuvastatin concentrations were used to identify patients
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as being under-predicted or well-predicted using the original rosuvastatin systemic exposure
model. Because we were limited to selecting 48 patients for next generation sequencing (NGS),
all of the patients who were underpredicted using the current systemic exposure model were
chosen for sequencing, and the remaining sequencing slots were filled by randomly sampling
the patients in the well-predicted category. A number of patients had already undergone NGS;
these were also included in the analysis.
The Sequence Kernel Association Test (SKAT) was used to analyse the data and identify
genetic regions that were associated with distinctions between the under-predicted and well-
predicted individuals who had undergone additional sequencing. This test su↵ered from a
severe lack of power, given the large number of genes to be tested for association with case or
control group membership, and the small number of patients who had undergone NGS. Despite
this, 41 out of 1212 total candidate regions had P values that were lower than 1.0, indicating
that they may have the potential to be predictive of whether or not a patient’s plasma con-
centration on rosuvastatin was likely to be higher than anticipated based on the current dose-
prediction model. The top three candidate genetic regions for prediction were within ABCC1,
PXR (NR1I2), and SLCO1B3. All three genes have been shown to be associated with cellular
rosuvastatin uptake (ABCC1 and SLCO1B3) or statin transporter expression (PXR), suggest-
ing a plausible causal mechanism for directly impacting rosuvastatin plasma concentration.
We recommend that further biological research be conducted to confirm a causal relationship
between the genetic variation identified and rosuvastatin plasma concentration.. In particu-
lar, further research into the polymorphisms identified in these regions observed to have large
di↵erences in frequency between cases (under-predicted plasma concentration) and controls
(well-predicted plasma concentration). Ideally, this research will be able to elucidate which
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polymorphisms in these genes are most relevant for predicting rosuvastatin.
A significant challenge faced in performing the NGS analysis was installing and integrating
all of the currently available tools for processing this type of data. We found that this type of
analysis has an extremely high technical burden, which imposes barriers and decreases the
accessibility of these statistical techniques to genetic researchers who want to use them to
advance our understanding of the human genome. We suggest that the development of a user-
friendly integrated open-source tool for performing analysis on genetic data be considered as
an open software-engineering problem.
7.2 Strengths and Limitations
7.2.1 Strengths
A notable strength of the work performed in this thesis is the emphasis on addressing chal-
lenges of modelling patient data from a practical user-oriented perspective. Often the exact
details for performing modelling in a clinical context are left out of publications, which cre-
ates barriers for other researchers to use the methods described for their own data. This is
particularly a problem in the NGS variant prioritization literature, given how quickly research
is progressing in this field, and the newness of the statistical tools appropriate for this type of
analysis. Another user-oriented contribution in this work was that the concomitant medication
algorithm was developed for use with both small and large sample sizes. The availability of
statistical techniques appropriate for small sample sizes is an important consideration in this
field of research, since patient populations are usually small due to the resources required to
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collect and process the data.
7.2.2 Limitations
A key limitation of the current work was the sample size of the atorvastatin and rosuvastatin
cohorts for the modelling activities performed in this thesis. While the sample size for both
cohorts is relatively large from the perspective of clinical pharmacology research, the number
of potential additional predictors we examined vastly outnumbered the patient observations
available to us. This was particularly a problem for accurately gauging the performance of the
non-linear modelling techniques using CV, since it was infeasible to include all of the covariates
identified in the atorvastatin concomitant medication analysis with the extra model parameters
that required fitting, such as cost and epsilon for SVR.
Another limitation of the current work was the di culty encountered in using the software
tools currently available for NGS analysis. Because the software did not work as intended
with our data (and no possible causes for this were found), the NGS analysis used a simpler
technique than would perhaps be optimal, given that it did not include the modification to allow
examination of both common and rare variants.
7.3 Implication of Key Contributions
The findings of the work performed in the completion of this thesis have many potential impli-
cations for improving personalized medicine in the context of dose guidance for atorvastatin
and rosuvastatin. These implications largely target the research activities of modelling and pre-
dictive dosing-guidance, given the emphasis on methodological improvements and identifying
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potentially predictive factors for further biological analysis. The development of a concomi-
tant medication selection algorithm will allow researchers to create more feature-rich datasets
that include relevant clinical information, in a format that is accessible to clinical researchers.
Additionally, the concomitant medications found to be associated with changes in atorvastatin
plasma concentration may impact the future clinical use of these substances in order to better
prevent adverse events from taking place. The genes identified in the NGS analysis have the
potential to increase our understanding of the factors a↵ecting lipid metabolism in the human
body, which could in turn improve clinical care for patients with dyslipidemia.
7.4 Future Directions
A substantial amount of work presented in this thesis was exploratory, with the goal of hypoth-
esis generation for confirmatory biological analysis. Further analyses that must be performed
to validate the findings in this work include in vitro testing to confirm a causal relationship
between the identified concomitant medications included in the atorvastatin systemic expo-
sure model and changes in statin exposure. Similarly, further in vitro biological research is
necessary to support the relationship between specific genetic variation in ABCC1, NR1I2 and
SLCO1B3, and changes in rosuvastatin plasma concentration.
The current work failed to find benefit in using more complex non-linear and machine
learning techniques with the datasets from the atorvastatin and rosuvastatin cohorts. These
analyses need to be repeated with larger datasets, as it is possible that the extra parameter
estimates necessary to model non-linear relationships in the data were too numerous compared
to the number of observations available for parameter selection and training.
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A substantial amount of work remains to be done with respect to improving access to
complex statistical techniques for non-experts in statistical analysis. An important next step
in paving the way for the use of appropriate (though complex) statistical techniques in clinical
pharmacology and other areas is the implementation of a user-friendly interface for non-linear
analysis, as well as increased education on the availability of di↵erent statistical techniques for
experts in other fields. Appendix D describes initial steps towards this work, in the form of an
interactive statistical platform that was partially developed during the completion of this thesis.
Finally, one of the most surprising and concerning discoveries of this thesis was the dif-
ficulty of performing variant calling and prioritization with NGS data even for experienced
bioinformaticians and experts in biostatistical analysis. As genetic data becomes increasingly
available for decision making in healthcare, the more urgent the need for user-friendly, accurate
and transparent tools for NGS data analysis becomes. As mentioned previously in this thesis,
developing improved, stable, transparent and user-friendly techniques for this purpose should
be considered an open software engineering problem. Without such tools, we may never be
able to explore the full potential of genetic variation in the context of clinical decision support.
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Appendix A
Concomitant Medication Selection
A.1 Mapping of Generic Drugs to Functional Classes
Table A.1: Drug class/ generic drug mapping
Medication Class Generic Drug Name
5↵ Reductase Inhibitor Dutasteride
↵1 Blocker Alfuzosin
↵1 Blocker Doxazosin
↵1 Blocker Tamsulosin
↵1 Blocker Terazosin
↵2 Adrenergic Agonist Brimonidine
↵2 Adrenergic Agonist Clonidine
Ace Inhibitor Cilazapril
Ace Inhibitor Enalapril
Ace Inhibitor Fosinopril
Ace Inhibitor Lisinopril
Ace Inhibitor Perindopril
Ace Inhibitor Quinapril
Ace Inhibitor Ramipril
Ace Inhibitor Trandolapril
Alkaloid Quinine
Analgesic Acetaminophen
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Drug class/ generic drug mapping (A-A)
Medication Class Generic Drug Name
Angiotensin II Receptor Agonist Candesartan
Angiotensin II Receptor Agonist Irbesartan
Angiotensin II Receptor Agonist Losartan
Angiotensin II Receptor Agonist Olmesartan
Angiotensin II Receptor Agonist Telmisartan
Angiotensin II Receptor Agonist Valsartan
Antiarrhythmic Propafenone
Antibiotic Amoxicillin
Antibiotic Gentamicin
Antibiotic Sulfacetamide
Antibiotic Tetracycline
Anticholinergic Oxybutynin
Anticholinergic Bronchodilator Ipratropium
Anticholinergic Bronchodilator Tiotropium Bromide
Anticholinesterase Donepezil
Anticoagulant Warfarin
Anticonvulsant Phenobarbital
Anticonvulsant Phenytoin
Anticonvulsant Topiramate
Anticonvulsant Trazodone
Anticonvulsant/Analgesic Gabapentin
Antidiabetic Metformin
Antiemetic Dimenhydrinate
Antihistamine Cetirizine
Antihistamine Desloratadine
Antihistamine Diphenhydramine
Anti-Inflammatory Colchicine
Anti-Inflammatory Sulfasalazine
Antimalarial Hydroxychloroquine
Antimuscarinic Tolterodine
Antiplatelet Plavix
Antiviral Famciclovir
Antiviral Valacyclovir
Artificial Tears Eye Lubricant
Atypical Antipsychotic Risperidone
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Drug class/ generic drug mapping (B-C)
Medication Class Generic Drug Name
Benzodiazepine Alprazolam
Benzodiazepine Clonazepam
Benzodiazepine Lorazepam
Benzodiazepine Oxazepam
Benzodiazepine Temazepam
Beta Agonist Betaxolol
Beta Agonist Formoterol
Beta Agonist Salbutamol
Beta Agonist Salmeterol Xinafoate
Beta Blocker Acebutolol
Beta Blocker Atenolol
Beta Blocker Bisoprolol
Beta Blocker Carvedilol
Beta Blocker Cavedilol
Beta Blocker Metoprolol
Beta Blocker Nadolol
Beta Blocker Sotalol
Beta Blocker Timolol
Bile Acid Sequestrant Cholestyramine
Bisphosphonate Alendronate
Bisphosphonate Etidronate
Bisphosphonate Risedronate
Bisphosphonate Zoledronate
Calcium Channel Blocker Amlodipine
Calcium Channel Blocker Diltiazem
Calcium Channel Blocker Felodipine
Calcium Channel Blocker Nifedipine
Calcium Channel Blocker Verapamil
Carbonic Anhydrase Inhibitor Dorzolamide
Cardiac Glycoside Digoxin
Chemotherapy Melphalan
Chemotherapy Methotrexate
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Drug class/ generic drug mapping (C-G)
Medication Class Generic Drug Name
Cholesterol Absorption Blocker Ezetimibe
Cholinergic Bethanechol
Cholinesterase Inhibitor Donepezil
Co Q10 Co Q10
Contraceptive Contraceptive
Corticosteroid Budesonide
Corticosteroid Dexamethasone
Corticosteroid Fluticasone
Corticosteroid Fluticasone Propionate
Corticosteroid Mometasone
Corticosteroid Prednisone
COX Inhibitor Celecoxib
Cyclopyrrolone Zopiclone
Direct Renin Inhibitor Aliskiren
Diuretic Chlorthalidone
Diuretic Furosemide
Diuretic Hydrochlorothiazide
Diuretic Indapamide
Diuretic Spironolactone
Dopamine Serotonin Adrenergic Antagonist Quetiapine
DPP4 Inhibitor Sitagliptin
Estrogen Receptor Antagonist Tamoxifen
Eye Drops Multivitamin
Fatty Acid Cetyl Myristoleate
Fibrate Bezafibrate
Fibrate Fenofibrate
Fibrate Gemfibrozil
Gastroprokinetic Domperidone
Glucosidase Inhibitor Acarbose
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Drug class/ generic drug mapping (H-O)
Medication Class Generic Drug Name
Herbal Curcumin
Herbal Herbal
Histamine II Blocker Ranitidine
Hormone Estrogen
Hormone Progesterone
Hormone Testosterone Undecanoate
Immunosupressant Mycophenolate Mofetil
Immunosupressant Sirolimus
Insulin Insulin
Ion Exchange Resin Sodium Polystyrene Sulfonate
Laxative Sodium Citrate
Leukotriene Receptor Antagonist Montelukast
LHRH Agonist Goserelin
Meglitinide Repaglinide
Multivitamin Multivitamin
Muscle Relaxant Baclofen
Muscle Relaxant Cyclobenzaprine
Muscle Relaxant Methocarbamol
Nassa Mirtazapine
NDRI Bupropion
Nitrate Glyceryl Trinitrate
NSAID Acetylsalicylic Acid
NSAID Diclofenac
NSAID Ibuprofen
NSAID Ketorolac
NSAID Meloxicam
NSAID Naproxen
Opioid Fentanyl
Opioid Hydromorphone
Opioid Morphine
Opioid Oxycodone
Opioid Tramadol
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Drug class/ generic drug mapping (P-S)
Medication Class Generic Drug Name
PDE5 Inhibitor Sildenafil
PDE5 Inhibitor Tadalafil
PPARg Agonist Rosiglitazone
Probiotic Lactobacillus Acidophilus
Prostaglandin Analogue Bimatoprost
Prostaglandin Analogue Lanatoprost
Prostaglandin Analogue Misoprostol
Proton Pump Inhibitor Esomeprazole
Proton Pump Inhibitor Lansoprazole
Proton Pump Inhibitor Omeprazole
Proton Pump Inhibitor Pantoprazole
Proton Pump Inhibitor Rabeprazole
Proton Pump Inhibitor Unknown
Selective Estrogen Receptor Modulator Raloxifene
SNRI Duloxetine
SSRI Citalopram
SSRI Escitalopram
SSRI Fluoxetine
SSRI Paroxetine
SSRI Sertraline
SSRI/SNRI Venlafaxine
Statin Atorvastatin
Statin Rosuvastatin
Stimulant Dextroamphetamine
Sulfonylurea Gliclazide
Sulfonylurea Glyburide
Supplement Calcium Supplement
Supplement Chondritin
Supplement Fish Oil
Supplement Glucosamine
Supplement Iron Supplement
Supplement Magnesium Supplement
Supplement Omega 3
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Drug class/ generic drug mapping (T-Z)
Medication Class Generic Drug Name
Thiazolidinedione Pioglitazone
Thyroid Hormone Levothyroxine
Tricyclic Amitriptyline
Tricyclic Nortriptyline
Triptan Rizatriptan
Triptan Sumatriptan
Unknown Unknown
Urinary Alkalinizers Potassium Citrate
Vasodilator Isosorbide Dinitrate
Vasodilator Nitroglycerin
Vitamin B Vitamin B
Vitamin B Vitamin B12
Vitamin B Vitamin B2
Vitamin B Vitamin B3
Vitamin B Vitamin B6
Vitamin B Vitamin B9
Vitamin C Vitamin C
Vitamin D Vitamin D
Vitamin D Vitamin D3
Vitamin E Vitamin E
Vitamin K Vitamin K
Xanthine Oxidase Inhibitor Allopurinol
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A.2 Atorvastatin Concomitant Medication Analysis
Supplemental Tables
A.2.1 Overview of Concomitant Medications Present in the Prospective
Cohorts
Table A.2: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (A-B)
Atorvastatin (n=128) Rosuvastatin (n=130)
Acarbose 1 -
Acebutolol 3 2.3% 2 1.5%
Acetaminophen 8 6.2% 6 4.6%
Acetylsalicylic.acid 86 67.2% 73 56.2%
Alendronate 1 - 1 -
Alfuzosin 1 -
Aliskiren 2 1.6% 1 -
Allopurinol 3 2.3% 6 4.6%
Alprazolam 1 - 2 1.5
Amitriptyline 3 2.3% 1 -
Amlodipine 23 18% 19 14.6%
Amoxicillin 1 -
Atenolol 14 10.9% 10 7.7%
Atorvastatin 128 100%
Baclofen 1 -
Betaxolol 1 -
Bethanechol 1 -
Bezafibrate 2 1.6%
Bimatoprost 1 - 2 1.5%
Bisoprolol 12 9.4% 9 6.9%
Brimonidine 1 -
Budesonide 2 1.5%
Bupropion 2 1.6% 4 3.1%
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Table A.3: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (C)
Atorvastatin (n=128) Rosuvastatin (n=130)
Calcium Supplement 11 8.6% 11 8.5%
Candesartan 3 2.3% 3 2.3%
Carvedilol 1 -
Cavedilol 1 -
Celecoxib 4 3.1% 1 -
Cetirizine 2 1.5%
Cetyl Myristoleate 1 -
Chlorthalidone 3 2.3% 1 -
Cholestyramine 1 - 1 -
Chondritin 1 -
Cilazapril 1 -
Citalopram 2 1.6% 2 1.5%
Clonazepam 2 1.6%
Clonidine 1 -
Co-Q10 7 5.5% 9 6.9%
Colchicine 2 1.5%
Contraceptive 2 1.6%
Curcumin 1 -
Cyclobenzaprine 2 1.6%
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Table A.4: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (D-H)
Atorvastatin (n=128) Rosuvastatin (n=130)
Desloratadine 1 -
Dexamethasone 1 -
Dextroamphetamine 1 -
Diclofenac 2 1.6% 3 2.3%
Digoxin 5 3.9%
Diltiazem 6 4.7% 3 2.3%
Dimenhydrinate 1 -
Diphenhydramine 1 -
Domperidone 1 - 7 5.4%
Donepezil 1 - 1 -
Doxazosin 3 2.3%
Duloxetine 1 -
Dutasteride 1 - 1 -
Enalapril 1 - 3 2.3%
Escitalopram 2 1.5%
Esomeprazole 3 2.3% 1 -
Estrogen 1 -
Etidronate 1 -
Eye Lubricant 1 - 1 -
Ezetimibe 39 30.5% 52 40%
Famciclovir 1 -
Felodipine 2 1.5%
Fenofibrate 15 11.7% 23 17.7%
Fentanyl 1 -
Fish Oil 6 4.7% 4 3.1%
Fluoxetine 1 -
Fluticasone 1 - 1 -
Formoterol 1 - 2 1.5%
Fosinopril 1 -
Furosemide 7 5.5% 4 3.1%
Gabapentin 1 - 2 1.5%
Gemfibrozil 3 2.3% 1 -
Gentamicin 1 -
Gliclazide 5 3.9% 3 2.3%
Glucosamine 4 3.1% 3 2.3%
Glyburide 5 3.9% 5 3.8%
Glyceryl Trinitrate 1 -
Goserelin 1 -
Herbal 4 3.1%
Hydrochlorothiazide 17 13.3% 16 12.3%
Hydromorphone 1 - 1 -
Hydroxychloroquine 3 2.3%
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Table A.5: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (I-O)
Atorvastatin (n=128) Rosuvastatin (n=130)
Ibuprofen 2 1.6% 2 1.5%
Indapamide 2 1.6% 3 2.3%
Insulin 9 7.0% 9 6.9%
Ipratropium 1 -
Irbesartan 7 5.5% 7 5.4%
Iron Supplement 3 2.3% 4 3.1%
Isosorbide.dinitrate 1 -
Ketorolac 1 -
Lactobacillus.acidophilus 1 -
Lanatoprost 1 -
Lansoprazole 5 3.9% 5 3.8%
Levothyroxine 10 7.8% 13 10.0%
Lisinopril 2 1.6% 2 1.5%
Lorazepam 3 2.3% 1 -
Losartan 5 3.9% 2 1.5%
Magnesium.supplement 1 -
Meloxicam 2 1.6% 1 -
Melphalan 1 -
Metformin 24 18.8% 16 12.3%
Methotrexate 1 - 2 1.5%
Metoprolol 28 21.9% 21 16.2%
Mirtazapine 1 - 1 -
Misoprostol 2 1.6%
Mometasone 1 -
Montelukast 1 -
Morphine 1 -
Multivitamin 14 10.9% 13 10.0%
Mycophenolate Mofetil 1 -
Nadolol 1 -
Naproxen 1 - 1 -
Nifedipine 4 3.1% 3 2.3%
Nitroglycerin 15 11.7% 16 12.3%
Nortriptyline 1 - 1 -
Olmesartan 1 -
Omega 3 7 5.5% 8 6.2%
Omeprazole 4 3.1% 6 4.6%
Oxazepam 1 -
Oxybutynin 1 -
Oxycodone 1 - 1 -
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Table A.6: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (P-S)
Atorvastatin (n=128) Rosuvastatin (n=130)
Pantoprazole 3 2.3% 11 8.5%
Paroxetine 1 -
Perindopril 9 7.0% 12 9.2%
Phenobarbital 1 -
Phenytoin 2 1.6% 1 -
Pioglitazone 1 - 1 -
Plavix 23 18.0% 19 14.6%
Potassium Citrate 1 -
Prednisone 2 1.6%
Progesterone 1 -
Propafenone 1 -
Quetiapine 3 2.3%
Quinapril 1 - 4 3.1%
Quinine 2 1.6% 2 1.5%
Rabeprazole 10 7.8% 13 10.0%
Raloxifene 1 -
Ramipril 49 38.3% 30 23.1%
Ranitidine 2 1.6% 2 1.5%
Repaglinide 1 -
Risedronate 2 1.5%
Risperidone 1 -
Rizatriptan 1 -
Rosiglitazone 3 2.3% 1 -
Rosuvastatin 1 - 130 100%
Salbutamol 2 1.6% 2 1.5%
Salmeterol Xinafoate 2 1.5%
Sertraline 2 1.6%
Sildenafil 1 -
Sirolimus 1 -
Sitagliptin 2 1.6% 1 -
Sodium Citrate 1 -
Sodium Polystyrene Sulfonate 1 -
Sotalol 1 -
Spironolactone 8 6.2% 3 2.3%
Sulfacetamide 1 -
Sulfasalazine 1 -
Sumatriptan 1 -
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Table A.7: Generic drugs in the atorvastatin and rosuvastatin prospective cohorts (T-Z)
Atorvastatin (n=128) Rosuvastatin (n=130)
Tadalafil 1 - 2 1.5%
Tamoxifen 1 -
Tamsulosin 3 2.3% 4 3.1%
Telmisartan 4 3.1% 2 1.5%
Temazepam 1 - 2 1.5%
Terazosin 2 1.5%
Testosterone Undecanoate 1 -
Tetracycline 1 -
Timolol 2 1.5%
Tiotropium Bromide 1 - 1 -
Tolterodine 2 1.5%
Topiramate 2 1.6% 1 -
Trandolapril 2 1.5%
Trazodone 3 2.3%
Unknown 3 2.3% 2 1.5%
Valacyclovir 1 -
Valsartan 5 3.9% 7 5.4%
Venlafaxine 4 3.1% 2 1.5%
Verapamil 1 -
Vitamin B 3 2.3%
Vitamin B12 11 8.6% 13 10.0%
Vitamin B2 1 -
Vitamin B3 10 7.8% 11 8.5%
Vitamin B6 4 3.1% 4 3.1%
Vitamin B9 9 7.0% 10 7.7%
Vitamin C 8 6.2% 4 3.1%
Vitamin D 22 17.2% 22 16.9%
Vitamin D 2 1.5%
Vitamin E 4 3.1% 3 2.3%
Vitamin K 1 -
Warfarin 11 8.6% 1 -
Zoledronate 1 -
Zopiclone 1 -
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A.2.2 Initial Approach: Group Lasso
Table A.8: Initial concomitant medication coe cient values for atorvastatin with group lasso
Medication Coe cient
Ace Inhibitor
Lisinopril 0
Perindopril 0
Ramipril 0
Alkaloid
Quinine 0
Alpha I Blocker
Tamsulosin 0.683
Analgesic
Acetaminophen 0.075
Angiotensin II Receptor Antagonist
Candesartan 0.305
Irbesartan -0.400
Losartan 0.564
Telmisartan 0.191
Valsartan 0.002
Anticoagulant
Warfarin -0.024
Anticonvulsant
Phenytoin 0
Topiramate 0
Antidiabetic
Metformin -0.119
Antiplatelet
Plavix 0
Benzodiazepine
Clonazepam 0
Lorazepam 0
Beta Agonist
Salbutamol 0
Beta Blocker
Acebutolol 0
Atenolol 0
Bisoprolol 0
Metoprolol 0
Calcium Channel Blocker
Amlodipine 0
Diltiazem 0
Nifedipine 0
Cardiac Glycoside
Digoxin 0.201
Cholesterol Absorption Blocker
Ezetimibe 0
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Initial concomitant medication coe cient values for atorvastatin with group lasso
Medication Coe cient
Co-Q10
Co-Q10 0
Contraceptive
Contraceptive 0
Corticosteroid
Prednisone 0
Cox Inhibitor
Celecoxib 0.369
Direct Renin Inhibitor
Aliskiren 0
Diuretic
Chlorthalidone 0
Furosemide 0
Hydrochlorothiazide 0
Indapamide 0
Spironolactone 0
DPP4 Inhibitor
Sitagliptin 0
Eye Drops
Multivitamin 0
Fibrate
Bezafibrate 0
Fenofibrate 0
Gemfibrozil 0
Histamine II Blocker
Ranitidine 0
Insulin
Insulin 0
Muscle Relaxant
Cyclobenzaprine 0
NDRI
Bupropion 0
NSAID
Acetylsalicylic Acid 0.070
Diclofenac 0.330
Ibuprofen 0.040
Meloxicam -0.060
PPARg Agonist
Rosiglitazone 0
Prostaglandin Analogue
Misoprostol 0.395
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Initial concomitant medication coe cient values for atorvastatin with group lasso
Medication Coe cient
Proton Pump Inhibitor
Esomeprazole 0
Lansoprazole 0
Omeprazole 0
Pantoprazole 0
Rabeprazole 0
SSRI
Citalopram 0
Sertraline 0
SSRI-SNRI
Venlafaxine -0.262
Sulfonylurea
Gliclazide 0
Glyburide 0
Supplement
Calcium Supplement 0
Fish Oil 0
glucosamine 0
Herbal 0
Iron Supplement 0
Omega 3 0
Thyroid Hormone
Levothyroxine -0.232
Tricyclic
Amitriptyline 0
Vasodilator
Nitroglycerin 0
Vitamin B
Vitamin B 0
Vitamin B12 0
Vitamin B3 0
Vitamin B6 0
Vitamin B9 0
Vitamin C
Vitamin C 0
Vitamin D
Vitamin D 0
Vitamin E
Vitamin E 0
Xanthine Oxidase Inhibitor
Allopurinol 0
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A.2.3 Concomitant Selection Algorithm Proportions
Table A.9: Atorvastatin selection algorithm proportions - 1000 repetitions
Proportion Nonzero Coe cient Mean Coe cient SD
Beta Blocker 0.001 0 0
Acebutolol 0 0 0
Atenolol 0.995 -0.14 0.031
Bisoprolol 0 0 0
Metoprolol 0 0 0
Analgesic 0 0 0
Acetaminophen 0 0 0
NSAID 0.999 0.182 0.021
Acetylsalicylic Acid 0.998 0.086 0.02
Diclofenac 0.998 0.406 0.085
Ibuprofen 0 0 0
Meloxicam 0 0 0
Direct Renin Inhibitor 0 0 0
Aliskiren 0 0 0
Xanthine Oxidase Inhibitor 0 0 0
Allopurinol 0 0 0
Tricyclic 0.001 0 0.001
Amitriptyline 0 0 0
Calcium Channel Blocker 0.999 0.068 0.011
Amlodipine 0 0 0
Diltiazem 0 0 0
Nifedipine 0.035 0.001 0.005
Fibrate 0 0 0
Bezafibrate 0 0 0
Fenofibrate 0 0 0
Gemfibrozil 0 0 0
NDRI 0 0 0
Bupropion 0 0 0
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Atorvastatin selection algorithm proportions - 1000 repetitions (2/4)
Proportion Nonzero Coe cient Mean Coe cient SD
Supplement 0 0 0
Calcium Supplement 0 0 0
Fish Oil 0 0 0
Glucosamine 0.999 0.273 0.042
Iron Supplement 0 0 0
Omega 3 0 0 0
Angiotensin II Receptor Agonist 0.997 0.103 0.025
Candesartan 0.249 0.014 0.026
Irbesartan 0 0 0
Losartan 0.999 0.853 0.026
Telmisartan 0 0 0
Valsartan 0.816 -0.017 0.015
COX Inhibitor 0 0 0
Celecoxib 0 0 0
Diuretic 0.989 0.043 0.015
Chlorthalidone 0 0 0
Furosemide 0 0 0
Hydrochlorothiazide 0.001 0 0
Indapamide 0 0 0
Spironolactone 0 0 0
SSRI 0.085 0.004 0.017
Citalopram 0 0 0
Sertraline 0 0 0
Benzodiazepine 0 0 0
Clonazepam 0 0 0
Lorazepam 0 0 0
Co Q10 0 0 0
0 0 0
Contraceptive 0.382 0.032 0.056
0.035 0 0.002
Muscle Relaxant 0 0 0
Cyclobenzaprine 0 0 0
Cardiac Glycoside 0.997 0.252 0.068
Digoxin 0.816 0.066 0.047
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Atorvastatin selection algorithm proportions - 1000 repetitions (3/4)
Proportion Nonzero Coe cient Mean Coe cient SD
Proton Pump Inhibitor 0 0 0
Esomeprazole 0.999 0.34 0.052
Lansoprazole 0.249 -0.007 0.014
Omeprazole 0.249 -0.004 0.009
Pantoprazole 0 0 0
Rabeprazole 0 0 0
Cholesterol Abs. Blocker 0.085 -0.001 0.002
Ezetimibe 0 0 0
Sulfonylurea 0 0 0
Gliclazide 0.999 -0.095 0.004
Glyburide 0 0 0
Insulin 0 0 0
0 0 0
Thyroid Hormone 0.999 -0.152 0.009
Levothyroxine 0.999 -0.134 0.02
Ace Inhibitor 0 0 0
Lisinopril 0 0 0
Perindopril 0 0 0
Ramipril 0 0 0
Antidiabetic 0.999 -0.214 0.041
Metformin 0.995 -0.125 0.029
Prostaglandin Analogue 0.989 0.21 0.068
Misoprostol 0.001 0 0.001
Eye Drops 0 0 0
Multivitamin 0 0 0
Vasodilator 0 0 0
Nitroglycerin 0 0 0
Anticonvulsant 0 0 0
Phenytoin 0 0 0
Topiramate 0 0 0
Antiplatelet 0.001 0 0
Plavix 0 0 0
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Atorvastatin selection algorithm proportions - 1000 repetitions (4/4)
Proportion Nonzero Coe cient Mean Coe cient SD
Corticosteroid 0.008 0 0.003
Prednisone 0 0 0
Alkaloid 0 0 0
Quinine 0 0 0
Histamine II Blocker 0.008 0 0.005
Ranitidine 0.001 0 0
PPARg Agonist 0 0 0
Rosiglitazone 0 0 0
Beta Agonist 0.188 -0.005 0.016
Salbutamol 0.001 0 0
Alpha1 Blocker 0.999 0.588 0.087
Tamsulosin 0.999 0.507 0.059
SSRI/SNRI 0.998 -0.127 0.037
Venlafaxine 0.995 -0.116 0.024
Vitamin B 0.906 -0.046 0.034
Vitamin B 0 0 0
Vitamin B12 0 0 0
Vitamin B3 0.551 -0.013 0.019
Vitamin B6 0 0 0
Vitamin B9 0 0 0
vitamin C 0 0 0
Vitamin C 0 0 0
Vitamin D 0 0 0
0 0 0
Vitamin E 0.001 0 0.001
0 0 0
Anticoagulant 0.03 0 0.003
Warfarin 0 0 0
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A.2.4 Regression Results for Di↵erent Selection Thresholds
Table A.10: Atorvastatin linear regression: 90% cuto↵ inclusion threshold
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.338 -1.454 to 0.779 0.55
SLCO1B1 c.521T>C 0.411 0.166 to 0.656 0.001 **
SLCO1B1 c.388A>G -0.141 -0.343 to 0.061 0.169
Age 0.016 0.006 to 0.026 0.002 **
4 -hydroxholesterol -0.02 -0.03 to -0.01 <0.001 ***
Dose (20mg) 0.741 0.323 to 1.159 0.001 ***
Dose (40mg) 1.1 0.729 to 1.472 <0.001 ***
Dose (80mg) 1.601 1.175 to 2.027 <0.001 ***
Time Post Dose (hr) -0.085 -0.109 to -0.06 <0.001 ***
BMI (kg/m2) 0.015 -0.009 to 0.04 0.225
Gender (Male = 1) -0.051 -0.295 to 0.192 0.677
Ethnicity (Non-Caucasian = 1) 0.063 -0.296 to 0.422 0.729
Acetylsalicylic Acid 0.186 -0.089 to 0.461 0.183
Atenolol -0.304 -0.741 to 0.134 0.172
Candesartan 0.756 -0.004 to 1.517 0.051 .
Diclofenac 1.073 -0.041 to 2.187 0.059 .
Digoxin 0.585 -0.061 to 1.231 0.075 .
Esomeprazole 0.602 -0.231 to 1.435 0.155
Gliclazide -0.347 -1.083 to 0.39 0.353
Glucosamine 0.448 -0.401 to 1.297 0.298
Hydrochlorothiazide 0.095 -0.277 to 0.467 0.613
Levothyroxine -0.395 -0.855 to 0.065 0.091 .
Losartan 0.978 0.392 to 1.564 0.001 **
Metformin -0.349 -0.674 to -0.023 0.036 *
Misoprostol 0.162 -0.905 to 1.23 0.764
Nifedipine 0.34 -0.348 to 1.028 0.329
Tamsulosin 1.076 0.25 to 1.903 0.011 *
Valsartan -0.114 -0.81 to 0.582 0.746
Venlafaxine -0.247 -0.967 to 0.472 0.497
Vitamin B3 -0.392 -0.839 to 0.054 0.084 .
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Table A.11: Atorvastatin linear regression: 95% cuto↵ inclusion threshold
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.53 -1.636 to 0.577 0.344
SLCO1B1 c.521T>C 0.385 0.14 to 0.631 0.002 **
SLCO1B1 c.388A>G -0.136 -0.34 to 0.068 0.188
Age 0.017 0.007 to 0.027 0.001 ***
4 -hydroxholesterol -0.019 -0.028 to -0.009 <0.001 ***
Dose (20mg) 0.773 0.352 to 1.194 <0.001 ***
Dose (40mg) 1.137 0.764 to 1.51 <0.001 ***
Dose (80mg) 1.637 1.208 to 2.066 <0.001 ***
Time Post Dose (hr) -0.081 -0.105 to -0.056 <0.001 ***
BMI (kg/m2) 0.015 -0.01 to 0.04 0.227
Gender (Male = 1) -0.031 -0.276 to 0.214 0.802
Ethnicity (Non-Caucasian = 1) 0.068 -0.295 to 0.431 0.712
Acetylsalicylic Acid 0.17 -0.107 to 0.447 0.227
Atenolol -0.39 -0.821 to 0.04 0.075 .
Candesartan 0.639 -0.117 to 1.395 0.097 .
Diclofenac 1.012 -0.111 to 2.136 0.077 .
Digoxin 0.582 -0.07 to 1.235 0.08 .
Esomeprazole 0.703 -0.13 to 1.536 0.097 .
Gliclazide -0.322 -1.065 to 0.422 0.393
Glucosamine 0.563 -0.285 to 1.41 0.191
Hydrochlorothiazide 0.086 -0.29 to 0.462 0.649
Levothyroxine -0.352 -0.814 to 0.11 0.134
Losartan 1.019 0.429 to 1.61 0.001 ***
Metformin -0.323 -0.651 to 0.005 0.054 .
Misoprostol 0.14 -0.938 to 1.219 0.797
Nifedipine 0.353 -0.342 to 1.047 0.316
Tamsulosin 0.953 0.13 to 1.776 0.024 *
Valsartan -0.155 -0.856 to 0.547 0.663
Venlafaxine -0.252 -0.979 to 0.475 0.493
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Table A.12: Atorvastatin linear regression: 99% cuto↵ inclusion threshold
Estimate Confidence Interval P-Value Sig.
(Intercept) -0.534 -1.635 to 0.568 0.339
SLCO1B1 c.521T>C 0.388 0.144 to 0.633 0.002 **
SLCO1B1 c.388A>G -0.141 -0.343 to 0.061 0.169
Age 0.017 0.007 to 0.027 0.001 ***
4 -hydroxholesterol -0.019 -0.028 to -0.009 <0.001 ***
Dose (20mg) 0.764 0.347 to 1.182 <0.001 ***
Dose (40mg) 1.128 0.759 to 1.497 <0.001 ***
Dose (80mg) 1.627 1.202 to 2.051 <0.001 ***
Time Post Dose (hr) -0.08 -0.104 to -0.056 <0.001 ***
BMI (kg/m2) 0.016 -0.009 to 0.04 0.217
Gender (Male = 1) -0.023 -0.265 to 0.218 0.85
Ethnicity (Non-Caucasian = 1) 0.066 -0.295 to 0.428 0.717
Acetylsalicylic Acid 0.166 -0.11 to 0.441 0.235
Atenolol -0.381 -0.808 to 0.046 0.08 .
Candesartan 0.637 -0.116 to 1.39 0.096 .
Diclofenac 1.011 -0.107 to 2.13 0.076 .
Digoxin 0.584 -0.066 to 1.234 0.078 .
Esomeprazole 0.731 -0.09 to 1.552 0.08 .
Gliclazide -0.307 -1.045 to 0.431 0.411
Glucosamine 0.615 -0.199 to 1.428 0.137
Levothyroxine -0.357 -0.817 to 0.102 0.126
Losartan 1.026 0.438 to 1.613 0.001 ***
Metformin -0.325 -0.652 to 0.001 0.051 .
Misoprostol 0.154 -0.918 to 1.226 0.776
Nifedipine 0.382 -0.298 to 1.062 0.268
Tamsulosin 0.935 0.119 to 1.75 0.025 *
Valsartan -0.163 -0.86 to 0.534 0.643
Venlafaxine -0.256 -0.98 to 0.468 0.484
A.3 Rosuvastatin Concomitant Medication Analysis
Supplemental Tables
A.3.1 Concomitant Selection Algorithm Proportions
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Table A.13: Rosuvastatin selection algorithm proportions
Proportion Nonzero Coe cient Mean Coe cient SD
Beta Blocker 0.022 0 0.005
Acebutolol 0 0 0
Atenolol 0 0 0
Bisoprolol 0 0 0
Metoprolol 0 0 0
Timolol 0 0 0
Analgesic 0.003 0.002 0.061
Acetaminophen 0 0 0
Xanthine Oxidase Inhibitor 0.001 0 0.005
Allopurinol 0 0 0
Benzodiazepine 0.091 -0.011 0.057
Alprazolam 0 0 0
Temazepam 0 0 0
Calcium Channel Blocker 0.002 0 0.004
Amlodipine 0 0 0
Diltiazem 0 0 0
Felodipine 0 0 0
Nifedipine 0 0 0
Prostaglandin Analogue 0.001 0 0.012
Bimatoprost 0 0 0
Corticosteroid 0.002 0.001 0.02
Budesonide 0 0 0
NDRI 0.003 0.001 0.03
Bupropion 0 0 0
Angiotensin II Receptor Agonist 0.003 0 0.003
Candesartan 0 0 0
Irbesartan 0.019 -0.004 0.027
Losartan 0 0 0
Telmisartan 0 0 0
Valsartan 0 0 0
Antihistamine 0.001 0.001 0.017
Cetirizine 0 0 0
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Rosuvastatin selection algorithm proportions (2/3)
Proportion Nonzero Coe cient Mean Coe cient SD
SSRI 0.035 0.003 0.016
Citalopram 0 0 0
Escitalopram 0 0 0
Antiinflammatory 0.002 0 0.006
Colchicine 0 0 0
NSAID 0.144 -0.023 0.075
Diclofenac 0 0 0
Ibuprofen 0.149 -0.079 0.226
Gastroprokinetic 0.002 -0.001 0.017
Domperidone 0 0 0
Alpha1 Blocker 0.014 0.001 0.014
Doxazosin 0 0 0
Tamsulosin 0 0 0
Terazosin 0 0 0
Ace Inhibitor 0.001 0 0.005
Enalapril 0 0 0
Lisinopril 0 0 0
Perindopril 0 0 0
Quinapril 0 0 0
Ramipril 0 0 0
Trandolapril 0 0 0
Cholesterol Absorption Blocker 0.001 0 0.001
Ezetimibe 0 0 0
Fibrate 0.001 0 0.005
Fenofibrate 0 0 0
Beta Agonist 0.001 0 0.002
Formoterol 0 0 0
Salbutamol 0 0 0
Diuretic 0.153 0.013 0.035
Furosemide 0 0 0
Hydrochlorothiazide 0.013 0.001 0.005
Indapamide 0 0 0
Spironolactone 0 0 0
Anticonvulsant Analgesic 0.002 0.003 0.069
Gabapentin 0 0 0
Sulfonylurea 0.121 0.006 0.021
Gliclazide 0 0 0
Glyburide 0.006 0 0.002
Supplement 0.003 0.002 0.035
Glucosamine 0 0 0
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Rosuvastatin selection algorithm proportions (3/3)
Proportion Nonzero Coe cient Mean Coe cient SD
Antimalarial 0.001 0 0.008
Hydroxychloroquine 0 0 0
Insulin 0.035 0.001 0.011
0 0 0
Proton Pump Inhibitor 0.001 0 0.003
Lansoprazole 0 0 0
Omeprazole 0 0 0
Pantoprazole 0 0 0
Rabeprazole 0 0 0
Thyroid Hormone 0.002 0 0.005
Levothyroxine 0 0 0
Antidiabetic 0.001 0 0.003
Metformin 0 0 0
Chemotherapy 0.001 0.002 0.05
Methotrexate 0 0 0
Eye Drops 0.167 -0.054 0.123
Multivitamin 0.112 -0.018 0.06
Vasodilator 0.001 0 0.001
Nitroglycerin 0 0 0
Antiplatelet 0.002 0 0.006
Plavix 0 0 0
Dopamine Serotonin
Adrenergic Antagonist 0.002 -0.006 0.154
Quetiapine 0 0 0
Alkaloid 0.001 0.001 0.016
Quinine 0 0 0
Histamine II Blocker 0.999 -0.43 0.576
Ranitidine 0.896 -0.221 0.335
Bisphosphonate 0.035 -0.006 0.059
Risedronate 0 0 0
PDE-5 Inhibitor 0.001 0 0.012
Tadalafil 0 0 0
Antimuscarinic 0.001 0 0.013
Tolterodine 0 0 0
Anticonvulsant 0.035 0.01 0.152
Trazodone 0 0 0
SSRI/SNRI 0.001 0 0.004
Venlafaxine 0 0 0
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Appendix B
Non-Linear Modelling Supplemental
Results
B.1 GAM Smoothing Parameter Graphs
B.1.1 Atorvastatin
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Figure B.1: Atorvastatin GAM smoothing for Age covariate
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(b) Fixed smoothing parameters
Figure B.2: Atorvastatin GAM smoothing for 4 -hydroxycholesterol covariate
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(b) Fixed smoothing parameters
Figure B.3: Atorvastatin GAM smoothing for BMI covariate
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(b) Fixed smoothing parameters
Figure B.4: Atorvastatin GAM smoothing for Time Post Dose (h) covariate
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Figure B.5: Rosuvastatin reduced-model linear kernel SVR tuning
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Figure B.6: Rosuvastatin GAM smoothing for BMI covariate
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Figure B.7: Rosuvastatin GAM smoothing for Time Post Dose (h) covariate
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B.2 SVR Model Tuning Graphs
B.2.1 Atorvastatin
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Figure B.8: Atorvastatin reduced-model linear kernel SVR tuning
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Figure B.9: Atorvastatin reduced-model degree 3 polynomial SVR tuning
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Figure B.10: Atorvastatin reduced-model degree 5 polynomial SVR tuning
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Figure B.11: Atorvastatin reduced-model radial kernel SVR tuning
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Figure B.12: Atorvastatin full concomitant medication model linear kernel SVR tuning
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Figure B.13: Atorvastatin full concomitant medication model degree 3 polynomial SVR tuning
B.2. SVR Model Tuning Graphs 203
0.96
0.98
1.00
1.02
1.04
0.2 0.4 0.6 0.8 1.0
100
200
300
400
500
Performance of ‘svm'
epsilon
co
st
(a) SVR coarse tune
0.96
0.97
0.98
0.99
1.00
1.01
0.0 0.1 0.2 0.3 0.4 0.5
100
150
200
250
300
350
400
Performance of ‘svm'
epsilon
co
st
(b) SVR fine tune
Figure B.14: Atorvastatin full concomitant medication model degree 5 polynomial SVR tuning
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Figure B.15: Atorvastatin full concomitant medication model radial kernel SVR tuning
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B.2.2 Rosuvastatin
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Figure B.16: Rosuvastatin linear kernel SVR tuning
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Figure B.17: Rosuvastatin degree 3 polynomial kernel SVR tuning
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Figure B.18: Rosuvastatin degree 5 polynomial kernel SVR tuning
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Figure B.19: Rosuvastatin radial kernel SVR tuning
Appendix C
Rosuvastatin NGS Novel Variant
Identification
C.1 Supplemental Tables: Identified Variant Allele
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Table C.1: ABCC1 variant allele frequencies
Chromosome Position Case MAF (%) Control MAF (%)
16 16043022 0 1
16 16043174 70 70
16 16101875 2.5 2
16 16108282 35 27
16 16108642 7.5 5
16 16108730 0 1
16 16110244 32.5 42
16 16110253 27.5 41
16 16110848 0 1
16 16126758 20 13
16 16126764 5 26
16 16126986 0 1
16 16127235 22.5 17
16 16130491 0 2
16 16130514 5 16
16 16130524 22.5 14
16 16130701 0 1
16 16138076 7.5 13
16 16138086 2.5 6
16 16138204 0 1
16 16138313 5 3
16 16138322 27.5 24
16 16139714 27.5 24
16 16139878 27.5 24
16 16140041 10 5
16 16141810 12.5 8
16 16141823 25 6
16 16141835 0 1
16 16142224 5 2
16 16142358 10 5
16 16146795 15 11
16 16149759 0 1
16 16149871 10 7
16 16149901 10 4
16 16150208 5 9
16 16150364 2.5 0
16 16150375 0 2
16 16161928 7.5 3
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ABCC1 variant minor allele frequencies (continued)
Chromosome Position Case MAF (%) Control MAF (%)
16 16161976 35 40
16 16162019 75 79
16 16162039 0 9
16 16162264 0 6
16 16162338 5 2
16 16165289 5 11
16 16170477 0 1
16 16173221 0 1
16 16173232 0 4
16 16173548 2.5 3
16 16180896 0 1
16 16184232 32.5 42
16 16184235 0 1
16 16184623 40 44
16 16192565 5 5
16 16196309 7.5 9
16 16196833 0 1
16 16196839 0 1
16 16200756 40 52
16 16200908 40 52
16 16205141 15 27
16 16205143 15 27
16 16205161 15 27
16 16205501 7.5 21
16 16208928 0 1
16 16216139 0 1
16 16218641 0 1
16 16225538 5 0
16 16225971 0 2
16 16228242 20 17
16 16228282 2.5 0
16 16228482 0 1
16 16228548 0 1
16 16230069 5 1
16 16230290 25 16
16 16230427 0 1
16 16232433 5 10
16 16232607 0 10
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ABCC1 variant minor allele frequencies (continued)
Chromosome Position Case MAF (%) Control MAF (%)
16 16235366 2.5 1
16 16235515 0 1
16 16235681 10 16
16 16235939 37.5 42
16 16236004 22.5 37
16 16236138 0 1
16 16236431 0 3
16 16236483 2.5 0
16 16236523 90 92
16 16236650 12.5 14
16 16237379 5 5
16 16237456 0 1
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Table C.2: NR1I2 variant minor allele frequencies
Chromosome Position Case MAF (%) Control MAF (%)
3 119498808 5 15
3 119499015 90 92
3 119499507 52.5 46
3 119499608 90 91
3 119499856 0 1
3 119500035 25 25
3 119500664 90 91
3 119501039 50 46
3 119501263 0 1
3 119501307 17.5 16
3 119501327 2.5 0
3 119501780 40 51
3 119501798 40 52
3 119526203 5 2
3 119526349 20 34
3 119526372 20 34
3 119526654 0 2
3 119529113 40 50
3 119529605 0 1
3 119529689 2.5 6
3 119530027 97.5 87
3 119530141 2.5 2
3 119530858 2.5 10
3 119532652 5 5
3 119532980 0 1
3 119533733 17.5 28
3 119533773 37.5 50
3 119533910 100 100
3 119534097 0 1
3 119534153 10 7
3 119535780 5 2
3 119535795 2.5 8
3 119536429 85 80
3 119536559 10 9
3 119536575 0 1
3 119536581 70 76
3 119536718 5 6
3 119536817 100 97
3 119536897 10 9
3 119536926 100 96
3 119537254 2.5 10
3 119537291 2.5 10
3 119537353 40 52
3 119537625 0 1
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Table C.3: SLCO1B3 variant minor allele frequencies
Chromosome Position Case MAF (%) Control MAF (%)
12 20963135 5 6
12 20963307 2.5 0
12 20966330 7.5 5
12 20966451 5 1
12 20966548 47.5 54
12 20966590 0 4
12 20966681 2.5 2
12 20966722 7.5 3
12 20968527 0 1
12 20968828 40 46
12 20968982 7.5 5
12 20975338 7.5 5
12 20975408 7.5 22
12 20975801 0 1
12 21008356 0 4
12 21011235 20 42
12 21011296 20 42
12 21011310 20 42
12 21011480 77.5 74
12 21011581 17.5 29
12 21013641 0 2
12 21013678 5 6
12 21013948 77.5 74
12 21014025 2.5 0
12 21014062 2.5 0
12 21014139 20 42
12 21014163 20 42
12 21014178 5 5
12 21014269 15 22
12 21014343 0 2
12 21015046 0 15
12 21015075 27.5 24
12 21015119 2.5 1
12 21015139 27.5 38
12 21015205 20 42
12 21015243 20 42
12 21015526 0 1
12 21015610 20 42
12 21015760 77.5 74
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SLCO1B3 variant minor allele frequencies (continued)
Chromosome Position Case MAF (%) Control MAF (%)
12 21015815 5 1
12 21015864 5 1
12 21015906 10 14
12 21028093 17.5 41
12 21028208 10 14
12 21030454 0 2
12 21030582 20 42
12 21030584 2.5 1
12 21030590 17.5 29
12 21030672 0 1
12 21031020 20 42
12 21031076 17.5 14
12 21031153 5 4
12 21032173 5 4
12 21032242 25 44
12 21034017 2.5 1
12 21034198 0 1
12 21036102 0 14
12 21036168 20 43
12 21036270 20 42
12 21036300 2.5 0
12 21036411 77.5 74
12 21036502 0 1
12 21036634 0 1
12 21036683 35 34
12 21036686 2.5 0
12 21051169 0 1
12 21051489 30 31
12 21054369 80 78
12 21068699 10 17
12 21069049 7.5 1
12 21069690 0 1
12 21069803 0 1
12 21070135 5 0
12 21070137 100 92
12 21070243 0 1
Appendix D
Machine Learning Clinic (MLC)
D.1 Overall Development Goal
Throughout the completion of this doctoral thesis, I have gained an immeasurable wealth of
experience from collaborating with many clinical and pharmacological researchers. These
researchers are experts in their field, and make meaningful substantive research possible for
biostatisticians and other researchers interested in interdisciplinary modelling. A barrier that
I have noticed in many of these interactions has been the unavailability and inaccessibility of
advanced modelling techniques to researchers who are experts in their substantive field, but not
necessarily experts in statistical modelling. There are many opportunities for interdisciplinary
knowledge transfer going forward, particularly in the area of medical research, as statisticians
also need to know the substantive questions that are meaningful and of interest to clinicians. In
order to facilitate easier access to statistical modelling that does not involve knowing a statisti-
cal programming language (like R, SAS, or Stata), I began developing an interactive statistical
platform called Machine Learning Clinic (MLC). Initially, the goal of development was to pro-
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vide a platform to perform the analysis needed for the di↵erent research questions addressed in
this thesis, and that could be easily adaptable to other research domains within clinical pharma-
cology, epidemiology, and other substantive areas. Eventually, the goal of the platform became
helping researchers more broadly to make informed decisions about regression and modelling
parameter selection for the specific context of clinical pharmacology, and providing extensive
documentation allowing the user to see exactly what model parameters are being used in each
model, and why. MLC integrates information about statistical interpretation for use as an edu-
cational tool and to improve statistical interpretation in journal publications about the statistics
used for di↵erent analyses. Because the eventual dissertation did not include quality testing
and research about the e cacy of the platform, I have included it in the appendix as supple-
mental material. The remainder of the appendix will document the development process, and
provide screenshots of the application to show the user interface and statistical outputs.
D.2 MLC Software Development
The software was developed in Shiny, a web application framework for R1. RStudio was used
as a development environment for writing this application2.
D.2.1 Data Import Design
The data loading interface provides a file browser for the user to select a comma separated
values (.csv) file containing their data. The first row of the file is expected to contain variable
names for each column in the data set. The file may contain an arbitrary number of rows,
and having more covariates than observations is permissible. After the file loads, the user is
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provided with a preview table, and a warning message detailing the number of missing obser-
vations removed from the data set, as MLC does not yet include data imputation functionality
(Figure D.1).
Figure D.1: MLC: Data loading interface
After reviewing the previewed data, an interface is available to specify the structure of the
data for analysis. The user is given the option to center and scale their data, which would
be of use in cases where interpreting variables in the original scale is di↵erent. The user
may then choose the outcome variable, and whether this should be log transformed; this is
particularly important for outcomes such as plasma concentration of drugs with a shorter half
life that display non-linear characteristics over time. A primary use case of the application
is modelling clinical information and and possibly a column of patient identifiers; the user is
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required to specify whether there is a patient ID variable, and if so, which variable contains
this information before selecting options for the remaining variables in the data set so as to not
accidentally include patient IDs as regressors in any model.
Because a main intended application of the platform is for use with clinical pharmaco-
logical data sets, specific options are available for encoding genetic variables such as single
nucleotide polymorphisms (SNPs). It is expected that the format of any genetic variables con-
tained in the data file will take the form of a pair of gene bases (ie. ’A/T’, ’C/G’). Variables
containing this pattern of data are automatically detected, and after selecting the base of inter-
est (A, T, C or G), the user is given the following encoding options for each genetic variable
detected: “Count (0,1,2)”, a raw measure of the number of times the base appears in the pair;
“Present/absent (0,1)”, whether or not the base appears in the pair given; “Homozygous (0,1)”,
whether or not both members of the pair are the base of interest; and “Exclude”, to remove the
variable from any analyses (Figure D.2).
Finally, the user has the option to exclude any dichotomous variables, which are automati-
cally detected by the software, and to exclude any continuous variables or indicate whether any
of the variables should be treated as factors (Figure D.3).
D.2.2 Logistic and Linear Regression Implementation
Linear regression results are obtained using a linear model (lm()) or generalized linear model
(glm()). For data sets with a continuous outcome variable, the family is specified as Gaus-
sian; for dichotomous outcomes, the family is specified as Binomial. Model performance is
calculated as per the user’s choice of 5- or 10-fold CV. This process is repeated 30 times to
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Figure D.2: MLC: Initial variable setup
obtain more stable performance estimates for smaller data sets, and performance measures are
averaged over all resultant folds. Calculated CV measures include AIC, RMSE, Adjusted R2
for linear models, and classification performance for logistic models.
For both linear and logistic regression, the outcome variable and number of observations
present in the analysis are displayed, followed by a table of covariates, coe cient estimates,
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Figure D.3: MLC: Variable exclusion and factor representation
a 95% confidence interval, and corresponding P-value, indicated with stars for those whose
CI’s do not cross zero (P-value<0.05). Below the table is a slider to give the user the option of
adjusting the number of significant digits to appear in the table. For logistic regression models,
the coe cient estimates are converted to odds ratios for ease of interpretation. Alongside the
regression summary table is an interface for interpreting regression coe cients, including a
possible interpretation for the intercept (Figure D.4). The user also has the option to output the
model fit of the linear regression to an .RData file in order to conduct comparisons with other
similar models using ANOVA etc.
Following the regression summary table are the raw output of the regression model as given
by summary(lm), and the explicit regression equation, should users need to reference it. An
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Figure D.4: MLC: Linear regression results table and coe cient interpretation
evaluation of model performance follows; performance across folds and a table containing
performance per fold are shown, as well as options for the user to choose between 5- or 10-fold
CV and a panel for more information on CV topics. In both the 5- and 10-fold CV protocols,
100 random splits of the data are taken and the CV is repeated on each. The final summary CV
numbers are the average of all of the folds from all of the splits.
For linear regression, the additional visual display to help with model understanding is an
array of diagnostic regression plots, with corresponding explanations for how to interpret each
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of the four plots: residuals vs. fitted, normal Q-Q, scale-location, and residuals vs. leverage. At
the bottom of the plots is a link to the resource used to help formulate the explanations, which
contains additional specific examples of what the plots might show if the regression model
assumptions are violated3.
The additional visual display for logistic regressions has not yet been implemented, but
will contain an interactive ROC curve with sliders to change the cuto↵ probability for classi-
fying a case as 0 or 1, as classical regression diagnostic plots can be misleading to interpret
when generated from logistic models3. This is meant to help the user explore the relationship
between sensitivity, specificity and overall accuracy with regard to how one chooses to define
the probability of a positive or negative classification outcome.
D.3 Future Work
Because of time constraints associated with finishing the analyses outlined in the research goals
for this thesis, the GAM interface was not fully developed and the CV procedure was not in-
corporated into the application. Similarly, the tuning process and statistical output for the SVR
analysis has yet to be transferred from regular R code to code appropriate for use with Shiny.
Once these statistical functions are implemented, development will focus on implementing
tools for visual analytics and interactive visualization, in order to help the user have a more
intuitive understanding of model fit quality, and the relationship between the output and the
statistical parameters chosen.
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